

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number  
**WO 01/74783 A1**

(51) International Patent Classification<sup>7</sup>: C07D 223/18, 243/24, 401/12, 223/12, 403/12, 223/16, 243/14, 401/06, A61K 31/55, 31/551, 31/5513, A61P 25/28, C07K 5/06, 5/08, A61K 38/00

(74) Agent: LARSEN, Scott, K.; Dupont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(21) International Application Number: PCT/US01/10667

(81) Designated States (*national*): AL, AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, IN, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, VN, ZA.

(22) International Filing Date: 3 April 2001 (03.04.2001)

(25) Filing Language: English

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(26) Publication Language: English

(30) Priority Data:  
60/194,503 3 April 2000 (03.04.2000) US


Published:  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant: DUPONT PHARMACEUTICALS COMPANY [US/US]; Chestnut Run Plaza, 974 Cetnre Road, Wilmington, DE 19805 (US).

(72) Inventors: OLSON, Richard, E.; 7 Pelham Road, Wilmington, DE 19803 (US). YANG, Michael, G.; 15 South Hampshire Court, Wilmington, DE 19807 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYCLIC LACTAMS AS INHIBITORS OF A $\beta$  PROTEIN PRODUCTION



(57) Abstract: This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A $\beta$ -peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention

relates to the treatment of neurological disorders related to  $\beta$ -amyloid production such as Alzheimer's disease and Down's Syndrome.

WO 01/74783 A1

AL

TITLE

## CYCLIC LACTAMS AS INHIBITORS OF A-BETA-PROTEIN PRODUCTION

FIELD OF THE INVENTION

5 This invention relates to novel cyclic malonamides having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of  
10 A $\beta$ -peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to  $\beta$ -amyloid production such as Alzheimer's disease and Down's Syndrome.

15

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, temporal and local orientation, cognition,  
20 reasoning, judgment and emotionally stability. AD is a common cause of progressive dementia in humans and is one of the major causes of death in the United States. AD has been observed in all races and ethnic groups worldwide, and is a major present and future health problem. No treatment  
25 that effectively prevents AD or reverses the clinical symptoms and underlying pathophysiology is currently available (for review, Dennis J. Selkoe; Cell Biology of the amyloid (beta)-protein precursor and the mechanism of Alzheimer's disease, Annu Rev Cell Biol, 1994, 10: 373-  
30 403).

Histopathological examination of brain tissue derived upon autopsy or from neurosurgical specimens in effected individuals revealed the occurrence of amyloid plaques and neurofibrillar tangles in the cerebral cortex of such  
35 patients. Similar alterations were observed in patients with Trisomy 21 (Down's syndrome), and hereditary cerebral hemorrhage with amyloidosis of the Dutch-type.

Neurofibrillar tangles are nonmembrane-bound bundles of abnormal proteinaceous filaments and biochemical and immunochemical studies led to the conclusion that their principle protein subunit is an altered phosphorylated form of the tau protein (reviewed in Selkoe, 1994).

Biochemical and immunological studies revealed that the dominant proteinaceous component of the amyloid plaque is an approximately 4.2 kilodalton (kD) protein of about 39 to 43 amino acids. This protein was designated A $\beta$ ,  $\beta$ -amyloid peptide, and sometimes  $\beta$ /A4; referred to herein as A $\beta$ . In addition to its deposition in amyloid plaques, A $\beta$  is also found in the walls of meningeal and parenchymal arterioles, small arteries, capillaries, and sometimes, venules. A $\beta$  was first purified and a partial amino acid reported in 1984 (Glenner and Wong, Biochem. Biophys. Res. Commun. 120: 885-890). The isolation and sequence data for the first 28 amino acids are described in U.S. Pat. No 4,666,829.

Compelling evidence accumulated during the last decade revealed that A $\beta$  is an internal polypeptide derived from a type 1 integral membrane protein, termed  $\beta$  amyloid precursor protein (APP).  $\beta$  APP is normally produced by many cells both in vivo and in cultured cells, derived from various animals and humans. A $\beta$  is derived from cleavage of  $\beta$  APP by as yet unknown enzyme (protease) system(s), collectively termed secretases.

The existence of at least four proteolytic activities has been postulated. They include  $\beta$  secretase(s), generating the N-terminus of A $\beta$ ,  $\alpha$  secretase(s) cleaving around the 16/17 peptide bond in A $\beta$ , and  $\gamma$  secretases, generating C-terminal A $\beta$  fragments ending at position 38, 39, 40, 42, and 43 or generating C-terminal extended precursors which are subsequently truncated to the above polypeptides.

Several lines of evidence suggest that abnormal accumulation of A $\beta$  plays a key role in the pathogenesis of AD. Firstly, A $\beta$  is the major protein found in amyloid


plaques. Secondly, A $\beta$  is neurotoxic and be causally related to neuronal death observed in AD patients. Thirdly, missense DNA mutations at position 717 in the 770 isoform of  $\beta$  APP can be found in effected members but not unaffected members of several families with a genetically determined (familiar) form of AD. In addition, several other  $\beta$  APP mutations have been described in familiar forms of AD. Fourthly, similar neuropathological changes have been observed in transgenic animals overexpressing mutant forms of human  $\beta$  APP. Fifthly, individuals with Down's syndrome have an increased gene dosage of  $\beta$  APP and develop early-onset AD. Taken together, these observations strongly suggest that A $\beta$  depositions may be causally related to the AD.

Best Available Copy

It is hypothesized that inhibiting the production of A $\beta$  will prevent and reduce neurological degeneration, by controlling the formation of amyloid plaques, reducing neurotoxicity and, generally, mediating the pathology associated with A $\beta$  production. One method of treatment methods would therefore be based on drugs that inhibit the formation of A $\beta$  in vivo.

Methods of treatment could target the formation of A $\beta$  through the enzymes involved in the proteolytic processing of  $\beta$  amyloid precursor protein. Compounds that inhibit  $\beta$  or  $\gamma$  secretase activity, either directly or indirectly, could control the production of A $\beta$ . Advantageously, compounds that specifically target  $\gamma$  secretases, could control the production of A $\beta$ . Such inhibition of  $\beta$  or  $\gamma$  secretases could thereby reduce production of A $\beta$ , which, thereby, could reduce or prevent the neurological disorders associated with A $\beta$  protein.


PCT publication number WO 96/29313 discloses the general formula:






covering metalloprotease inhibiting compounds useful for the treatment of diseases associated with excess and/or unwanted matrix metalloprotease activity, particularly collagenase and or stromelysin activity.

5 Compounds of general formula:




are disclosed in PCT publication number WO 95/22966  
 10 relating to matrix metalloprotease inhibitors. The compounds of the invention are useful for the treatment of conditions associated with the destruction of cartilage, including corneal ulceration, osteoporosis, periodontitis and cancer.

15 European Patent Application number EP 0652009A1 relates to the general formula:



20 and discloses compounds that are protease inhibitors that inhibit A $\beta$  production.


US Patent Number 5703129 discloses the general formula:



25 which covers 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives that inhibit A $\beta$  production and are useful in the treatment of Alzheimer's disease.

Copending, commonly assigned U.S. patent application Serial Number 09/370089 filed August 7, 1999 (equivalent to international application PCT US99/17717) discloses lactams of general formula:

5



wherein the lactam ring B is substituted by succinamide and a carbocyclic, aryl, or heteroaryl group. These compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A $\beta$ -peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein.

None of the above references teaches or suggests the compounds of the present invention which are described in detail below.

#### SUMMARY OF THE INVENTION


One object of the present invention is to provide novel compounds which are useful as inhibitors of the production of A $\beta$  protein or pharmaceutically acceptable salts or prodrugs thereof.

It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

It is another object of the present invention to provide a method for treating degenerative neurological disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of Formula (I):

5




or a stereoisomer, pharmaceutically acceptable salt or prodrug forms thereof, wherein  $R^3$ ,  $R^6$ , B, C, W, X, Y, and Z are defined below, are effective inhibitors of the production of  $A\beta$ .

10

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Thus, in a first embodiment, the present invention provides a novel compound of Formula (I):

15



or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, wherein:

20

L is  $-NR^{26}C(=O)-$ ,  $-C(=O)NR^{26}-$ ,  $-NR^{26}C(=O)O-$ ,  $-OC(=O)NR^{26}$ , or  $-NR^{26}C(=O)NR^{26}-$ ;

25

$R^3$  is  $-(CR^7R^{7a})_n-R^4$ ,  
 $-(CR^7R^{7a})_1-S-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-O-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-N(R^{7b})-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-S(=O)-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-S(=O)_2-(CR^7R^{7a})_m-R^4$ ,

30

- (CR<sup>7</sup>R<sup>7a</sup>)<sub>1</sub>-C(=O)-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>,  
 - (CR<sup>7</sup>R<sup>7a</sup>)<sub>1</sub>-N(R<sup>7b</sup>)C(=O)-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>,  
 - (CR<sup>7</sup>R<sup>7a</sup>)<sub>1</sub>-C(=O)N(R<sup>7b</sup>)-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>,  
 - (CR<sup>7</sup>R<sup>7a</sup>)<sub>1</sub>-N(R<sup>7b</sup>)S(=O)<sub>2</sub>-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>, or  
 5 - (CR<sup>7</sup>R<sup>7a</sup>)<sub>1</sub>-S(=O)<sub>2</sub>N(R<sup>7b</sup>)-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>;

n is 0, 1, 2, or 3;

m is 0, 1, 2, or 3;

10

l is 1, 2, or 3;

Ring C is a 3 to 8 membered carbocycle,

15

wherein the carbocycle is saturated or partially saturated;

optionally, the carbocycle contains a heteroatom selected from -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, and -N(R<sup>20</sup>)-; and

wherein the carbocycle is substituted with 0-4 R<sup>21</sup>;

20

R<sup>4</sup> is H, OH, OR<sup>14a</sup>,

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>4a</sup>,

C<sub>2</sub>-C<sub>8</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,

C<sub>2</sub>-C<sub>8</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,

25

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, or

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle

30

is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,

35

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, and

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>4b</sup>;

5 R<sup>4b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10 R<sup>6</sup> is H;  
C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>6a</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>6b</sup>; or  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>6b</sup>;

15 R<sup>6a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, aryl and CF<sub>3</sub>;

20 R<sup>6b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

25 R<sup>7</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl substituted with 0-5 R<sup>7c</sup>;

R<sup>7a</sup>, at each occurrence, is independently selected from H, Cl, F, Br, I, CN, CF<sub>3</sub>, and C<sub>1</sub>-C<sub>4</sub> alkyl;

30 R<sup>7b</sup> is independently selected from H and C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>7c</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;

35 B is a 5 to 10 membered lactam,  
wherein the lactam is saturated, partially saturated or unsaturated;

wherein each additional lactam carbon is substituted  
with 0-2 R<sup>11</sup>; and,

optionally, the lactam contains an additional  
heteroatom selected from -O-, -S-, -S(=O)-,  
-S(=O)<sub>2</sub>-, -N=, -NH-, and -N(R<sup>10</sup>)-;

R<sup>10</sup> is H, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>,  
S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>R<sup>17</sup>;

C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>10a</sup>;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>10b</sup>;

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>10b</sup>; or

5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>10b</sup>;

R<sup>10a</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, aryl substituted with 0-4 R<sup>10b</sup>; C<sub>3</sub>-C<sub>10</sub> carbocycle  
substituted with 0-3 R<sup>10b</sup>, and 5 to 10 membered  
heterocycle containing 1 to 4 heteroatoms selected  
from nitrogen, oxygen, and sulphur, wherein said 5 to  
10 membered heterocycle is substituted with 0-3 R<sup>10b</sup>;

R<sup>10b</sup>, at each occurrence, is independently selected from H,  
OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>,  
NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub>  
alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy,  
and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>11</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>,  
C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>11a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>11b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;

5

R<sup>11a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>;

phenyl substituted with 0-3 R<sup>11b</sup>;

10

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>11b</sup>; and

5 to 6 membered heterocycle containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;

15

R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

20

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-3 R<sup>13</sup>;

25

additionally, two R<sup>11</sup> substituents on the same or adjacent carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>13</sup>;

30

additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-4 R<sup>13</sup>;

35

W is -(CR<sup>8</sup>R<sup>8a</sup>)<sub>p</sub>-;

p is 0, 1, 2, 3, or 4;

5  $R^8$  and  $R^{8a}$ , at each occurrence, are independently selected from H, F,  $C_1$ - $C_4$  alkyl,  $C_2$ - $C_4$  alkenyl,  $C_2$ - $C_4$  alkynyl and  $C_3$ - $C_8$  cycloalkyl;

X is a bond;

10  $C_6$ - $C_{10}$  aryl substituted with 0-3  $R^{Xb}$ ;  
 $C_3$ - $C_{10}$  carbocycle substituted with 0-3  $R^{Xb}$ ; or  
5 to 10 membered heterocycle substituted with 0-2  $R^{Xb}$ ;

15  $R^{Xb}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  $S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  haloalkoxy, and  $C_1$ - $C_4$  halothioalkoxy;

Y is a bond or  $-(CR^9R^{9a})_t-V-(CR^9R^{9a})_u-$ ;

20 t is 0, 1, 2, or 3;

u is 0, 1, 2, or 3;

25  $R^9$  and  $R^{9a}$ , at each occurrence, are independently selected from H, F,  $C_1$ - $C_6$  alkyl and  $C_3$ - $C_8$  cycloalkyl;

V is a bond,  $-C(=O)-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$ ,  $-S(=O)_2-$ ,  
 $-N(R^{19})-$ ,  $-C(=O)NR^{19b}-$ ,  $-NR^{19b}C(=O)-$ ,  $-NR^{19b}S(=O)_2-$ ,  
30  $S(=O)_2NR^{19b}-$ ,  $-NR^{19b}S(=O)-$ ,  $-S(=O)NR^{19b}-$ ,  $-C(=O)O-$ , or  
 $-OC(=O)-$ ;

Z is H;

35  $C_1$ - $C_8$  alkyl substituted with 1-3  $R^{12}$ ;  
 $C_2$ - $C_4$  alkenyl substituted with 1-3  $R^{12}$ ;  
 $C_2$ - $C_4$  alkynyl substituted with 1-3  $R^{12}$ ;  
 $C_1$ - $C_8$  alkyl substituted with 0-3  $R^{12a}$ ;  
 $C_2$ - $C_4$  alkenyl substituted with 0-3  $R^{12a}$ ;



C<sub>2</sub>-C<sub>4</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
5 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

R<sup>12</sup>, at each occurrence, is independently selected from  
10 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and  
- 5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
15 is substituted with 0-3 R<sup>12b</sup>;

R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
20 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
25 SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>13</sup>, at each occurrence, is independently selected from  
30 H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

R<sup>14</sup> is H, phenyl substituted with 0-4 R<sup>14b</sup>, benzyl  
substituted with 0-4 R<sup>14b</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub>  
35 alkoxyalkyl, or C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>14a</sup> is H, C<sub>6</sub>-C<sub>10</sub> aryl, benzyl, heterocycle, or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>14b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
5 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10 R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub> alkyl)- wherein the aryl is  
substituted with 0-4 R<sup>15b</sup>, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

15 R<sup>15b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

20 R<sup>16</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

25 R<sup>17</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl,  
aryl substituted by 0-4 R<sup>17a</sup>, or  
-CH<sub>2</sub>-aryl substituted by 0-4 R<sup>17a</sup>;

30 R<sup>17a</sup> is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
propoxy, butoxy, -OH, F, Cl, Br, I, CF<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>,  
S(O)CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, -NH<sub>2</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

35 R<sup>18</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

R<sup>19</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

R<sup>20</sup> is H, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>,  
S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>R<sup>17</sup>;  
C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-2 R<sup>20a</sup>;  
5 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>20b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>20b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
10 is substituted with 0-3 R<sup>20b</sup>;

R<sup>20a</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, F, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, aryl  
substituted with 0-4 R<sup>20b</sup>, and heterocycle substituted  
15 with 0-4 R<sup>20b</sup>;

R<sup>20b</sup>, at each occurrence, is independently selected from H,  
OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>,  
NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub>  
20 alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy,  
and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>21</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>,  
25 C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>21a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>21b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>21b</sup>; and  
5 to 10 membered heterocycle containing 1 to 4  
30 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>21b</sup>;

R<sup>21a</sup>, at each occurrence, is independently selected from  
35 H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>,  
NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>;  
phenyl substituted with 0-3 R<sup>21b</sup>;

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>21b</sup>; and  
5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
5 is substituted with 0-3 R<sup>21b</sup>;

R<sup>21b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

10 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

additionally, two R<sup>21</sup> substituents on adjacent atoms may be  
combined to form a 5 to 6 membered heteroaryl fused  
15 radical, wherein said 5 to 6 membered heteroaryl fused  
radical comprises 1 or 2 heteroatoms selected from N,  
O, and S; wherein said 5 to 6 membered heteroaryl  
fused radical is substituted with 0-3 R<sup>23</sup>;

20 additionally, two R<sup>21</sup> substituents on the same or adjacent  
carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub>  
carbocycle substituted with 0-3 R<sup>23</sup>;

additionally, two R<sup>21</sup> substituents on adjacent atoms may be  
25 combined to form a benzo fused radical; wherein said  
benzo fused radical is substituted with 0-4 R<sup>23</sup>;

R<sup>23</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
30 NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

R<sup>26</sup> is H;

C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>26a</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>26b</sup>; or  
35 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>26b</sup>;

R<sup>26a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, aryl and CF<sub>3</sub>; and

- 5 R<sup>26b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkoxy.

[2] In a preferred embodiment the present invention  
10 provides a compound of Formula (I), wherein:

L is -NR<sup>26</sup>C(=O)-, -C(=O)NR<sup>26</sup>-, or -OC(=O)NR<sup>26</sup>-;

R<sup>3</sup> is -(CHR<sup>7</sup>)<sub>n</sub>-R<sup>4</sup>,  
15 -(CHR<sup>7</sup>)<sub>1</sub>-N-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>, or  
-(CHR<sup>7</sup>)<sub>1</sub>-O-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>;

n is 0, 1 or 2;

20 m is 0, 1 or 2;

l is 1;

Ring C is a 3 to 8 membered carbocycle substituted with 0-4  
25 R<sup>21</sup>; optionally, the carbocycle contains a heteroatom  
selected from -O- and -N(R<sup>20</sup>)-;

R<sup>4</sup> is H, OH, OR<sup>14a</sup>,  
C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
30 C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-2 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-1 R<sup>4a</sup>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 4  
35 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>, phenyl substituted with 0-3 R<sup>4b</sup>, and 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>4b</sup>;

R<sup>4b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

R<sup>6</sup> is H;

R<sup>7</sup>, at each occurrence, is independently selected from H, OH, F, CF<sub>3</sub>, methyl, and ethyl;

Ring B is a 7 membered lactam, wherein the lactam is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 R<sup>11</sup>; and, optionally, the lactam contains a heteroatom selected from -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N=, -NH-, and -N(R<sup>10</sup>)-;

R<sup>10</sup> is H, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>R<sup>17</sup>; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-2 R<sup>10a</sup>; C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>10b</sup>; C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>10b</sup>; or 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>10b</sup>;

5 R<sup>10a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, phenyl substituted with 0-4 R<sup>10b</sup>; and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 10 0-3 R<sup>10b</sup>;

R<sup>10b</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

15 R<sup>11</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>11a</sup>; 20 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>11b</sup>; C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;

25 R<sup>11a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl substituted with 0-3 R<sup>11b</sup>;

30 R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

35

additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-2 R<sup>13</sup>;

5 additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-2 R<sup>13</sup>;

additionally, two R<sup>11</sup> substituents on the same or adjacent carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-2 R<sup>13</sup>;

15 W is a bond,  $-\text{CH}_2-$ ,  $-\text{CH}(\text{CH}_3)-$ ,  $-\text{CH}_2\text{CH}_2-$  or  $-\text{CH}(\text{CH}_3)\text{CH}_2-$ ;

X is a bond;  
phenyl substituted with 0-2 R<sup>Xb</sup>;  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-2 R<sup>Xb</sup>; or  
5 to 6 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;

$R^{Xb}$ , at each occurrence, is independently selected from H, OH, Cl, F,  $NR^{15}R^{16}$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  $S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_3$  alkoxy,  $C_1$ - $C_2$  haloalkyl, and  $C_1$ - $C_2$  haloalkoxy;

Y is a bond,  $-\text{CH}_2\text{-V-}$ ,  $-\text{V-}$ , or  $-\text{V-CH}_2\text{-}$ ;

30 V is a bond,  $-C(=O)-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$ ,  $-S(=O)_2-$ ,  $-NH-$ ,  
 $-N(CH_3)-$ , or  $-N(CH_2CH_3)-$ ,

35 Z is H; C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>2</sub>-C<sub>4</sub> alkenyl; C<sub>2</sub>-C<sub>4</sub> alkynyl;  
C<sub>1</sub>-C<sub>3</sub> alkyl substituted with 1-2 R<sup>12</sup>;  
C<sub>2</sub>-C<sub>3</sub> alkenyl substituted with 1-2 R<sup>12</sup>;  
C<sub>2</sub>-C<sub>3</sub> alkynyl substituted with 1-2 R<sup>12</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;



C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>12b</sup>; or  
5 to 10 membered heterocycle substituted with 0-3  
R<sup>12b</sup>;

5 R<sup>12</sup>, at each occurrence, is independently selected from  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
10 sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
15 SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>13</sup>, at each occurrence, is independently selected from  
20 H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>2</sub>-C<sub>4</sub> alkoxyalkyl;

25 R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>4</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-,  
and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

30 R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>4</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

35 R<sup>17</sup> is H, methyl, ethyl, propyl, butyl, methoxymethyl,  
ethoxymethyl, methoxyethyl, ethoxyethyl,  
phenyl substituted by 0-3 R<sup>17a</sup>, or

-CH<sub>2</sub>-phenyl substituted by 0-3 R<sup>17a</sup>;

R<sup>17a</sup> is H, methyl, methoxy, -OH, F, Cl, CF<sub>3</sub>, or OCF<sub>3</sub>;

5 R<sup>18</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and  
phenethyl;


10 R<sup>19</sup>, at each occurrence, is independently selected from  
H, methyl, and ethyl;

R<sup>20</sup> is H or C(=O)OR<sup>17</sup>;

15 R<sup>26</sup> is H, methyl, or ethyl.


[3] In another preferred embodiment the present  
invention provides a compound of Formula (I), wherein:


20 Ring C is selected from:



wherein Ring C is substituted with 0-2 R<sup>21</sup>; and

25 Ring B is selected from:





[4] In another more preferred embodiment the present invention provides a compound of Formula (I), wherein:

5

L is  $\text{-NHC(=O)-}$ ,  $\text{-C(=O)NH-}$ , or  $\text{-OC(=O)NH-}$ ;

$\text{R}^3$  is  $\text{R}^4$ ,  $\text{-CH}_2\text{OR}^4$ , or  $\text{-CH}_2\text{CH}_2\text{OR}^4$ ;

10  $\text{R}^4$  is  $\text{C}_1\text{-C}_6$  alkyl substituted with 0-3  $\text{R}^{4a}$ ,  
 $\text{C}_2\text{-C}_6$  alkenyl substituted with 0-1  $\text{R}^{4a}$ , or  
 $\text{C}_2\text{-C}_6$  alkynyl substituted with 0-1  $\text{R}^{4a}$ ;

15  $\text{R}^{4a}$ , at each occurrence, is independently selected from  
H, OH, F,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ ,  
 $\text{C}_3\text{-C}_6$  carbocycle substituted with 0-3  $\text{R}^{4b}$ ,  
phenyl substituted with 0-3  $\text{R}^{4b}$ , and  
5 to 6 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
20 sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3  $\text{R}^{4b}$ ; wherein said 5 to 6  
membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl,  
thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
25 pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and  
tetrazolyl;

30  $\text{R}^{4b}$ , at each occurrence, is independently selected from H,  
OH, Cl, F,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ , acetyl,  $\text{SCH}_3$ ,  $\text{S(=O)CH}_3$ ,  
 $\text{S(=O)}_2\text{CH}_3$ , methyl, ethyl, propyl, butyl, methoxy,  
ethoxy, propoxy,  $\text{C}_1\text{-C}_2$  haloalkyl, and  $\text{C}_1\text{-C}_2$   
haloalkoxy;

W is a bond,  $\text{-CH}_2\text{-}$ ,  $\text{-CH(CH}_3\text{)-}$ ,  $\text{-CH}_2\text{CH}_2\text{-}$  or  $\text{-CH(CH}_3\text{)CH}_2\text{-}$ ;

X is a bond, phenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or  
5 to 6 membered heterocycle;

5 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-,  
-N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-,

Z is H; C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl,  
C<sub>1</sub>-C<sub>3</sub> alkyl substituted with 1-2 R<sup>12</sup>;  
10 C<sub>2</sub>-C<sub>3</sub> alkenyl substituted with 1-2 R<sup>12</sup>;  
C<sub>2</sub>-C<sub>3</sub> alkynyl substituted with 1-2 R<sup>12</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>12b</sup>; or  
5 to 6 membered heterocycle containing 1 to 4  
15 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>; wherein said 5 to 6  
membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl,  
20 thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and  
tetrazolyl;

R<sup>12</sup>, at each occurrence, is independently selected from  
25 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>12b</sup>; and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle is  
30 substituted with 0-3 R<sup>12b</sup>; wherein said 5 to 6  
membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,  
pyrrolyl, piperazinyl, piperidinyl, pyrazolyl,  
imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

35 R<sup>12b</sup>, at each occurrence, is independently selected from

H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

5

R<sup>13</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, Cl, F, Br, CN, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

10 R<sup>14</sup> is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;

R<sup>15</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;

15 R<sup>16</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl, methyl-C(=O)-, ethyl-C(=O)-, methyl-S(=O)<sub>2</sub>-, ethyl-S(=O)<sub>2</sub>-, and propyl-S(=O)<sub>2</sub>-;

20 R<sup>18</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl;

R<sup>19</sup>, at each occurrence, is independently selected from  
25 H, methyl, and ethyl;

R<sup>20</sup> is H.


[5] In another more preferred embodiment the present  
30 invention provides a compound of Formula (I), wherein:

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

35 R<sup>3</sup> is -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,  
-CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>(CH<sub>3</sub>)<sub>2</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
-CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>,  
-CH(OH)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH(OH)CH(CH<sub>3</sub>)<sub>2</sub>, -CH(NH<sub>2</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,


$-\text{CH}_2\text{CH}_2\text{OCH}_3$ ,  $-\text{CH}_2\text{OCH}_2\text{CH}_3$ ,  $-\text{CF}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 $-\text{CH}(\text{NHCH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $-\text{CH}(\text{NH}\text{SO}_2\text{CH}_2\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
cyclohexyl-, cyclopentyl-, cyclopropyl- $\text{CH}_2$ -,  
cyclobutyl- $\text{CH}_2$ -, cyclopentyl- $\text{CH}_2$ -, cyclohexyl- $\text{CH}_2$ -,  
5 cyclopropyl- $\text{CH}_2\text{CH}_2$ -, cyclobutyl- $\text{CH}_2\text{CH}_2$ -,  
cyclopentyl- $\text{CH}_2\text{CH}_2$ -, cyclohexyl- $\text{CH}(\text{OH})$ -,  
cyclohexyl- $\text{CH}_2\text{CH}_2$ -, 1- $\text{NH}_2$ -cyclopentyl, phenyl- $\text{CH}_2$ -,  
(2-F-phenyl) $\text{CH}_2$ -, (3-F-phenyl) $\text{CH}_2$ -, (4-F-phenyl) $\text{CH}_2$ -,  
(2-Cl-phenyl) $\text{CH}_2$ -, (3-Cl-phenyl) $\text{CH}_2$ -, (4-Cl-phenyl) $\text{CH}_2$ -,  
10 (2,3-diF-phenyl) $\text{CH}_2$ -, (2,4-diF-phenyl) $\text{CH}_2$ -,  
(2,5-diF-phenyl) $\text{CH}_2$ -, (2,6-diF-phenyl) $\text{CH}_2$ -,  
(3,4-diF-phenyl) $\text{CH}_2$ -, (3,5-diF-phenyl) $\text{CH}_2$ -,  
(2,3-diCl-phenyl) $\text{CH}_2$ -, (2,4-diCl-phenyl) $\text{CH}_2$ -,  
(2,5-diCl-phenyl) $\text{CH}_2$ -, (2,6-diCl-phenyl) $\text{CH}_2$ -,  
15 (3,4-diCl-phenyl) $\text{CH}_2$ -, (3,5-diCl-phenyl) $\text{CH}_2$ -,  
(3-F-4-Cl-phenyl) $\text{CH}_2$ -, (3-F-5-Cl-phenyl) $\text{CH}_2$ -,  
(3-Cl-4-F-phenyl) $\text{CH}_2$ -, phenyl- $\text{CH}_2\text{CH}_2$ -,  
(2-F-phenyl) $\text{CH}_2\text{CH}_2$ -, (3-F-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(4-F-phenyl) $\text{CH}_2\text{CH}_2$ -, (2-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
20 (3-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -, (4-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(2,3-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,4-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(2,5-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,6-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(3,4-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (3,5-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(2,3-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,4-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
25 (2,5-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,6-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(3,4-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -, (3,5-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(3-F-4-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -, (3-F-5-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
4-piperidinyl- $\text{CH}_2\text{CH}_2$ -, phenyl- $\text{CH}_2\text{CH}_2\text{CF}_2$ -,  
phenyl- $\text{CH}_2\text{CH}(\text{OH})$ -, imidazolyl- $\text{CH}_2\text{CH}(\text{OH})$ -, or  
30 phenyl- $\text{CH}_2\text{OCH}_2$ -;

Ring C is selected from:



35

Ring B is selected from:




5

wherein each benzo fused ring is substituted with 0-1  $R^{13}$ ;

10 W is a bond or  $-CH_2-$ ;

X is a bond;



15

Y is a bond,  $-C(=O)-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$ ,  $-S(=O)_2-$ ,  $-NH-$ , or  $-N(CH_3)-$ ,

20

Z is phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl, 2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl, 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl, 2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl,

25

3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl,  
3-F-5-Cl-phenyl, 3-Cl-4-F-phenyl, 2-MeO-phenyl,  
3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl,  
4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl,  
5 2-CF<sub>3</sub>O-phenyl, 3-CF<sub>3</sub>O-phenyl, 4-CF<sub>3</sub>O-phenyl, furanyl,  
thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl,  
4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl,  
1-benzimidazolyl, cyclopropyl, cyclobutyl,  
cyclopentyl, cyclohexyl, morpholino, N-piperinyl,  
10 phenyl-CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-,  
(4-F-phenyl)CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>-,  
(2,6-diF-phenyl)CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>-,  
15 (3,5-diF-phenyl)CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>-,  
(3-F-5-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>-,  
20 (2-MeO-phenyl)CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>-,  
4-MeS-phenyl)CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
25 (3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(furanyl)CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>-, (1-imidazolyl)CH<sub>2</sub>-,  
(oxazolyl)CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>-,  
30 (1-benzimidazolyl)CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>-,  
(cyclohexyl)CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>-,  
(N-piperidinyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
(phenyl)<sub>2</sub>CHCH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
35 (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,



(2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 5 (2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 10 (3-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (furanyl)CH<sub>2</sub>CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 15 (2-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (imidazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (oxazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (benzimidazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 20 (cyclohexyl)CH<sub>2</sub>CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>CH<sub>2</sub>-, or  
 (N-pipridinyl)CH<sub>2</sub>CH<sub>2</sub>-;

R<sup>10</sup> is H, methyl, ethyl, phenyl, benzyl, phenethyl,  
 4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 25 4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-CH<sub>3</sub>-phenyl, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-CF<sub>3</sub>-phenyl, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>-, or  
 (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-;

30 R<sup>11</sup>, at each occurrence, is independently selected from  
 H, =O, methyl, ethyl, phenyl, benzyl, phenethyl,  
 4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 3-F-phenyl, (3-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 2-F-phenyl, (2-F-phenyl)CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 35 4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 3-Cl-phenyl, (3-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-CH<sub>3</sub>-phenyl, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,

3-CH<sub>3</sub>-phenyl, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-CF<sub>3</sub>-phenyl, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
cyclopentyl, pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl;

5 R<sup>13</sup>, at each occurrence, is independently selected from  
H, F, Cl, OH, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, and -CF<sub>3</sub>; and

R<sup>20</sup> is H.

10 In another preferred embodiment the present invention  
provides a compound of Formula (I), wherein:

R<sup>3</sup> is -(CR<sup>7</sup>R<sup>7a</sup>)<sub>n</sub>-R<sup>4</sup>,  
-(CR<sup>7</sup>R<sup>7a</sup>)<sub>1</sub>-S-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>,  
15 -(CR<sup>7</sup>R<sup>7a</sup>)<sub>1</sub>-O-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>, or  
-(CR<sup>7</sup>R<sup>7a</sup>)<sub>1</sub>-N(R<sup>7b</sup>)-(CR<sup>7</sup>R<sup>7a</sup>)<sub>m</sub>-R<sup>4</sup>;

n is 0, 1, or 2;

20 m is 0, 1, or 2;

l is 1 or 2;

25 Ring C is a 3 to 8 membered carbocycle substituted with 0-4  
R<sup>21</sup>; optionally, the carbocycle contains a heteroatom  
selected from -O-, and -N(R<sup>20</sup>)-;

R<sup>4</sup> is H, OH, OR<sup>14a</sup>,

30 C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, or  
5 to 10 membered heterocycle containing 1 to 4  
35 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from is  
H, F, Cl, Br, I, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
5 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

10

R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub>  
haloalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

15

R<sup>6</sup> is H, methyl, or ethyl;

R<sup>7</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, phenyl and C<sub>1</sub>-C<sub>4</sub>  
20 alkyl;

R<sup>7a</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, and C<sub>1</sub>-C<sub>4</sub> alkyl;

25 R<sup>7b</sup> is independently selected from H, methyl, ethyl,  
propyl, and butyl;

Ring B is a 7 membered lactam,  
wherein the lactam is saturated, partially saturated  
30 or unsaturated;  
wherein each additional lactam carbon is substituted  
with 0-2 R<sup>11</sup>; and,  
optionally, the lactam contains a heteroatom selected  
from, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N=, -NH-, and -  
35 N(R<sup>10</sup>)-;

R<sup>10</sup> is H, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>,

$S(=O)_2NR^{15}R^{19}$ ,  $S(=O)_2R^{17}$ ;

$C_1-C_6$  alkyl optionally substituted with 0-2  $R^{10a}$ ;

$C_6-C_{10}$  aryl substituted with 0-4  $R^{10b}$ ;

$C_3-C_{10}$  carbocycle substituted with 0-3  $R^{10b}$ ; or

5     5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $R^{10b}$ ;

10      $R^{10a}$ , at each occurrence, is independently selected from H,  
 $C_1-C_6$  alkyl,  $OR^{14}$ , Cl, F, Br, I, =O, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  
 $CF_3$ , phenyl substituted with 0-4  $R^{10b}$ ; or 5 to 10  
membered heterocycle containing 1 to 4 heteroatoms  
selected from nitrogen, oxygen, and sulphur, wherein  
15     said 5 to 10 membered heterocycle is substituted with  
0-3  $R^{10b}$ ;

$R^{10b}$ , at each occurrence, is independently selected from H,  
OH,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxy, Cl, F, Br, I, CN,  $NO_2$ ,  
20      $NR^{15}R^{16}$ , or  $CF_3$ ;

$R^{11}$ , at each occurrence, is independently selected from  
H,  $C_1-C_4$  alkoxy, Cl, F, Br, I, =O, CN,  $NO_2$ ,  $NR^{18}R^{19}$ ,  
 $C(=O)R^{17}$ ,  $C(=O)OR^{17}$ ,  $C(=O)NR^{18}R^{19}$ ,  $S(=O)_2NR^{18}R^{19}$ ,  $CF_3$ ;  
25      $C_1-C_6$  alkyl optionally substituted with 0-3  $R^{11a}$ ;  
 $C_6-C_{10}$  aryl substituted with 0-3  $R^{11b}$ ;  
 $C_3-C_{10}$  carbocycle substituted with 0-3  $R^{11b}$ ; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
30     sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $R^{11b}$ ;

$R^{11a}$ , at each occurrence, is independently selected from H,  
 $C_1-C_6$  alkyl,  $OR^{14}$ , Cl, F, Br, I, =O, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  
35      $CF_3$ , or phenyl substituted with 0-3  $R^{11b}$ ;

$R^{11b}$ , at each occurrence, is independently selected from

H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

5 additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-3 R<sup>13</sup>;

10 additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-3 R<sup>13</sup>;

15 additionally, two R<sup>11</sup> substituents on the same or adjacent carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>13</sup>;

20 W is -(CR<sup>8</sup>R<sup>8a</sup>)<sub>p</sub>-;

p is 0, 1, or 2;

25 R<sup>8</sup> and R<sup>8a</sup>, at each occurrence, are independently selected from H, F, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>2</sub>-C<sub>3</sub> alkenyl, C<sub>2</sub>-C<sub>3</sub> alkynyl and C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

X is a bond;  
30 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>Xb</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-2 R<sup>Xb</sup>; or  
5 to 10 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;

35 R<sup>Xb</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

Y is a bond or  $-(CR^9R^{9a})_t-V-(CR^9R^{9a})_u-$ ;

t is 0, 1, or 2;

5 u is 0, 1, or 2;

$R^9$  and  $R^{9a}$ , at each occurrence, are independently selected from H, F,  $C_1$ - $C_4$  alkyl or  $C_3$ - $C_6$  cycloalkyl;

10 V is a bond,  $-C(=O)-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$ ,  $-S(=O)_2-$ ,  $-N(R^{19})-$ ,  $-C(=O)NR^{19b}-$ ,  $-NR^{19b}C(=O)-$ ,  $-NR^{19b}S(=O)_2-$ ,  $-S(=O)_2NR^{19b}-$ ,  $-NR^{19b}S(=O)-$ , or  $-S(=O)NR^{19b}-$ ;

Z is H;

15  $C_1$ - $C_3$  alkyl substituted with 1-2  $R^{12}$ ;  
 $C_6$ - $C_{10}$  aryl substituted with 0-4  $R^{12b}$ ;  
 $C_3$ - $C_{10}$  carbocycle substituted with 0-4  $R^{12b}$ ; or  
 5 to 10 membered heterocycle substituted with 0-3  $R^{12b}$ ;

20

$R^{12a}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  $S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  haloalkyl, and  $C_1$ - $C_4$  haloalkoxy;

25

$R^{13}$ , at each occurrence, is independently selected from H, OH,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ , and  $CF_3$ ;

30  $R^{14}$  is H, phenyl, benzyl,  $C_1$ - $C_6$  alkyl, or  $C_2$ - $C_6$  alkoxyalkyl;

$R^{14a}$  is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;

35  $R^{15}$ , at each occurrence, is independently selected from H,  $C_1$ - $C_6$  alkyl, benzyl, phenethyl,  $(C_1$ - $C_6$  alkyl)- $C(=O)-$ , and  $(C_1$ - $C_6$  alkyl)- $S(=O)_2-$ ;

R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

5 R<sup>17</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl,  
aryl substituted by 0-4 R<sup>17a</sup>, or  
-CH<sub>2</sub>-aryl substituted by 0-4 R<sup>17a</sup>;

10 R<sup>17a</sup> is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
propoxy, butoxy, -OH, F, Cl, Br, I, CF<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>,  
S(O)CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, -NH<sub>2</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

15 R<sup>18</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-; and

R<sup>19</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-

20 R<sup>20</sup> is H or C(=O)R<sup>17</sup>;

25 R<sup>21</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>,  
C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>21a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>21b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>21b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
30 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>21b</sup>;

35 R<sup>21a</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>,  
NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>;  
phenyl substituted with 0-3 R<sup>21b</sup>;

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>21b</sup>; and  
 5 to 6 membered heterocycle containing 1 to 3  
 heteroatoms selected from nitrogen, oxygen, and  
 sulphur, wherein said 5 to 6 membered heterocycle  
 is substituted with 0-3 R<sup>21b</sup>;

R<sup>21b</sup>, at each occurrence, is independently selected from H,  
 OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
 S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,


C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

additionally, two R<sup>21</sup> substituents on the same or adjacent  
 carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub>  
 carbocycle substituted with 0-3 R<sup>23</sup>;

additionally, two R<sup>21</sup> substituents on adjacent atoms may be  
 combined to form a benzo fused radical; wherein said  
 benzo fused radical is substituted with 0-4 R<sup>23</sup>; and

R<sup>23</sup>, at each occurrence, is independently selected from  
 H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>,  
 NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>.

[6] In another preferred embodiment the present  
 invention provides a compound of Formula (I):



or a stereoisomer, pharmaceutically acceptable salt or  
 prodrug thereof, wherein:



L is  $-\text{NR}^{26}\text{C}(=\text{O})-$ ,  $-\text{C}(=\text{O})\text{NR}^{26}-$ ,  $-\text{NR}^{26}\text{C}(=\text{O})\text{O}-$ ,  $-\text{OC}(=\text{O})\text{NR}^{26}$ , or  $-\text{NR}^{26}\text{C}(=\text{O})\text{NR}^{26}-$ ;

5  $\text{R}^3$  is  $-(\text{CR}^7\text{R}^{7a})_n-\text{R}^4$ ,  
 $-(\text{CR}^7\text{R}^{7a})_1-\text{S}-\text{R}^4$ ,  
 $-(\text{CR}^7\text{R}^{7a})_1-\text{O}-\text{R}^4$ ;  
 $-(\text{CR}^7\text{R}^{7a})_1-\text{N}(\text{R}^{7b})-\text{R}^4$ ,  
 $-(\text{CR}^7\text{R}^{7a})_1-\text{S}(=\text{O})-\text{R}^4$ , or  
 $-(\text{CR}^7\text{R}^{7a})_1-\text{S}(=\text{O})_2-\text{R}^4$ ;

10

n is 0, 1 or 2;

l is 1 or 2;

15  $\text{R}^4$  is H,  
 $\text{C}_1-\text{C}_8$  alkyl substituted with 0-3  $\text{R}^{4a}$ ,  
 $\text{C}_2-\text{C}_8$  alkenyl substituted with 0-3  $\text{R}^{4a}$ ,  
 $\text{C}_2-\text{C}_8$  alkynyl substituted with 0-3  $\text{R}^{4a}$ ,  
 $\text{C}_3-\text{C}_{10}$  carbocycle substituted with 0-3  $\text{R}^{4b}$ ,  
20  $\text{C}_6-\text{C}_{10}$  aryl substituted with 0-3  $\text{R}^{4b}$ , or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $\text{R}^{4b}$ ;

25

$\text{R}^{4a}$ , at each occurrence, is independently selected from  
H, OH, F, Cl, Br, I,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ ,  
 $\text{C}_3-\text{C}_{10}$  carbocycle substituted with 0-3  $\text{R}^{4b}$ ,  
 $\text{C}_6-\text{C}_{10}$  aryl substituted with 0-3  $\text{R}^{4b}$ , and

30

5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $\text{R}^{4b}$ ;

35  $\text{R}^{4b}$ , at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN,  $\text{NO}_2$ ,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ , acetyl,  $\text{SCH}_3$ ,  
 $\text{S}(=\text{O})\text{CH}_3$ ,  $\text{S}(=\text{O})_2\text{CH}_3$ ,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

Ring C is a 3-8 membered carbocycle;

5        wherein said 3-8 membered carbocycle is saturated or  
         partially unsaturated;  
         wherein said 3-8 membered carbocycle is substituted  
         with 0-4 R<sup>21</sup>; and  
         optionally, the carbocycle contains a heteroatom  
10        selected from -O- and -N(R<sup>20</sup>)-;

         additionally, two R<sup>21</sup> substituents on adjacent atoms may be  
         combined to form a benzo fused radical; wherein said  
         benzo fused radical is substituted with 0-4 R<sup>23</sup>; (.

15

         additionally, two R<sup>21</sup> substituents on adjacent atoms may be  
         combined to form a 5 to 6 membered heteroaryl fused  
         radical, wherein said 5 to 6 membered heteroaryl fused  
         radical comprises 1 or 2 heteroatoms selected from N,  
20        O, and S; wherein said 5 to 6 membered heteroaryl  
         fused radical is substituted with 0-3 R<sup>23</sup>;

20

         additionally, two R<sup>21</sup> substituents on the same or adjacent  
         carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub>  
25        carbocycle substituted with 0-3 R<sup>23</sup>;

25

R<sup>21</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, NR<sup>15</sup>R<sup>16</sup>, OR<sup>14a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>6</sub>  
30        alkenyl, alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
C<sub>3</sub>-C<sub>6</sub> carbocycle, phenyl, and a  
5 to 6 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
35        sulphur;

35

R<sup>6</sup> is H, methyl, or ethyl;


R<sup>7</sup>, at each occurrence, is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>7a</sup>, at each occurrence, is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;

5

R<sup>7b</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

Ring B is selected from:



15

R<sup>10</sup> is H, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>,  
S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>R<sup>17</sup>;

C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>10a</sup>;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>10b</sup>;

20

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>10b</sup>; or

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle

is substituted with 0-3 R<sup>10b</sup>;

25

R<sup>10a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or aryl substituted with 0-4 R<sup>10b</sup>;

5 R<sup>10b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10 R<sup>11</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>11a</sup>;

15 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>11b</sup>; C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;

20 R<sup>11a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>;

phenyl substituted with 0-3 R<sup>11b</sup>;

25 C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>11b</sup>; and 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;

30 R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

35 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

W is a bond or -(CH<sub>2</sub>)<sub>p</sub>-;

p is 1 or 2;

x is a bond;

- 5 phenyl substituted with 0-2  $R^{Xb}$ ;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-2  $R^{Xb}$ ; or  
5 to 6 membered heterocycle substituted with 0-2  $R^{Xb}$ ;

10  $R^{Xb}$ , at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub>  
haloalkyl, C<sub>1</sub>-C<sub>3</sub> haloalkoxy, and C<sub>1</sub>-C<sub>3</sub> halothioalkoxy;

15 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N(R<sup>19</sup>)-  
, -C(=O)NR<sup>19b</sup>-, -NR<sup>19b</sup>C(=O)-, -NR<sup>19b</sup>S(=O)<sub>2</sub>-,  
-S(=O)<sub>2</sub>NR<sup>19b</sup>-, -NR<sup>19b</sup>S(=O)-, -S(=O)NR<sup>19b</sup>-, -C(=O)O-, or  
-OC(=O)-;

Z is H;

- 20 C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
25 5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

30 R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
35 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

5

R<sup>12b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10

R<sup>13</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

15

R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, or C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

20

R<sup>15</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

25

R<sup>16</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

30

R<sup>17</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, aryl substituted by 0-4 R<sup>17a</sup>, or -CH<sub>2</sub>-aryl substituted by 0-4 R<sup>17a</sup>;

35

R<sup>17a</sup> is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, -OH, F, Cl, Br, I, CF<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>, S(O)CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, -NH<sub>2</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

R<sup>18</sup>, at each occurrence, is independently selected from

H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

5 R<sup>19</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, phenyl, benzyl,  
and phenethyl;


R<sup>19b</sup>, at each occurrence, is independently is H or C<sub>1</sub>-C<sub>4</sub>  
alkyl;

10 R<sup>20</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, or C(=O)OR<sup>17</sup>;

R<sup>23</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
15 NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>; and

R<sup>26</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.


[7] In another preferred embodiment the present  
20 invention provides a compound of Formula (Ia):



25 or a stereoisomer, pharmaceutically acceptable salt or  
prodrug thereof, wherein:

L is -NR<sup>26</sup>C(=O)-, -C(=O)NR<sup>26</sup>-, -NR<sup>26</sup>C(=O)O-, -OC(=O)NR<sup>26</sup>, or  
-NR<sup>26</sup>C(=O)NR<sup>26</sup>-;

30 R<sup>3</sup> is -(CHR<sup>7</sup>)<sub>n</sub>-R<sup>4</sup>,  
-(CHR<sup>7</sup>)<sub>1</sub>-S-R<sup>4</sup>,  
-(CHR<sup>7</sup>)<sub>1</sub>-O-R<sup>4</sup>;  
-(CR<sup>7</sup>R<sup>7a</sup>)<sub>1</sub>-N(R<sup>7b</sup>)-R<sup>4</sup>,



n is 0, 1 or 2;

5

l is 1 or 2;

R<sup>4</sup> is H,

10

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>8</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>8</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

15

R<sup>4a</sup>, at each occurrence, is independently selected from  
20 H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

25

R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
30 S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

30

Ring C is a 3-8 membered carbocycle;  
35 wherein said 3-8 membered carbocycle is saturated or  
partially unsaturated;



wherein said 3-8 membered carbocycle is substituted with 0-4  $R^{21}$ ;  
 optionally, the carbocycle contains a heteroatom selected from -O-, and -N( $R^{20}$ )-;

- 5 additionally, two  $R^{21}$  substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-4  $R^{23}$ ;
- 10 additionally, two  $R^{21}$  substituents on the same or adjacent carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3  $R^{23}$ ;


15  $R^{21}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, NR<sup>15</sup>R<sup>16</sup>, OR<sup>14a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
 20 C<sub>3</sub>-C<sub>6</sub> carbocycle, phenyl, and a 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur;


25  $R^7$ , at each occurrence, is independently H, methyl, or ethyl;

$R^{7b}$  is H, methyl, or ethyl;

Ring B is selected from:

30





R<sup>11</sup>, at each occurrence, is independently selected from  
 H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>,  
 5 C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
 C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>11a</sup>;  
 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>11b</sup>;  
 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and  
 5 to 10 membered heterocycle containing 1 to 4  
 10 heteroatoms selected from nitrogen, oxygen, and  
 sulphur, wherein said 5 to 10 membered heterocycle  
 is substituted with 0-3 R<sup>11b</sup>;

R<sup>11a</sup>, at each occurrence, is independently selected from  
 15 H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>,  
 NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>;  
 phenyl substituted with 0-3 R<sup>11b</sup>;  
 C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>11b</sup>; and  
 5 to 6 membered heterocycle containing 1 to 4  
 20 heteroatoms selected from nitrogen, oxygen, and  
 sulphur, wherein said 5 to 6 membered heterocycle  
 is substituted with 0-3 R<sup>11b</sup>;

R<sup>11b</sup>, at each occurrence, is independently selected from H,  
 25 OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
 S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

30 W is a bond or -(CH<sub>2</sub>)<sub>p</sub>-;

p is 1 or 2;

X is a bond;

35 phenyl substituted with 0-2 R<sup>Xb</sup>;

C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-2 R<sup>Xb</sup>; or  
5 to 6 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;

5 R<sup>Xb</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub>  
haloalkyl, C<sub>1</sub>-C<sub>3</sub> haloalkoxy, and C<sub>1</sub>-C<sub>3</sub> halothioalkoxy;

10 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N(R<sup>19</sup>)-  
, -C(=O)NR<sup>19b</sup>-, -NR<sup>19b</sup>C(=O)-, -NR<sup>19b</sup>S(=O)<sub>2</sub>-,  
-S(=O)<sub>2</sub>NR<sup>19b</sup>-, -NR<sup>19b</sup>S(=O)-, -S(=O)NR<sup>19b</sup>-, -C(=O)O-, or  
-OC(=O)-;

15 Z is H;  
C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
20 5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

25 R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
30 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
35 is substituted with 0-3 R<sup>12b</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from

H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

5

R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

10 R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, or  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

15 R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-,  
and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

20 R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

25 R<sup>17</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl,  
aryl substituted by 0-4 R<sup>17a</sup>, or  
-CH<sub>2</sub>-aryl substituted by 0-4 R<sup>17a</sup>;

30 R<sup>17a</sup> is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
propoxy, butoxy, -OH, F, Cl, Br, I, CF<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>,  
S(O)CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, -NH<sub>2</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

35 R<sup>18</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;


R<sup>19</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, phenyl, benzyl,  
phenethyl;

$R^{20}$  is H,  $C_1$ - $C_4$  alkyl, or  $C(=O)OR^{17}$ ;

5  $R^{23}$ , at each occurrence, is independently selected from H, OH,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ , and  $CF_3$ ; and

$R^{26}$  is H or  $C_1$ - $C_4$  alkyl.

10 [8] In another preferred embodiment the present invention provides a compound of Formula (Ic):



15 or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, wherein:

L is  $-NHC(=O)-$ ,  $-C(=O)NH-$ , or  $-OC(=O)NH-$ ;

20  $R^3$  is  $-(CH_2)_n-R^4$ ,  
 $-(CH_2)_1-S-R^4$ ,  
 $-(CH_2)_1-O-R^4$ , or  
 $-(CH_2)_1-N(R^{7b})-R^4$ ;

25 n is 0, 1 or 2;

l is 1 or 2;

30  $R^4$  is  $C_1$ - $C_8$  alkyl substituted with 0-3  $R^{4a}$ ,  
 $C_2$ - $C_8$  alkenyl substituted with 0-3  $R^{4a}$ ,  
 $C_2$ - $C_8$  alkynyl substituted with 0-3  $R^{4a}$ ,  
 $C_3$ - $C_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
5 is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from  
H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
10 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

15 R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
20 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>7b</sup> is H, methyl, or ethyl;

Ring C is a 3-8 membered carbocycle;  
25 wherein said 3-8 membered carbocycle is saturated or  
partially unsaturated;  
wherein said 3-8 membered carbocycle is substituted  
with 0-3 R<sup>21</sup>;  
optionally, the carbocycle contains a heteroatom  
30 selected from -O-, and -N(R<sup>20</sup>)-;

R<sup>21</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, NR<sup>15</sup>R<sup>16</sup>, OR<sup>14a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub>  
35 alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

W is a bond,  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$ ;

X is a bond;

phenyl substituted with 0-2  $\text{R}^{\text{Xb}}$ ;  
5  $\text{C}_3$ - $\text{C}_6$  cycloalkyl substituted with 0-2  $\text{R}^{\text{Xb}}$ ; or  
5 to 6 membered heterocycle substituted with 0-2  $\text{R}^{\text{Xb}}$ ;

$\text{R}^{\text{Xb}}$ , at each occurrence, is independently selected from H,  
OH, Cl, F,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ , acetyl,  $\text{SCH}_3$ ,  $\text{S}(=\text{O})\text{CH}_3$ ,  
10  $\text{S}(=\text{O})_2\text{CH}_3$ ,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_3$  alkoxy,  $\text{C}_1$ - $\text{C}_2$  haloalkyl,  
and  $\text{C}_1$ - $\text{C}_2$  haloalkoxy;

Y is a bond,  $-\text{C}(=\text{O})-$ ,  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{S}(=\text{O})-$ ,  $-\text{S}(=\text{O})_2-$ ,  
 $-\text{N}(\text{R}^{19})-$ ,  $-\text{C}(=\text{O})\text{NR}^{19\text{b}}-$ ,  $-\text{NR}^{19\text{b}}\text{C}(=\text{O})-$ ,  $-\text{NR}^{19\text{b}}\text{S}(=\text{O})_2-$ ,  
15  $-\text{S}(=\text{O})_2\text{NR}^{19\text{b}}-$ ,  $-\text{NR}^{19\text{b}}\text{S}(=\text{O})-$ ,  $-\text{S}(=\text{O})\text{NR}^{19\text{b}}-$ ,  $-\text{C}(=\text{O})\text{O}-$ ,  
or  $-\text{OC}(=\text{O})-$ ;

Z is H;

$\text{C}_1$ - $\text{C}_8$  alkyl substituted with 0-3  $\text{R}^{12\text{a}}$ ;  
20  $\text{C}_2$ - $\text{C}_6$  alkenyl substituted with 0-3  $\text{R}^{12\text{a}}$ ;  
 $\text{C}_2$ - $\text{C}_6$  alkynyl substituted with 0-3  $\text{R}^{12\text{a}}$ ;  
 $\text{C}_6$ - $\text{C}_{10}$  aryl substituted with 0-4  $\text{R}^{12\text{b}}$ ;  
 $\text{C}_3$ - $\text{C}_{10}$  carbocycle substituted with 0-4  $\text{R}^{12\text{b}}$ ; or  
5 to 10 membered heterocycle containing 1 to 4  
25 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $\text{R}^{12\text{b}}$ ;

$\text{R}^{12\text{a}}$ , at each occurrence, is independently selected from  
30 H, OH, Cl, F, Br, I, CN,  $\text{NO}_2$ ,  $\text{NR}^{15}\text{R}^{16}$ ,  $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$ ,  
 $\text{CF}_3$ , acetyl,  $\text{SCH}_3$ ,  $\text{S}(=\text{O})\text{CH}_3$ ,  $\text{S}(=\text{O})_2\text{CH}_3$ ,  
 $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_1$ - $\text{C}_4$  alkoxy,  $\text{C}_1$ - $\text{C}_4$  haloalkyl,  
 $\text{C}_1$ - $\text{C}_4$  haloalkoxy,  $\text{C}_1$ - $\text{C}_4$  haloalkyl-S-,  
 $\text{C}_6$ - $\text{C}_{10}$  aryl substituted with 0-4  $\text{R}^{12\text{b}}$ ;  
35  $\text{C}_3$ - $\text{C}_{10}$  carbocycle substituted with 0-4  $\text{R}^{12\text{b}}$ ; and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

5 R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10 R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

15 R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-,  
and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

20 R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-; and

R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

25

[9] In another preferred embodiment the present invention provides a compound of Formula (Ic) wherein:

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

30

R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;

R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,  
35 C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or



5 to 6 membered heterocycle containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>4b</sup>;

5

R<sup>4a</sup>, at each occurrence, is independently selected from H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>, phenyl substituted with 0-3 R<sup>4b</sup>, and

10

5 to 6 membered heterocycle containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>4b</sup>;

15

R<sup>4b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

20

Ring C is a 3-6 membered carbocycle;

wherein said 3-6 membered carbocycle is saturated or partially unsaturated;

wherein said 3-6 membered carbocycle is substituted

25

with 0-2 R<sup>21</sup>;

optionally, the carbocycle contains a heteroatom selected from -O-, and -N(R<sup>20</sup>)-;

30

R<sup>21</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, methyl, ethyl, methoxy, ethoxy, allyl, -OCF<sub>3</sub>, and -SCF<sub>3</sub>;

W is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-;

35 X is a bond;

phenyl substituted with 0-1 R<sup>Xb</sup>;

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-1 R<sup>Xb</sup>; or

5 to 6 membered heterocycle substituted with 0-1 R<sup>Xb</sup>;

R<sup>Xb</sup> is selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl,  
5 methoxy, ethoxy, propoxy, and -OCF<sub>3</sub>;

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-,  
-N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;

10 Z is H;

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;

C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

15 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or

5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

20

R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

25 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

30 sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
35 SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>13</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

5

R<sup>15</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, and benzyl;

10 R<sup>16</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl, methyl-C(=O)-, ethyl-C(=O)-, methyl-S(=O)<sub>2</sub>-, ethyl-S(=O)<sub>2</sub>-, and propyl-S(=O)<sub>2</sub>-; and

R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

15

[10] In another preferred embodiment the present invention provides a compound of Formula (Ic) wherein:

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

20

R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;

R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>, or  
25 C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>;

25

R<sup>4a</sup>, at each occurrence, is independently selected from is H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,

30

C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, and

5 to 6 membered heterocycle containing 1 to 3


heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>4b</sup>; wherein said 5 to 6 membered heterocycle is selected from pyridinyl,  
35 pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl,

35

pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

5  $R^{4b}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10 Ring C is a 3-6 membered carbocycle selected from:



wherein said 3-6 membered carbocycle is substituted with 0-1 R<sup>21</sup>;

15

R<sup>21</sup> is selected from H, OH, Cl, F, CN, CF<sub>3</sub>, methyl, ethyl, methoxy, ethoxy, allyl, and -OCF<sub>3</sub>;

W is a bond or -CH<sub>2</sub>-;

20

X is a bond, phenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or 5 to 6 membered heterocycle;

25

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, -N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;

Z is H;

30

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

5 R<sup>12a</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;  
phenyl substituted with 0-4 R<sup>12b</sup>;  
10 C<sub>3</sub>-6 carbocycle substituted with 0-4 R<sup>12b</sup>; and  
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

15 R<sup>12b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;  
20

R<sup>13</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, Cl, F, Br, CN, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

25 R<sup>15</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl; and


30 R<sup>16</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, benzyl, and phenethyl; and

R<sup>20</sup> is H, methyl, or ethyl.

35 [11] In another preferred embodiment the present invention provides a compound of Formula (Ic) wherein:

L is  $\text{-NHC(=O)-}$ ,  $\text{-C(=O)NH-}$ , or  $\text{-OC(=O)NH-}$ ;

Ring C is selected from:




$R^3$  is  $\text{-CH}_3$ ,  $\text{-CH}_2\text{CH}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  
 $\text{-CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}_2(\text{CH}_3)_2$ ,  $\text{-CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ ,  $\text{-CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 $\text{-CH}_2\text{C}(\text{CH}_3)_3$ ,  $\text{-CF}_3$ ,  $\text{-CH}_2\text{CF}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CF}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_2\text{CF}_3$ ,  
10  $\text{-CH}(\text{OH})\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}(\text{OH})\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}(\text{NH}_2)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 $\text{-CH}_2\text{CH}_2\text{OCH}_3$ ,  $\text{-CH}_2\text{OCH}_2\text{CH}_3$ ,  $\text{-CF}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 $\text{-CH}(\text{NHCH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}(\text{NHSO}_2\text{CH}_2\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
cyclohexyl-, cyclopentyl-, cyclopropyl- $\text{CH}_2$ -,  
cyclobutyl- $\text{CH}_2$ -, cyclopentyl- $\text{CH}_2$ -, cyclohexyl- $\text{CH}_2$ -,  
15 cyclopropyl- $\text{CH}_2\text{CH}_2$ -, cyclobutyl- $\text{CH}_2\text{CH}_2$ -,  
cyclopentyl- $\text{CH}_2\text{CH}_2$ -, cyclohexyl- $\text{CH}(\text{OH})$ -,  
cyclohexyl- $\text{CH}_2\text{CH}_2$ -, 1- $\text{NH}_2$ -cyclopentyl, phenyl- $\text{CH}_2$ -,  
(2-F-phenyl) $\text{CH}_2$ -, (3-F-phenyl) $\text{CH}_2$ -, (4-F-phenyl) $\text{CH}_2$ -,  
(2-Cl-phenyl) $\text{CH}_2$ -, (3-Cl-phenyl) $\text{CH}_2$ -, (4-Cl-phenyl) $\text{CH}_2$ -,  
20 (2,3-diF-phenyl) $\text{CH}_2$ -, (2,4-diF-phenyl) $\text{CH}_2$ -,  
(2,5-diF-phenyl) $\text{CH}_2$ -, (2,6-diF-phenyl) $\text{CH}_2$ -,  
(3,4-diF-phenyl) $\text{CH}_2$ -, (3,5-diF-phenyl) $\text{CH}_2$ -,  
(2,3-diCl-phenyl) $\text{CH}_2$ -, (2,4-diCl-phenyl) $\text{CH}_2$ -,  
(2,5-diCl-phenyl) $\text{CH}_2$ -, (2,6-diCl-phenyl) $\text{CH}_2$ -,  
25 (3,4-diCl-phenyl) $\text{CH}_2$ -, (3,5-diCl-phenyl) $\text{CH}_2$ -,  
(3-F-4-Cl-phenyl) $\text{CH}_2$ -, (3-F-5-Cl-phenyl) $\text{CH}_2$ -,  
(3-Cl-4-F-phenyl) $\text{CH}_2$ -, phenyl- $\text{CH}_2\text{CH}_2$ -,  
(2-F-phenyl) $\text{CH}_2\text{CH}_2$ -, (3-F-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(4-F-phenyl) $\text{CH}_2\text{CH}_2$ -, (2-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
30 (3-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -, (4-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(2,3-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,4-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(2,5-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,6-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(3,4-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (3,5-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(2,3-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,4-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
35 (2,5-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,6-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -,

(3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-piperidinyl-CH<sub>2</sub>CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>CF<sub>2</sub>-,  
 phenyl-CH<sub>2</sub>CH(OH)-, imidazolyl-CH<sub>2</sub>CH(OH)-, or  
 5 phenyl-CH<sub>2</sub>OCH<sub>2</sub>-;

W is a bond or -CH<sub>2</sub>-;

X is a bond;

10



15 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, or  
 -N(CH<sub>3</sub>)-,

Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl,  
 s-butyl, t-butyl, allyl, phenyl, 2-F-phenyl,  
 20 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl,  
 4-Cl-phenyl, 2,3-diF-phenyl,  
 2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl,  
 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl,  
 2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl,  
 25 3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl,  
 3-F-5-Cl-phenyl, 3-Cl-4-F-phenyl, 2-MeO-phenyl,  
 3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl,  
 4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl,  
 2-CF<sub>3</sub>O-phenyl, 3-CF<sub>3</sub>O-phenyl, 4-CF<sub>3</sub>O-phenyl, furanyl,  
 30 thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl,  
 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl,  
 1-benzimidazolyl, cyclopropyl, cyclobutyl,  
 cyclopentyl, cyclohexyl, morpholino, N-piperinyl,  
 phenyl-CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-,

- (4-F-phenyl)CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>,  
(4-Cl-phenyl)CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>-,  
(2,6-diF-phenyl)CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>-,  
5 (3,5-diF-phenyl)CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>-,  
(3-F-5-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>-,  
10 (2-MeO-phenyl)CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>-,  
4-MeS-phenyl)CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
15 (3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(furanyl)CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>-, (1-imidazolyl)CH<sub>2</sub>-,  
(oxazolyl)CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>-,  
20 (1-benzimidazolyl)CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>-,  
(cyclohexyl)CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>-,  
(N-pipridinyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
(phenyl)<sub>2</sub>CHCH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
25 (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
30 (3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
35 (2-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,



(2-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (furanyl)CH<sub>2</sub>CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 5 (2-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (imidazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (oxazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (benzimidazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 10 (cyclohexyl)CH<sub>2</sub>CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>CH<sub>2</sub>-, or  
 (N-pipridinyl)CH<sub>2</sub>CH<sub>2</sub>-;



R<sup>13</sup>, at each occurrence, is independently selected from  
 H, F, Cl, OH, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, or -CF<sub>3</sub>.

15

R<sup>20</sup> is H, methyl, or ethyl.

[12] In another preferred embodiment the present  
 invention provides a compound of Formula (Id) and (Ie)

20



or a stereoisomer, pharmaceutically acceptable salt or  
 prodrug thereof, wherein:

25

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

R<sup>3</sup> is -(CH<sub>2</sub>)<sub>n</sub>-R<sup>4</sup>,  
 -(CH<sub>2</sub>)<sub>1</sub>-S-R<sup>4</sup>,  
 30 -(CH<sub>2</sub>)<sub>1</sub>-O-R<sup>4</sup>, or  
 -(CH<sub>2</sub>)<sub>1</sub>-N(R<sup>7b</sup>)-R<sup>4</sup>;

n is 0, 1 or 2;

1 is 1 or 2;

R<sup>4</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>4a</sup>,

5 C<sub>2</sub>-C<sub>8</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,

C<sub>2</sub>-C<sub>8</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, or

5 to 10 membered heterocycle containing 1 to 4

10 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from

15 H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, and

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

20 sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

R<sup>4b</sup>, at each occurrence, is independently selected from H,

OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,

25 S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>7b</sup> is H, methyl, or ethyl;

30

Ring C is a 3-8 membered carbocycle;

wherein said 3-8 membered carbocyclic moiety is  
saturated or partially saturated;

wherein said 3-8 membered carbocyclic moiety is

35 substituted with 0-3 R<sup>21</sup>;

optionally, the carbocycle contains a heteroatom  
selected from -O- and -N(R<sup>20</sup>)-;

R<sup>21</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, NR<sup>15</sup>R<sup>16</sup>, OR<sup>14a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>11</sup>, at each occurrence, is independently selected from H, =O, NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>; C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1 R<sup>11a</sup>; phenyl substituted with 0-3 R<sup>11b</sup>; C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and 5 to 7 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 7 membered heterocycle is substituted with 0-3 R<sup>11b</sup>; wherein said 5 to 7 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, homopiperidinyl, and tetrazolyl;

R<sup>11a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkyl, OR<sup>14</sup>, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl substituted with 0-3 R<sup>11b</sup>;

R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

W is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-;

X is a bond; phenyl substituted with 0-2 R<sup>Xb</sup>; C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-2 R<sup>Xb</sup>; or 5 to 6 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;

$R^{Xb}$ , at each occurrence, is independently selected from H, OH, Cl, F,  $NR^{15}R^{16}$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  $S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,  $C_1-C_4$  alkyl,  $C_1-C_3$  alkoxy,  $C_1-C_2$  haloalkyl, and  $C_1-C_2$  haloalkoxy;

Y is a bond,  $-C(=O)-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$ ,  $-S(=O)_2-$ ,  $-N(R^{19})-$ ,  $-C(=O)NR^{19b}-$ ,  $-NR^{19b}C(=O)-$ ,  $-NR^{19b}S(=O)_2-$ ,  $-S(=O)_2NR^{19b}-$ ,  $-NR^{19b}S(=O)-$ ,  $-S(=O)NR^{19b}-$ ,  $-C(=O)O-$ , or  $-OC(=O)-$ ;

Z is H;

$C_1-C_8$  alkyl substituted with 0-3  $R^{12a}$ ;  
 $C_2-C_6$  alkenyl substituted with 0-3  $R^{12a}$ ;  
 $C_2-C_6$  alkynyl substituted with 0-3  $R^{12a}$ ;  
 $C_6-C_{10}$  aryl substituted with 0-4  $R^{12b}$ ;  
 $C_3-C_{10}$  carbocycle substituted with 0-4  $R^{12b}$ ; or  
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3  $R^{12b}$ ;

$R^{12a}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $-C(=O)NR^{15}R^{16}$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  $S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxy,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  haloalkoxy,  $C_1-C_4$  haloalkyl-S-,  $C_6-C_{10}$  aryl substituted with 0-4  $R^{12b}$ ,  $C_3-C_{10}$  carbocycle substituted with 0-4  $R^{12b}$ ; and  
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3  $R^{12b}$ ;

$R^{12b}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  $S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

5 R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, or  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

10 R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-,  
15 and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

20 R<sup>18</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

25 R<sup>19</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, phenyl, benzyl,  
phenethyl; and

R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

30 [13] In another preferred embodiment the present  
invention provides a compound of Formula (Id) and (Ie)  
wherein:

35 L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;

R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,  
5 C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
10 is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from is  
H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
15 phenyl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

20 R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
25 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

Ring C is a 3-6 membered carbocycle;  
wherein said 3-6 membered carbocyclic moiety is  
saturated or partially unsaturated;  
30 wherein said 3-6 membered carbocyclic moiety is  
substituted with 0-2 R<sup>21</sup>;  
optionally, the carbocycle contains a heteroatom  
selected from -O- and -N(R<sup>20</sup>)-;

35 R<sup>21</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, methyl,  
ethyl, methoxy, ethoxy, allyl, -OCF<sub>3</sub>, and -SCF<sub>3</sub>;

- R<sup>11</sup>, at each occurrence, is independently selected from  
H, =O, NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1 R<sup>11a</sup>;  
5 phenyl substituted with 0-3 R<sup>11b</sup>;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and  
5 to 7 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 7 membered heterocycle  
10 is substituted with 0-3 R<sup>11b</sup>; wherein said 5 to 7  
membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl,  
thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,  
15 homopiperidinyl, and tetrazolyl;
- R<sup>11a</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
propoxy, phenoxy, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl  
20 substituted with 0-3 R<sup>11b</sup>;
- R<sup>11b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl,  
methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
25 haloalkoxy;
- W is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-;
- X is a bond;  
30 phenyl substituted with 0-1 R<sup>Xb</sup>;  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-1 R<sup>Xb</sup>; or  
5 to 6 membered heterocycle substituted with 0-1 R<sup>Xb</sup>;
- R<sup>Xb</sup> is selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
35 SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl,  
methoxy, ethoxy, propoxy, and -OCF<sub>3</sub>;

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-,  
-N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;

Z is H;

- 5 C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
10 5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

- 15 R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
20 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
25 is substituted with 0-3 R<sup>12b</sup>;

- R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
30 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

- R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
35 NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>2</sub>-C<sub>4</sub> alkoxyalkyl;



- R<sup>15</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, benzyl, and phenethyl;
- 5 R<sup>16</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl, methyl-C(=O)-, ethyl-C(=O)-, methyl-S(=O)<sub>2</sub>-, and ethyl-S(=O)<sub>2</sub>-;
- 10 R<sup>18</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl;
- R<sup>19</sup>, at each occurrence, is independently selected from
- 15 H, methyl, ethyl, propyl, and butyl;
- R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.


[14] In another preferred embodiment the present  
20 invention provides a compound of Formula (Id) and (Ie) wherein:

- L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;
- 25 R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;
- R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>, or  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>;
- 30 R<sup>4a</sup>, at each occurrence, is independently selected from is H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or
- 35 5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle

is substituted with 0-3  $R^{4b}$ ; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

$R^{4b}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  $S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  haloalkoxy, and  $C_1$ - $C_4$  haloalkyl-S-;

Ring C is a 3-6 membered carbocycle selected from:



wherein said 3-6 membered carbocycle is substituted with 0-1  $R^{21}$ ;

$R^{21}$  is selected from H, OH, Cl, F, CN,  $CF_3$ , methyl, ethyl, methoxy, ethoxy, allyl, and  $-OCF_3$ ;

$R^{11}$ , at each occurrence, is independently selected from H, =O,  $NR^{18}R^{19}$ ;

$C_1$ - $C_4$  alkyl optionally substituted with 0-1  $R^{11a}$ ; phenyl substituted with 0-3  $R^{11b}$ ;

5 to 7 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 7 membered heterocycle

is substituted with 0-3  $R^{11b}$ ; wherein said 5 to 7 membered heterocycle is selected from pyridinyl,

pyrimidinyl, triazinyl, furanyl, thienyl,

thiazolyl, pyrrolyl, piperazinyl, piperidinyl,

pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,

homopiperidinyl, and tetrazolyl;

R<sup>11a</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, phenoxy, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl substituted with 0-3 R<sup>11b</sup>;

R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

W is a bond or -CH<sub>2</sub>-;

X is a bond, phenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or 5 to 6 membered heterocycle;

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, -N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;

Z is H;  
C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

R<sup>12a</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;  
phenyl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-6 carbocycle substituted with 0-4 R<sup>12b</sup>; or

5 to 6 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

5

R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy,  
ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;

10

R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
Cl, F, Br, CN, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

15

R<sup>14</sup> is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;

R<sup>15</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, and butyl; and

20

R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, benzyl, and  
phenethyl.

25

R<sup>18</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and  
phenethyl;

30

R<sup>19</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, and butyl; and


R<sup>20</sup> is H, methyl, or ethyl.

[15] In another preferred embodiment the present  
invention provides a compound of Formula (Id) and (Ie)  
wherein:

35

L is  $\text{-NHC(=O)-}$ ,  $\text{-C(=O)NH-}$ , or  $\text{-OC(=O)NH-}$ ;

Ring C is selected from:




$R^3$  is  $\text{-CH}_3$ ,  $\text{-CH}_2\text{CH}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  
 $\text{-CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}_2(\text{CH}_3)_2$ ,  $\text{-CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ ,  $\text{-CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 $\text{-CH}_2\text{C}(\text{CH}_3)_3$ ,  $\text{-CF}_3$ ,  $\text{-CH}_2\text{CF}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CF}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_2\text{CF}_3$ ,  
10  $\text{-CH}(\text{OH})\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}(\text{OH})\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}(\text{NH}_2)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 $\text{-CH}_2\text{CH}_2\text{OCH}_3$ ,  $\text{-CH}_2\text{OCH}_2\text{CH}_3$ ,  $\text{-CF}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 $\text{-CH}(\text{NHCH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}(\text{NHSO}_2\text{CH}_2\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
cyclohexyl-, cyclopentyl-, cyclopropyl- $\text{CH}_2$ -,  
cyclobutyl- $\text{CH}_2$ -, cyclopentyl- $\text{CH}_2$ -, cyclohexyl- $\text{CH}_2$ -,  
15 cyclopropyl- $\text{CH}_2\text{CH}_2$ -, cyclobutyl- $\text{CH}_2\text{CH}_2$ -,  
cyclopentyl- $\text{CH}_2\text{CH}_2$ -, cyclohexyl- $\text{CH}(\text{OH})$ -,  
cyclohexyl- $\text{CH}_2\text{CH}_2$ -, 1- $\text{NH}_2$ -cyclopentyl, phenyl- $\text{CH}_2$ -,  
(2-F-phenyl) $\text{CH}_2$ -, (3-F-phenyl) $\text{CH}_2$ -, (4-F-phenyl) $\text{CH}_2$ -,  
(2-Cl-phenyl) $\text{CH}_2$ -, (3-Cl-phenyl) $\text{CH}_2$ -, (4-Cl-phenyl) $\text{CH}_2$ -,  
20 (2,3-diF-phenyl) $\text{CH}_2$ -, (2,4-diF-phenyl) $\text{CH}_2$ -,  
(2,5-diF-phenyl) $\text{CH}_2$ -, (2,6-diF-phenyl) $\text{CH}_2$ -,  
(3,4-diF-phenyl) $\text{CH}_2$ -, (3,5-diF-phenyl) $\text{CH}_2$ -,  
(2,3-diCl-phenyl) $\text{CH}_2$ -, (2,4-diCl-phenyl) $\text{CH}_2$ -,  
(2,5-diCl-phenyl) $\text{CH}_2$ -, (2,6-diCl-phenyl) $\text{CH}_2$ -,  
25 (3,4-diCl-phenyl) $\text{CH}_2$ -, (3,5-diCl-phenyl) $\text{CH}_2$ -,  
(3-F-4-Cl-phenyl) $\text{CH}_2$ -, (3-F-5-Cl-phenyl) $\text{CH}_2$ -,  
(3-Cl-4-F-phenyl) $\text{CH}_2$ -, phenyl- $\text{CH}_2\text{CH}_2$ -,  
(2-F-phenyl) $\text{CH}_2\text{CH}_2$ -, (3-F-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(4-F-phenyl) $\text{CH}_2\text{CH}_2$ -, (2-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
30 (3-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -, (4-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(2,3-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,4-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(2,5-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,6-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(3,4-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (3,5-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
(2,3-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,4-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
35 (2,5-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,6-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -,

(3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-piperidinyl-CH<sub>2</sub>CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>CF<sub>2</sub>-,  
 phenyl-CH<sub>2</sub>CH(OH)-, imidazolyl-CH<sub>2</sub>CH(OH)-, or  
 5 phenyl-CH<sub>2</sub>OCH<sub>2</sub>-;

W is a bond or -CH<sub>2</sub>-;

X is a bond;

10



15 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, or  
 -N(CH<sub>3</sub>)-,

Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl,  
 s-butyl, t-butyl, allyl, phenyl, 2-F-phenyl,  
 20 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl,  
 4-Cl-phenyl, 2,3-diF-phenyl,  
 2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl,  
 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl,  
 2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl,  
 25 3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl,  
 3-F-5-Cl-phenyl, 3-Cl-4-F-phenyl, 2-MeO-phenyl,  
 3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl,  
 4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl,  
 2-CF<sub>3</sub>O-phenyl, 3-CF<sub>3</sub>O-phenyl, 4-CF<sub>3</sub>O-phenyl, furanyl,  
 30 thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl,  
 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl,  
 1-benzimidazolyl, cyclopropyl, cyclobutyl,  
 cyclopentyl, cyclohexyl, morpholino, N-piperinyl,  
 phenyl-CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-,

- (4-F-phenyl)CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>,  
(4-Cl-phenyl)CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>-,  
(2,6-diF-phenyl)CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>-,  
5 (3,5-diF-phenyl)CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>-,  
(3-F-5-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>-,  
10 (2-MeO-phenyl)CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>-,  
4-MeS-phenyl)CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
15 (3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(furanyl)CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>-, (1-imidazolyl)CH<sub>2</sub>-,  
(oxazolyl)CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>-,  
20 (1-benzimidazolyl)CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>-,  
(cyclohexyl)CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>-,  
(N-pipridinyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
(phenyl)<sub>2</sub>CHCH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
25 (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
30 (3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
35 (2-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,


(2-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (furanyl)CH<sub>2</sub>CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 5 (2-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (imidazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (oxazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (benzimidazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 10 (cyclohexyl)CH<sub>2</sub>CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>CH<sub>2</sub>-, or  
 (N-pipridinyl)CH<sub>2</sub>CH<sub>2</sub>-;

R<sup>11</sup>, at each occurrence, is independently selected from  
 H, =O, methyl, ethyl, phenyl, benzyl, phenethyl,  
 15 4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 3-F-phenyl, (3-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 2-F-phenyl, (2-F-phenyl)CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 3-Cl-phenyl, (3-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 20 4-CH<sub>3</sub>-phenyl, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 3-CH<sub>3</sub>-phenyl, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-CF<sub>3</sub>-phenyl, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 cyclopentyl, pyrid-2-yl, pyrid-3-yl, or pyrid-4-yl; and

25 R<sup>13</sup>, at each occurrence, is independently selected from  
 H, F, Cl, OH, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, or -CF<sub>3</sub>.

[16] In another preferred embodiment the present  
 invention provides a compound of Formula (If):

30





or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, wherein:

L is  $\text{-NHC(=O)-}$ ,  $\text{-C(=O)NH-}$ , or  $\text{-OC(=O)NH-}$ ;

5

$R^3$  is  $\text{-(CH}_2\text{)}_n\text{-R}^4$ ,  
 $\text{-(CH}_2\text{)}_1\text{-S-R}^4$ ,  
 $\text{-(CH}_2\text{)}_1\text{-O-R}^4$ , or  
 $\text{-(CH}_2\text{)}_1\text{-N(R}^{7b}\text{)-R}^4$ ;

10

n is 0, 1 or 2;

l is 1 or 2;

15  $R^4$  is  $\text{C}_1\text{-C}_8$  alkyl substituted with 0-3  $R^{4a}$ ,  
 $\text{C}_2\text{-C}_8$  alkenyl substituted with 0-3  $R^{4a}$ ,  
 $\text{C}_2\text{-C}_8$  alkynyl substituted with 0-3  $R^{4a}$ ,  
 $\text{C}_3\text{-C}_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,  
 $\text{C}_6\text{-C}_{10}$  aryl substituted with 0-3  $R^{4b}$ , or  
20 5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $R^{4b}$ ;

25  $R^{4a}$ , at each occurrence, is independently selected from  
H, OH, F, Cl, Br, I,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ ,  
 $\text{C}_3\text{-C}_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,  
 $\text{C}_6\text{-C}_{10}$  aryl substituted with 0-3  $R^{4b}$ , and  
5 to 10 membered heterocycle containing 1 to 4  
30 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $R^{4b}$ ;

35  $R^{4b}$ , at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN,  $\text{NO}_2$ ,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ , acetyl,  $\text{SCH}_3$ ,  
 $\text{S(=O)CH}_3$ ,  $\text{S(=O)}_2\text{CH}_3$ ,  
 $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_4$  alkoxy,  $\text{C}_1\text{-C}_4$  haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>7b</sup> is H, methyl, or ethyl;

- 5 Ring C is a 3-8 membered carbocycle;  
wherein said 3-8 membered carbocyclic moiety is  
saturated or partially saturated;  
wherein said 3-8 membered carbocyclic moiety is  
substituted with 0-3 R<sup>21</sup>;  
10 optionally, the carbocycle contains a heteroatom  
selected from -O- and -N(R<sup>20</sup>)-;

R<sup>21</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
15 S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, NR<sup>15</sup>R<sup>16</sup>, OR<sup>14a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub>  
alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>11</sup> is selected from  
20 H, =O, NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1 R<sup>11a</sup>;  
phenyl substituted with 0-3 R<sup>11b</sup>;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and  
5 to 7 membered heterocycle containing 1 to 4  
25 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 7 membered heterocycle  
is substituted with 0-3 R<sup>11b</sup>; wherein said 5 to 7  
membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl,  
30 thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,  
homopiperidinyl, and tetrazolyl;

R<sup>11a</sup>, at each occurrence, is independently selected from H,  
35 C<sub>1</sub>-C<sub>4</sub> alkyl, OR<sup>14</sup>, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl  
substituted with 0-3 R<sup>11b</sup>;

Best Available Copy

R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

5

W is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-;

X is a bond;

phenyl substituted with 0-2 R<sup>Xb</sup>;  
10 C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-2 R<sup>Xb</sup>; or  
5 to 6 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;

R<sup>Xb</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
15 S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-,  
-N(R<sup>19</sup>)-, -C(=O)NR<sup>19b</sup>-, -NR<sup>19b</sup>C(=O)-, -NR<sup>19b</sup>S(=O)<sub>2</sub>-,  
20 -S(=O)<sub>2</sub>NR<sup>19b</sup>-, -NR<sup>19b</sup>S(=O)-, -S(=O)NR<sup>19b</sup>-, -C(=O)O-,  
or -OC(=O)-;

Z is H;

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
25 C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
30 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

R<sup>12a</sup>, at each occurrence, is independently selected from  
35 H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and  
5 to 10 membered heterocycle containing 1 to 4  
5 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

10 R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

15 R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, or  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

20 R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-,  
and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

25 R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

30 R<sup>18</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

R<sup>19</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, phenyl, benzyl,  
phenethyl; and

35 R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

[17] In another preferred embodiment the present invention provides a compound of Formula (If) wherein:

L is  $\text{-NHC(=O)-}$ ,  $\text{-C(=O)NH-}$ , or  $\text{-OC(=O)NH-}$ ;

R<sup>3</sup> is  $\text{-R}^4$ ,  $\text{-CH}_2\text{R}^4$ ,  $\text{-CH}_2\text{CH}_2\text{R}^4$ ,  $\text{-CH}_2\text{OR}^4$ , or  $\text{-CH}_2\text{CH}_2\text{OR}^4$ ;

R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from is  
H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

Ring C is a 3-6 membered carbocycle;  
wherein said 3-6 membered carbocyclic moiety is  
saturated or partially unsaturated;  
wherein said 3-6 membered carbocyclic moiety is  
substituted with 0-2 R<sup>21</sup>;

optionally, the carbocycle contains a heteroatom  
selected from -O- and -N(R<sup>20</sup>)-;

5 R<sup>21</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, methyl,  
ethyl, methoxy, ethoxy, allyl, -OCF<sub>3</sub>, and -SCF<sub>3</sub>;

R<sup>11</sup> is selected from  
H, =O, NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
10 C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1 R<sup>11a</sup>;  
phenyl substituted with 0-3 R<sup>11b</sup>;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and  
5 to 7 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
15 sulphur, wherein said 5 to 7 membered heterocycle  
is substituted with 0-3 R<sup>11b</sup>; wherein said 5 to 7  
membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl,  
thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
20 pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,  
homopiperidinyl, and tetrazolyl;

R<sup>11a</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
25 propoxy, phenoxy, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl  
substituted with 0-3 R<sup>11b</sup>;

R<sup>11b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl,  
30 methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;

W is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-;

35 X is a bond;  
phenyl substituted with 0-1 R<sup>Xb</sup>;  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-1 R<sup>Xb</sup>; or

5 to 6 membered heterocycle substituted with 0-1 R<sup>Xb</sup>;

R<sup>Xb</sup> is selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, and -OCF<sub>3</sub>;

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, -N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;

10 Z is H;

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;

C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

15 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

20

R<sup>12a</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

25 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

30 sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from

H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,

35 SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>2</sub>-C<sub>4</sub> alkoxyalkyl;

5 R<sup>15</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, butyl, benzyl, and phenethyl;

10 R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, benzyl,  
phenethyl, methyl-C(=O)-, ethyl-C(=O)-,  
methyl-S(=O)<sub>2</sub>-, and ethyl-S(=O)<sub>2</sub>-;

15 R<sup>18</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and  
phenethyl;

R<sup>19</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, and butyl;

20 R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

[18] In another preferred embodiment the present  
invention provides a compound of Formula (If) wherein:

25 L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;

30 R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>, or  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>;


35 R<sup>4a</sup>, at each occurrence, is independently selected from is  
H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and



5 sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3  $R^{4b}$ ; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

10  $R^{4b}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

15 Ring C is a 3-6 membered carbocycle selected from:



wherein said 3-6 membered carbocycle is substituted with 0-1  $R^{21}$ ;

20  $R^{21}$  is selected from H, OH, Cl, F, CN, CF<sub>3</sub>, methyl, ethyl, methoxy, ethoxy, allyl, and -OCF<sub>3</sub>;

25  $R^{11}$  is selected from H, =O, NR<sup>18</sup>R<sup>19</sup>; C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1  $R^{11a}$ ; phenyl substituted with 0-3  $R^{11b}$ ;

30 5 to 7 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 7 membered heterocycle is substituted with 0-3  $R^{11b}$ ; wherein said 5 to 7 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl,

pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,  
homopiperidiny, and tetrazolyl;

5 R<sup>11a</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, methoxy, ethoxy, propoxy,  
phenoxy, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl  
substituted with 0-3 R<sup>11b</sup>;

10 R<sup>11b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl,  
methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;

W is a bond or -CH<sub>2</sub>-;

15 X is a bond, phenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or 5 to 6 membered  
heterocycle;

20 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-,  
-N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;

Z is H;

25 C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
30 sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

35 R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy,  
ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;

phenyl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-6 carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 6 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy,  
ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;

R<sup>14</sup> is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;

R<sup>15</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, and butyl; and

R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, benzyl, and  
phenethyl.

R<sup>18</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and  
phenethyl;


R<sup>19</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, and butyl; and

R<sup>20</sup> is H, methyl, or ethyl.

[19] In another preferred embodiment the present  
invention provides a compound of Formula (If) wherein:

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

Ring C is selected from:




- $R^3$  is  $-CH_3$ ,  $-CH_2CH_3$ ,  $-CH_2CH_2CH_3$ ,  $-CH_2CH_2CH_2CH_3$ ,  
 5  $-CH_2CH_2CH(CH_3)_2$ ,  $-CH_2(CH_3)_2$ ,  $-CH(CH_3)CH_2CH_3$ ,  $-CH_2CH(CH_3)_2$ ,  
 $-CH_2C(CH_3)_3$ ,  $-CF_3$ ,  $-CH_2CF_3$ ,  $-CH_2CH_2CF_3$ ,  $-CH_2CH_2CH_2CF_3$ ,  
 $-CH(OH)CH_2CH(CH_3)_2$ ,  $-CH(OH)CH(CH_3)_2$ ,  $-CH(NH_2)CH_2CH(CH_3)_2$ ,  
 $-CH_2CH_2OCH_3$ ,  $-CH_2OCH_2CH_3$ ,  $-CF_2CH_2CH(CH_3)_2$ ,  
 $-CH(NHCH_3)CH_2CH(CH_3)_2$ ,  $-CH(NHSO_2CH_2CH_2CH_3)CH_2CH(CH_3)_2$ ,  
 10 cyclohexyl-, cyclopentyl-, cyclopropyl- $CH_2$ -,  
 cyclobutyl- $CH_2$ -, cyclopentyl- $CH_2$ -, cyclohexyl- $CH_2$ -,  
 cyclopropyl- $CH_2CH_2$ -, cyclobutyl- $CH_2CH_2$ -,  
 cyclopentyl- $CH_2CH_2$ -, cyclohexyl- $CH(OH)$ -,  
 cyclohexyl- $CH_2CH_2$ -, 1- $NH_2$ -cyclopentyl, phenyl- $CH_2$ -,  
 15 (2-F-phenyl) $CH_2$ -, (3-F-phenyl) $CH_2$ -, (4-F-phenyl) $CH_2$ -,  
 (2-Cl-phenyl) $CH_2$ -, (3-Cl-phenyl) $CH_2$ -, (4-Cl-phenyl) $CH_2$ -,  
 (2,3-diF-phenyl) $CH_2$ -, (2,4-diF-phenyl) $CH_2$ -,  
 (2,5-diF-phenyl) $CH_2$ -, (2,6-diF-phenyl) $CH_2$ -,  
 (3,4-diF-phenyl) $CH_2$ -, (3,5-diF-phenyl) $CH_2$ -,  
 20 (2,3-diCl-phenyl) $CH_2$ -, (2,4-diCl-phenyl) $CH_2$ -,  
 (2,5-diCl-phenyl) $CH_2$ -, (2,6-diCl-phenyl) $CH_2$ -,  
 (3,4-diCl-phenyl) $CH_2$ -, (3,5-diCl-phenyl) $CH_2$ -,  
 (3-F-4-Cl-phenyl) $CH_2$ -, (3-F-5-Cl-phenyl) $CH_2$ -,  
 (3-Cl-4-F-phenyl) $CH_2$ -, phenyl- $CH_2CH_2$ -,  
 25 (2-F-phenyl) $CH_2CH_2$ -, (3-F-phenyl) $CH_2CH_2$ -,  
 (4-F-phenyl) $CH_2CH_2$ -, (2-Cl-phenyl) $CH_2CH_2$ -,  
 (3-Cl-phenyl) $CH_2CH_2$ -, (4-Cl-phenyl) $CH_2CH_2$ -,  
 (2,3-diF-phenyl) $CH_2CH_2$ -, (2,4-diF-phenyl) $CH_2CH_2$ -,  
 (2,5-diF-phenyl) $CH_2CH_2$ -, (2,6-diF-phenyl) $CH_2CH_2$ -,  
 30 (3,4-diF-phenyl) $CH_2CH_2$ -, (3,5-diF-phenyl) $CH_2CH_2$ -,  
 (2,3-diCl-phenyl) $CH_2CH_2$ -, (2,4-diCl-phenyl) $CH_2CH_2$ -,  
 (2,5-diCl-phenyl) $CH_2CH_2$ -, (2,6-diCl-phenyl) $CH_2CH_2$ -,  
 (3,4-diCl-phenyl) $CH_2CH_2$ -, (3,5-diCl-phenyl) $CH_2CH_2$ -,  
 (3-F-4-Cl-phenyl) $CH_2CH_2$ -, (3-F-5-Cl-phenyl) $CH_2CH_2$ -,  
 35 4-piperidinyl- $CH_2CH_2$ -, phenyl- $CH_2CH_2CF_2$ -,

phenyl-CH<sub>2</sub>CH(OH)-, imidazolyl-CH<sub>2</sub>CH(OH)-, or  
phenyl-CH<sub>2</sub>OCH<sub>2</sub>-;

W is a bond or -CH<sub>2</sub>-;

5

X is a bond;



10

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, or  
-N(CH<sub>3</sub>)-,

15 Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl,  
s-butyl, t-butyl, allyl, phenyl, 2-F-phenyl,  
3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl,  
4-Cl-phenyl, 2,3-diF-phenyl,  
2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl,  
20 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl,  
2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl,  
3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl,  
3-F-5-Cl-phenyl, 3-Cl-4-F-phenyl, 2-MeO-phenyl,  
3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl,  
25 4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl,  
2-CF<sub>3</sub>O-phenyl, 3-CF<sub>3</sub>O-phenyl, 4-CF<sub>3</sub>O-phenyl, furanyl,  
thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl,  
4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl,  
1-benzimidazolyl, cyclopropyl, cyclobutyl,  
30 cyclopentyl, cyclohexyl, morpholino, N-piperinyl,  
phenyl-CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-,  
(4-F-phenyl)CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>-,

- (2,6-diF-phenyl)CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>-,  
(3,5-diF-phenyl)CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>-,  
5 (3,5-diCl-phenyl)CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>-,  
(3-F-5-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>-,  
(2-MeO-phenyl)CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>-,  
10 (2-MeS-phenyl)CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>-,  
(4-MeS-phenyl)CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(furanyl)CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>-,  
15 (4-Me-pyridyl)CH<sub>2</sub>-, (1-imidazolyl)CH<sub>2</sub>-,  
(oxazolyl)CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>-,  
(1-benzimidazolyl)CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>-,  
(cyclohexyl)CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>-,  
20 (N-pipridinyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
(phenyl)<sub>2</sub>CHCH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
25 (2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
30 (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
35 (2-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,

(furanyl)CH<sub>2</sub>CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (imidazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(oxazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
5 (benzimidazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(cyclohexyl)CH<sub>2</sub>CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>CH<sub>2</sub>-, or  
(N-pipridinyl)CH<sub>2</sub>CH<sub>2</sub>-; and

10 R<sup>11</sup>, at each occurrence, is independently selected from  
H, =O, methyl, ethyl, phenyl, benzyl, phenethyl,  
4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-F-phenyl, (3-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
2-F-phenyl, (2-F-phenyl)CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
15 4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-Cl-phenyl, (3-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-CH<sub>3</sub>-phenyl, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-CH<sub>3</sub>-phenyl, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-CF<sub>3</sub>-phenyl, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
20 cyclopentyl, pyrid-2-yl, pyrid-3-yl, or pyrid-4-yl.

[20] In another preferred embodiment the present  
invention provides a compound of Formula (I) selected from:

25 {[N-(3-methylbutyl)carbamoyl]cyclopentyl}-N-(5-methyl-6-  
oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carboxamide;

{[N-(3-methylbutyl)carbamoyl]cyclopentyl}-N-(1-methyl-2-  
oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-  
30 yl))carboxamide;

[(N-butylcarbamoyl)cyclopentyl]-N-(1-methyl-2-oxo-5-  
phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carboxamide;

35 2-(3,5-difluorophenyl)-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-  
3H-benzo[f]1,4-diazepin-3-  
yl))carbamoyl]cyclohexyl}acetamide;

- 2-(3,5-difluorophenyl)-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]cyclopentyl}acetamide;
- 5 2-(3,5-difluorophenyl)-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]cyclopropyl}acetamide;
- 10 3-cyclopentyl-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]cyclohexyl}propanamide;
- 15 2-(3,5-difluorophenyl)-N-{4-[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl](4-piperidyl)}acetamide;
- 20 phenyl 4-[2-(3,5-difluorophenyl)acetyl amino]-4-[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]piperidinecarboxylate;
- 4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;
- 25 N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}{[(phenylmethoxy)carbonylamino]cyclopentyl}carboxamide;
- 30 (2S)-N-{[N-(1-{[3-(4-fluorophenoxy)phenyl]methyl}-2-oxoazaperhydroepin-3-yl) carbamoyl]cyclopropyl}-2-hydroxy-4-methylpentanamide;
- 35 (2S)-N-{[N-(1-{[3-(4-fluorophenoxy)phenyl]methyl}-2-oxoazaperhydroepin-3-yl) carbamoyl]cyclopentyl}-2-hydroxy-3-methylbutanamide;



2,2-difluoro-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]-4-phenylbutanamide;

5 N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]-3-(4-piperidyl)propanamide;

10 (2S)-2-hydroxy-4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]pentanamide;

15 3-cyclopropyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]propanamide;

(2R)-2-hydroxy-3-imidazol-2-yl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]propanamide;

20 2-ethoxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]acetamide;

25 3-cyclopentyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]propanamide;

30 (2S)-2-hydroxy-3-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]butanamide;

35 (2S)-2-cyclohexyl-2-hydroxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]acetamide;

(2R)-2-cyclohexyl-2-hydroxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]acetamide;

5 (2S)-2-amino-4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]pentanamide;

10 [(cyclohexylcarbonylamino)cyclopentyl]-N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl)}carboxamide;

15 {[N-(3-methylbutyl)carbamoyl]cyclopentyl}-N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl)}carboxamide;

20 4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]pentanamide;

(2S)-2-hydroxy-4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]pentanamide;

25 3-methoxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]propanamide;

30 (2S)-2-hydroxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]-3-phenylpropanamide;

35 N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]-2-(phenylmethoxy)acetamide;

- (2S)-2-hydroxy-3-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}butanamide;
- 5 (2S)-2-hydroxy-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;
- 10 3-cyclopentyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}propanamide;
- (2S)-2-cyclohexyl-2-hydroxy-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}acetamide;
- 15 3-cyclopropyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}propanamide;
- 20 N-{[N-(1-butyl-5-cyclopentyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]cyclopentyl}-4-methylpentanamide;
- N-{[N-(5-cyclopentyl-1-methyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]cyclopentyl}-4-
- 25 methylpentanamide;
- (2S)-2-hydroxy-3-methyl-N-({N-[2-oxo-1-benzyl(3H,4H,5H-benzo[f]azaperhydroepin-3-yl)] carbamoyl}cyclopentyl)butanamide;
- 30 (2S)-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}-2-[(propylsulfonyl) amino]pentanamide;
- 35 (2S)-2-amino-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;

2,2-difluoro-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;

5

4-methyl-N-{[N-(6-oxo(5H,7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;

10

N-({N-[5-(3,3-dimethyl-2-oxobutyl)-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)] carbamoyl}cyclopentyl)-4-methylpentanamide;

15

4-methyl-N-([N-{6-oxo-5-[(3-phenoxyphenyl)methyl](7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;

N-{[N-(5-butyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}-4-methylpentanamide;

20

4-methyl-N-({N-[6-oxo-5-benzyl(7H-dibenzo[d,f]azaperhydroepin-7-yl)] carbamoyl}cyclopentyl}pentanamide;

25

N-({N-[5-(tert-butyl)-1-methyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl)] carbamoyl}cyclopentyl)-4-methylpentanamide;

30


N-({N-[5-(tert-butyl)-1-butyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl)] carbamoyl}cyclopentyl)-4-methylpentanamide; and

35

N-({N-[5-butyl-2-oxo-1-(2-pyridylmethyl)(3H-benzo[f]1,4-diazepin-3-yl)] carbamoyl}cyclopentyl)-4-methylpentanamide.

In another embodiment the present invention provides for a method for the treatment of neurological disorders

associated with  $\beta$ -amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula (I):



or a pharmaceutically acceptable salt or prodrug thereof.

10 It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment to describe additional even more preferred embodiments of the present invention.

15 In a second embodiment, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.

20 In a third embodiment, the present invention provides a method for the treatment of neurological disorders associated with  $\beta$ -amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of Formula (I).

25 In a preferred embodiment the neurological disorder associated with  $\beta$ -amyloid production is Alzheimer's Disease.

30 In a fourth embodiment, the present invention provides a method for inhibiting  $\gamma$ -secretase activity for the treatment of a physiological disorder associated with inhibiting  $\gamma$ -secretase activity comprising administering to a host in need of such inhibition a therapeutically

effective amount of a compound of Formula (I) that inhibits  $\gamma$ -secretase activity.

Thus, the present invention provides a method for  
5 inhibiting  $\gamma$ -secretase activity comprising administering to  
a host in need of such inhibition a therapeutically  
effective amount of a compound of Formula (I) that inhibits  
 $\gamma$ -secretase activity.

10 In a preferred embodiment the physiological disorder  
associated with inhibiting  $\gamma$ -secretase activity is  
Alzheimer's Disease.

In a fifth embodiment, the present invention provides  
15 a compound of Formula (I) for use in therapy.

In a preferred embodiment the present invention  
provides a compound of Formula (I) for use in therapy of  
Alzheimer's Disease.

20 In a sixth embodiment, the present invention provides  
for the use of a compound of Formula (I) for the  
manufacture of a medicament for the treatment of  
Alzheimer's Disease.

25 It is understood that any and all embodiments of the  
present invention may be taken in conjunction with any  
other embodiment to describe additional even more preferred  
embodiments of the present invention.

30

#### DEFINITIONS

As used herein, the term " $A\beta$ " denotes the protein  
designated  $A\beta$ ,  $\beta$ -amyloid peptide, and sometimes  $\beta/A4$ , in  
the art.  $A\beta$  is an approximately 4.2 kilodalton (kD)  
35 protein of about 39 to 43 amino acids found in amyloid  
plaques, the walls of meningeal and parenchymal arterioles,  
small arteries, capillaries, and sometimes, venules. The

isolation and sequence data for the first 28 amino acids are described in U.S. Pat. No 4,666,829. The 43 amino acid sequence is:

1	Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr
11	Glu	Val	His	His	Gln	Lys	Leu	Val	Phe	Phe
21	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala
31	Ile	Ile	Gly	Leu	Met	Val	Gly	Gly	Val	Val
41	Ile	Ala	Thr							

5 The term "APP", as used herein, refers to the protein known in the art as  $\beta$  amyloid precursor protein. This protein is the precursor for A $\beta$  and through the activity of "secretase" enzymes, as used herein, it is processed into A $\beta$ . Differing secretase enzymes, known in the art, have been designated  $\beta$  secretase, generating the N-terminus of A $\beta$ ,  $\alpha$  secretase cleaving around the 16/17 peptide bond in A $\beta$ , and " $\gamma$  secretases", as used herein, generating C-terminal A $\beta$  fragments ending at position 38, 39, 40, 42, 10 and 43 or generating C-terminal extended precursors which 15 are subsequently truncated to the above polypeptides.

The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in 20 optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present 25 in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present

invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.

The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.

When any variable (e.g.,  $R^{5b}$ ) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2  $R^{5b}$ , then said group may optionally be substituted with up to two  $R^{5b}$  groups and  $R^{5b}$  at each occurrence is selected independently from the definition of  $R^{5b}$ . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein, "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; for example, "C<sub>1</sub>-C<sub>6</sub> alkyl" denotes alkyl having 1, 2, 3, 4, 5, or 6 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl,



i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl. Preferred "alkyl" group, unless otherwise specified, is "C<sub>1</sub>-C<sub>4</sub> alkyl". Additionally, unless otherwise specified, "propyl" denotes n-propyl or i-propyl;  
5 "butyl" denotes n-butyl, i-butyl, sec-butyl, or t-butyl.

As used herein, "alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point  
10 along the chain. Examples of "C<sub>2</sub>-C<sub>6</sub> alkenyl" include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 2-pentenyl, 3-pentenyl, hexenyl, and the like.

As used herein, "alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more carbon-carbon triple  
15 bonds which may occur in any stable point along the chain, such as ethynyl, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, and the like.

20 "Alkoxy" or "alkyloxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy,  
25 n-pentoxy, and s-pentoxy. Preferred alkoxy groups are methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy. Similarly, "alkylthio" or "thioalkoxy" is represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur  
30 bridge.

"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo. Unless otherwise specified, preferred halo is fluoro and chloro. "Counterion" is used to represent a small, negatively charged species such as  
35 chloride, bromide, hydroxide, acetate, sulfate, and the like.

"Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example  $-C_vF_w$  where  $v = 1$  to 3 and  $w = 1$  to  $(2v+1)$ ). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, heptafluoropropyl, and heptachloropropyl. "Haloalkoxy" is intended to mean a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge; for example trifluoromethoxy, pentafluoroethoxy, 2,2,2-trifluoroethoxy, and the like. "Halothioalkoxy" is intended to mean a haloalkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge.

"Cycloalkyl" is intended to include saturated ring groups, having the specified number of carbon atoms. For example, "C<sub>3</sub>-C<sub>6</sub> cycloalkyl" denotes such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

As used herein, "carbocycle" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin). Preferred "carbocycle" are cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

As used herein, the term "heterocycle" or "heterocyclic ring" is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 14-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic), and which consists

of carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.


Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyll, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, b-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolyl, imidazolyl, 1H-indazolyl, indolenyl, indolyl, indolizinyll, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl,

- piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl. Preferred 5 to 10 membered heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, tetrazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolidinyl, isoxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, quinolinyl, and isoquinolinyl. Preferred 5 to 6 membered heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, tetrazolyl; more preferred 5 to 6 membered heterocycles include, but are not limited to, pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, and tetrazolyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

As used herein, the term "aryl", "C<sub>6</sub>-C<sub>10</sub> aryl" or aromatic residue, is intended to mean an aromatic moiety containing the specified number of carbon atoms; for example phenyl, pyridinyl or naphthyl. Preferred "aryl" is phenyl. Unless otherwise specified, "aryl" may be unsubstituted or substituted with 0 to 3 groups selected from H, methyl, ethyl, propyl, butyl, methoxy, ethoxy,


propoxy, butoxy, amino, hydroxy, Cl, F, Br, I, CF<sub>3</sub>, SCH<sub>3</sub>, S(O)CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, N(CH<sub>3</sub>)H, CN, NO<sub>2</sub>, OCF<sub>3</sub>, C(=O)CH<sub>3</sub>, CO<sub>2</sub>H, CO<sub>2</sub>CH<sub>3</sub>, or C<sub>1</sub>-C<sub>4</sub> haloalkyl.

- The phrase "additional lactam carbons", as used herein, is intended to denote the number of optional carbon atoms in the lactam ring B of Formula (I). Formula (I''):



(I'')

- represents the lactam ring B of Formula (I). Additional lactam carbons are carbons in lactam ring B other than the carbons numbered 2 and 3 in the backbone of the formula. The additional lactam carbons may be optionally replaced by a heteroatom selected from oxygen, nitrogen and sulfur.
- Lactam ring B contains 1, 2, 3, 4, 5, 6 or 7 optional carbons, wherein one optional carbon may optionally be replaced by a heteroatom, such that the total number of members of lactam ring B, including atoms numbered 1, 2 and 3 in the backbone, does not exceed 10. It is preferred that the total number of atoms of lactam ring B is 6, 7 or 8; it is more preferred that the total number of atoms of lactam ring B is seven. It is further understood that lactam ring B may optionally be unsaturated or partially unsaturated (i.e. two adjacent atoms in the ring form a double bond) wherein the backbone of lactam ring B may contain one, two or three double bonds. Examples of lactam ring B include:




30 B1


B2

B3


B4




B5




B6




B8




B9




B10




B11




B12




B13



B14




B15




B16

but are not intended to limit the invention. Preferred examples of lactam ring B are B1, B2, B5, B6, B8, B9, B13, and B16; more preferred examples of lactam ring B are B1, B6, B8, B9, and B13. Preferred examples of substituent R<sup>10</sup> or R<sup>11</sup> on lactam B are methyl, ethyl, phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-trifluoromethylphenyl, (4-fluorophenyl)methyl, (4-chlorophenyl)methyl, (4-trifluoromethylphenyl)methyl, and 2-, 3-, and 4-pyridinyl. Preferred examples of R<sup>13</sup> on lactam B are F, Cl, OH, methyl, ethyl, methoxy, and trifluoromethyl.

The compounds herein described may have asymmetric centers. One enantiomer of a compound of Formula (I) may display superior biological activity over the opposite enantiomer. For example carbon 3 of lactam ring B Formula (I") may exist in either an S or R configuration. Thus, an R or S configuration at carbon 3 in Formula (I") is considered part of the invention. An example of such configuration includes,



and



but is not intended to be limited to this example of ring B. When required, separation of the racemic material can be achieved by methods known in the art.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the

parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

"Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying



functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I), and the like.

"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

#### SYNTHESIS


The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.

The novel compounds of this invention may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and which are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work-up procedures, are chosen to be the

conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods must then be used.


In a preferred method of synthesis, the compounds of Formula (I) of the present invention can be prepared from carboxylic acid 1 and amine 2 using amide bond syntheses known in the art, including methods commonly used in peptide syntheses, such as HATU, TBTU, BOP, EDC, CDI, and DCC-mediated couplings, as illustrated in Scheme 1. Depending on the structure of the final product, it is appreciated by those skilled in the art that protecting groups or precursor functionality convertible to the desired groups may be desirable. Protecting groups and their use in synthesis are described in Green and Wuts, *Protective Groups in Organic Synthesis*, (Wiley 1991).

Scheme 1




Additionally, the syntheses of a representative malonamide and a representative acetamide of Formula (I) are illustrated in Scheme 2 and Scheme 3, respectively. As will be readily apparent to those of ordinary skill in the art, the synthetic procedure illustrated in Scheme 2 and 3, and the reaction conditions described below can be modified by selecting the appropriate starting materials and reagents to allow the preparation of other compounds of the present invention.

Scheme 2




Scheme 3



5 Methods for the synthesis of lactams useful as intermediates in the synthesis of compounds of the present invention, including amino bisbenzodiazepine 5 and amino benzodiazepine 8, are known in the art and are disclosed in a number of references including PCT publication number WO 98/28268, WO 99/66934, and WO00/07995, which are hereby  
 10 incorporated by reference. Additional references include Bock, et. al., J. Org. Chem., 1987, 52, 3232-3239; Sherrill et. al., J. Org. Chem., 1995, 60, 730-734; Walsh, D. A., Synthesis, September 1980, p. 677; and Brown, at.  
 15 al., Tetrahedron Letters, 1971, 8, 667-670.


Cyclic carboxylic acid intermediates, such as 4, are useful for the synthesis of the current invention, and may be synthesized by a number of ways well known in the art. One of the preferred syntheses of the compounds of this invention is shown in Scheme 4. Typically a convergent  
 20 route is employed, which joins the acid 11 and the amine together to afford the key intermediate 12 using standard bond-forming procedures (Synthesis 1989, 37-38). The desired carboxylic acid 4 may be prepared from the known malonate ester 10 (e.g. Chung, S. K. Korean J. Med. Chem.  
 25 1995, 5, 94-111) via a three-step protocol as shown in Scheme 4.

Scheme 4



One of the preferred syntheses of cyclic amino acids, such as 7 which is useful in the preparation of compounds of Formula (I), is outlined in Scheme 5. As illustrated for the synthesis of carboxylic acid 7, the desired intermediate ester 18 is prepared by the initial coupling reaction of acid 14 and amine 13 under standard conditions using EDC and HOBt. Both the acids and the amines employed as starting materials in this invention are either commercially available or can be prepared from commercially available materials using conventional procedures and reagents. As apparent to those of ordinary skill in the art, the synthetic procedure illustrated in Scheme 5 and the reaction conditions described will allow the preparation of many other analogs of 7 by selecting the appropriate starting materials and reagents.

Scheme 5



Methods for the synthesis of lactams useful as intermediates in the synthesis of compounds of the present


invention are known in the art and are disclosed in a number of references including PCT publication number WO 98/28268, WO 99/66934, and WO00/07995, which are hereby incorporated by reference. Additional references include

5 Bock, et. al., J. Org. Chem., **1987**, *52*, 3232-3239; Sherrill et. al., J. Org. Chem., **1995**, *60*, 730-734; Walsh, D. A., Synthesis, September 1980, p. 677; and Brown, at. al., Tetrahedron Letters, 1971, *8*, 667-670.

One of the preferred syntheses of the lactam intermediates, such as **23**, is outlined in Scheme 6.

10

Scheme 6



15 a) Preparation of **21**

To a suspension of **19** (30.0 g, 155 mmol) in dry Et<sub>2</sub>O (300 mL) under N<sub>2</sub> at -70 °C was added *t*-BuLi (205 mL, 1.7 M in pentane) and stirred for 4 h between -20 °C and -10 °C. The reaction was cooled to -70 °C and transferred via

20 canula to a round bottom containing **20** (23.0 mL, 186 mmol) in dry Et<sub>2</sub>O (150 mL) under N<sub>2</sub> at -70 °C. The reaction was stirred while warming to rt for 14 h and quenched with 20% citric acid. The resulting layers were separated and the organic layer was washed with sat. NaHCO<sub>3</sub>, brine, dried

25 over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give a yellow oil. The oil was dissolved in EtOH-HCl (200 mL) and stirred overnight. The solvent was removed in vacuo at 70 °C and the resulting oil triturated with Et<sub>2</sub>O. The resultant solid was filtered and washed with Et<sub>2</sub>O to afford

30 **21** HCl (23.9 g, 64%) as a orange solid: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.10 (d, 1 H), 7.66 (t, 1 H), 7.56 (t, 1 H), 7.51 (d, 1 H), 1.41 (s, 9 H); ESI MS *m/z* = 178 [C<sub>11</sub>H<sub>15</sub>NO+H]<sup>+</sup>.

The orange solid was dissolved in 1N NaOH and EtOAc and the layers were separated. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to afford **21** (21 g, 99%) as a yellow oil: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.70 (d, 1 H), 7.16 (t, 1 H), 6.78 (d, 1 H), 6.59 (t, 1 H), 1.38 (s, 9 H).

**b) Preparation of Example 23**

To a solution of **22** (5.5 g, 17.0 mmol) in dry THF (50 mL) at 0 °C was added oxalyl chloride (1.47 mL, 17.0 mmol) and DMF (0.2 mL) and stirred for 1.25 h. A solution of **21** (3.3 g, 15.4 mmol) and N-methylmorpholine (4.7 mL, 42.4 mmol) in dry THF (20 mL) was added to the reaction dropwise and the reaction was stirred at rt for 1.5 h. The reaction was filtered and MeOH (100 mL) and NH<sub>4</sub>OH (50 mL) was added to the filtrate and the reaction was sealed. After 45 min, the reaction was concentrated to half its volume and added dropwise to a cooled solution (15 °C) of ammonium acetate (5.75 g) in acetic acid (120 mL). The reaction was stirred over night at rt, dissolved in Et<sub>2</sub>O (100 mL), made basic with 6 N NaOH, and cooled in ice while stirring for 1 h. The resulting solid was filtered, washed with H<sub>2</sub>O and Et<sub>2</sub>O, and dried in a vacuum oven at 30 °C to afford **23** (3.5 g, 63%) as a white solid: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.78-7.16 (m, 10 H), 5.12 (s, 2 H), 1.27 (s, 9 H).

Abbreviations used in the description of the chemistry and in the examples that follow are:

Ac	acetyl or acetate
30 aq	aqueous
Bn	benzyl
Boc	t-butyloxycarbonyl
Cbz	benzyloxycarbonyl
DIEA	N,N'-diisopropylethylamine
35 DMAP	4-dimethylaminopyridine
DME	ethylene glycol dimethyl ether
DMF	N,N'-dimethylformamide

DMSO	dimethylsulfoxide or methyl sulfoxide
EDC•HCl	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
HOBT	1-hydroxybenzotriazole
HPLC	high performance liquid chromatography
5 LiHMDS	lithium hexamethyldisilazide
MeCN	acetonitrile
MS	mass spectrometry
satd	saturated
rt or RT	room temperature
10 TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	thin layer chromatography


#### EXAMPLES

15 The examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrate of the invention and not limit the reasonable scope thereof.

20 Compounds of the present invention are generally purified by HPLC using conditions known to one skilled in the art. However, unless otherwise indicated, the following conditions are generally applicable. HPLC Condition A: reverse-phase HPLC can be carried out using a  
25 Vydac C-18 column with gradient elution from 10% to 100 % buffer B in buffer A (buffer A: water containing 0.1% trifluoroacetic acid, buffer B: 10% water, 90% acetonitrile containing 0.1% trifluoroacetic acid).  
Alternatively: HPLC Condition B: reverse-phase HPLC can be  
30 carried out using a Vydac C-18 column with gradient elution from 10% to 90 % acetonitrile in water.

#### Example 1

{[N-(3-methylbutyl)carbamoyl]cyclopentyl}-N-(5-methyl-6-  
35 oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carboxamide.



(a) Methyl 1-[N-(3-methylbutyl)carbamoyl]cyclopentane-carboxylate

- 5 To 1-(methoxycarbonyl)cyclopentanecarboxylic acid (630 mg, 3.7 mmol) in  $\text{CH}_2\text{Cl}_2/\text{DMF}$  (5:1, 37 mL) at  $0^\circ\text{C}$  was added HOBT (730 mg, 4.8 mmol) and EDC (920 mg, 4.8 mmol). The mixture was stirred for 10 min then 3-methylbutylamine (640 mg, 7.4 mmol) was added and stirring was continued for 1 h.
- 10 The solution was poured into water and the layers separated. The aqueous layer was extracted with methylene chloride and the combined extracts were washed with water, 1N HCl, sat'd  $\text{NaHCO}_3$ , dried over magnesium sulfate, and concentrated to a glassy solid (800 mg, 90%). MS  $[\text{M} + \text{H}]^+$
- 15 243.

(b) Methyl 1-[N-(3-methylbutyl)carbamoyl]cyclopentane-carboxylic acid

- To a solution of methyl 1-[N-(3-methylbutyl)carbamoyl]cyclopentanecarboxylate (820 mg, 3.4 mmol) in 25 mL of THF cooled to  $0^\circ\text{C}$  was added dropwise a solution of lithium hydroxide monohydrate (260 mg, 6.12 mmol) in 5.0 mL of water. The reaction mixture was stirred at rt for 16 h. THF was removed under reduced pressure to give a yellow oil
- 25 which was diluted with 10 mL of 1N HCl. The aqueous phase was extracted with  $\text{CH}_2\text{Cl}_2$  (8 x 15 mL), and the extracts were combined, dried over  $\text{Na}_2\text{SO}_4$ , and concentrated to afford 700mg (90%) of methyl 1-[N-(3-methylbutyl)carbamoyl]-
- 30 cyclopentanecarboxylic acid as a white solid. MS  $[\text{M} + \text{H}]^+$  228.


(c) {[N-(3-methylbutyl)carbamoyl]cyclopentyl}-N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)carboxamide



To 1-[N-(3-methylbutyl)carbamoyl]cyclopentane  
carboxylic acid (38 mg, 0.16 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/DMF (5:1, 15  
mL) at 0°C was added HOBT (28 mg, 0.18 mmol) and EDC (34  
mg, 0.18 mmol). The mixture was stirred for 10 min then 7-  
5 amino-5-methyl-7H-dibenzoazaperhydroepin-6-one (40 mg, 0.16  
mmol) (obtained as the first eluting peak of a racemic  
mixture on a CHIRALCEL OD column with 20% iPrOH/Hexane with  
diethylamine) was added and stirring was continued for 1 h.  
The solution was poured into water and the layers  
10 separated. The aqueous layer was extracted with methylene  
chloride and the combined extracts were washed with water,  
1N HCl, sat'd NaHCO<sub>3</sub>, dried over magnesium sulfate, and  
concentrated to a glassy solid (67 mg, 94%). <sup>1</sup>H NMR (300  
MHz, CD<sub>3</sub>OD) δ 7.20-7.80 (m, 9H), 6.25 (m, 1H), 5.25 (d,  
15 1H), 3.38 (s, 3H), 3.27 (m, 1H), 2.58-2.05 (m, 5H), 1.80-  
1.25 (m, 8H), 0.95, (m, 6H). MS [M + H]<sup>+</sup> 448.

### Example 2

{[N-(3-Methylbutyl)carbamoyl]cyclopentyl}-N-(1-methyl-2-  
20 oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carboxamide




The title compound was prepared in a manner similar to  
that described for Example 1. The product was obtained as  
a solid. MS [M + H]<sup>+</sup> 475.

25

### Example 3


[(N-Butylcarbamoyl)cyclopentyl]-N-(1-methyl-2-oxo-5-  
phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carboxamide



The title compound was prepared in a manner similar to that described for Example 1. The product was obtained as a solid. MS  $[M + H]^+$  461.

#### Example 4

2-(3,5-Difluorophenyl)-N-([N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclohexyl)-acetamide



(a) {[(tert-Butoxy)carbonylamino]cyclohexyl}-N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carboxamide Diisopropylethylamine (2.5 mL, 15.0 mmol) and HATU (2.85 g, 7.5 mmol) were added to a solution of 1-[(tert-butoxy)carbonylamino]cyclohexanecarboxylic acid (1.75 g, 7.2 mmol) in  $CH_2Cl_2$  (10 mL) at  $0^\circ C$  and stirred for 10 min. (S)-3-amino-1-methyl-5-phenyl-3H-benzodiazepin-2-one (3.0 g, 6.0 mmol) was then added. The solution was allowed to warm to room temperature and stirred overnight. The reaction was quenched with water. The organic layer was separated and washed with a saturated solution of  $NaHCO_3$ , 20% citric acid, brine, dried over  $Na_2SO_4$ , filtered and concentrated to afford a white solid (2.98 g, 99%). This compound underwent no further purification:  $^1H$  NMR (500 MHz,  $CD_3OD$ )  $\delta$  7.33-7.13 (m, 9 H), 5.35 (s, 1 H), 3.48 (s, 3 H), 2.21-1.29 (m, 10 H), 1.50, (s, 9 H).

(b) (Aminocyclohexyl)-N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carboxamide


A saturated solution of HCl in EtOAc (50 mL) was added to a solution of {[(tert-butoxy)carbonylamino]cyclohexyl}-(S)-3-N-(1-methyl-2-oxo-5-phenyl(3H-benzoazepin-3-yl))carboxamide (2.9 g, 5.9 mmol) in EtOAc (75 mL) and stirred at room temperature overnight. The reaction was quenched with 1N NaOH (100 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc. The organic layers were combined, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give a white solid (1.76 g, 77 %). mp 106-110 °C; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.33-7.13 (m, 9 H), 5.32 (s, 1 H), 3.48 (s, 3 H), 1.98-1.25 (m, 10 H); CI MS m/z = 391 [C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>+H]<sup>+</sup>; HPLC 100%, t<sub>r</sub> = 9.17 min. (HPLC Conditions A).

(c) 2-(3,5-Difluorophenyl)-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]-cyclohexyl}acetamide

Diisopropylethylamine (0.87 mL, 5.15 mmol) and HATU (979 mg, 2.58 mmol) were added to a solution of 2-(3,5-difluorophenyl)acetic acid (426 mg, 2.47 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) at 0°C and stirred for 5 min. (Aminocyclohexyl)-(S)-3-N-(1-methyl-2-oxo-5-phenyl(3H-benzoazepin-3-yl))carboxamide (800 mg, 2.06 mmol) was then added, and the solution was allowed to warm to room temperature and stirred overnight. The reaction was quenched with water. The organic layer was separated and washed with a saturated solution of NaHCO<sub>3</sub>, 20% citric acid, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give a white solid. Further purification by flash column chromatography afforded the title compound (659 mg, 60%) as a white solid: mp 126-129°C; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.72-7.32 (m, 9 H), 6.97 (d, 2 H), 6.80 (t, 1 H), 5.31 (s, 1 H), 3.70 (s, 2 H), 3.48 (s, 3 H), 2.24-1.30 (m 10 H); API MS m/z = 545 [C<sub>31</sub>H<sub>30</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub>+H]<sup>+</sup>; HPLC 99.5%, t<sub>r</sub> = 22.26 min. (HPLC Conditions A).

### Example 5

2-(3,5-Difluorophenyl)-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl}-acetamide




5

The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as a solid. mp 112-117°C; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.72-7.31(m, 9 H), 6.96 (d, 2 H), 6.81 (t, 1 H) 5.33 (s, 1 H), 3.63 (s, 2 H), 3.47 (s, 3 H), 2.41-1.72 (m, 8 H); API MS m/z = 531 [C<sub>30</sub>H<sub>28</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub>+H]<sup>+</sup>; HPLC 99.4%, t<sub>r</sub> = 21.23 min. (HPLC Conditions A).

10

#### Example 6

15 2-(3,5-Difluorophenyl)-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopropyl}-acetamide




20 The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as a solid. mp 212-214°C; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.71-7.30 (m, 9 H), 6.98 (d, 2 H), 6.81 (t, 1 H), 5.28 (s, 1 H), 3.65 (s, 2 H), 3.48 (s, 3 H), 1.48 (m, 2 H), 1.08 (m, 2 H); API MS m/z = 503 [C<sub>28</sub>H<sub>24</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> + H]<sup>+</sup>; HPLC 97.7%, t<sub>r</sub> = 19.48 min. (HPLC Conditions A).

25

#### Example 7


3-Cyclopentyl-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclohexyl}propanamide



The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as a solid. mp 88-103 °C; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.71-7.30 (m, 9 H), 5.28 (d, 1 H), 3.51 (d, 3 H), 2.39-0.82 (m, 23 H); CI MS m/z = 516 [C<sub>31</sub>H<sub>38</sub>N<sub>4</sub>O<sub>3</sub> + H]<sup>+</sup>; HPLC 96.5%, t<sub>r</sub> = 14.79 min. (HPLC Conditions A).

#### Example 8


2-(3,5-Difluorophenyl)-N-{4-[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carbamoyl](4-piperidyl)}acetamide



The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.15-7.60 (m, 10H), 6.05-6.80 (m, 3H), 5.40 (d, 1H), 3.60 (s, 2H), 3.40 (s, 3H), 2.90 (m, 2H), 2.60 (m, 2H), 2.05, (m, 4H). MS [M + H]<sup>+</sup> 546.

#### Example 9


Phenyl 4-[2-(3,5-difluorophenyl)acetylaminol]-4-[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]piperidine carboxylate



The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.20-7.40 (m, 15H), 6.45-6.80 (m, 3H), 5.40 (d, 1H), 5.15 (s, 2H), 4.85 (s, 3H), 3.85 (m, 1H), 3.60 (s, 2H), 3.40 (s, 3H), 2.20, (m, 4H). MS [M + H]<sup>+</sup> 680.

#### Example 10


4-Methyl-N-([N-(5-methyl-6-oxo(7H-dibenzo[d,f] azaperhydroepin-7-yl)) carbamoyl]cyclopentyl)pentanamide



The title compound was prepared in a manner similar to that described for Example 4. This compound was made from the amino bisbenzazepine obtained as the first eluting peak of a racemic mixture on a CHIRALCEL OD column with 20% iPrOH/Hexane with diethylamine. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.20-7.60 (m, 8H), 6.59 (s, 1H), 5.20 (d, 1H), 3.40 (s, 3H), 2.40-1.60 (m, 13H), 0.9, (d, 6H). MS [M + H]<sup>+</sup> 448.

#### Example 11

N-{1-Methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}{[(phenylmethoxy)carbonylamino]-cyclopentyl}carboxamide




The title compound was prepared in a manner similar to that described for Example 4. This compound was made from

the corresponding amino benzodiazepine that, as the CBz protected form, was the first eluting peak of the racemic mixture on a CHIRALCEL AD column using acetonitrile. The product was obtained as an oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$

5 7.20-7.40 (m, 13H), 5.2 (s, 2H), 5.60 (m, 1H), 5.40 (d, 1H), 5.15 (s, 2H), 3.45 (s, 3H), 2.40 (m, 2H), 2.05-1.80 (m, 6H). MS  $[\text{M} + \text{H}]^+$  579.

#### Example 12

10 (2S)-N-{[N-(1-{[3-(4-Fluorophenoxy)phenyl]methyl}-2-oxoazaperhydroepin-3-yl)carbamoyl]cyclopropyl}-2-hydroxy-4-methylpentanamide




15 The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  7.00-6.70 (m, 8H), 4.45 (m, 5H), 4.15 (m, 1H), 3.10-3.40 (m, 2H), 2.00-1.00 (m, 12H), 0.90, (m, 6H). MS  $[\text{M} + \text{H}]^+$  526.

20

#### Example 13

(2S)-N-{[N-(1-{[3-(4-Fluorophenoxy)phenyl]methyl}-2-oxoazaperhydroepin-3-yl)carbamoyl]cyclopentyl}-2-hydroxy-3-methylbutanamide




25

The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  7.20-6.80 (m, 8H), 4.60 (m, 3H), 4.00 (d, 1H), 3.5 (m, 1H), 3.20 (m, 1H), 2.40-1.05 (m, 17H), 1.00 (d, 3H), 0.90 (d, 3H). MS  $[\text{M} + \text{H}]^+$  540.

30

#### Example 14


2,2-Difluoro-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]-4-phenylbutanamide



5 The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  7.90-7.00 (m, 13H), 5.45 (d, 1H), 3.45 (s, 3H), 2.80 (m, 2H), 2.60-2.20 (m, 6H), 1.80-1.90 (m, 8H). MS  $[\text{M} + \text{H}]^+$  627.

#### Example 15

15 N-[(N-{1-Methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]-3-(4-piperidyl)propanamide




The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  $^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  8.00-7.20 (m, 9H), 6.10 (s, 1H), 5.40 (d, 1H), 5.15 (s, 2H), 3.60 (m, 1H), 3.40 (s, 3H), 3.15 (m, 1H), 2.60-1.20 (m, 14H). MS  $[\text{M} + \text{H}]^+$  584.

#### Example 16

25 (2S)-2-Hydroxy-4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]pentanamide






The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.

5 MS  $[M + H]^+$  559.

#### Example 17

3-Cyclopropyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]propanamide




The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.

15  $^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  7.60-7.20 (m, 8H), 5.40 (m, 1H), 3.45 (s, 3H), 2.70 (s, 2H), 2.40 (m, 4H), 2.05-1.09 (m, 14H), 0.4 (m, 1H), 0.00 (m, 1H). MS  $[M + H]^+$  541.

#### Example 18

20 (Aminocyclopentyl)-N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carboxamide




The title compound was prepared in a manner similar to that described for Example 4. This compound was made from the BZD amine that, as a CBz protected form, was the first peak of the racemic mixture on the CHIRALCEL AD column with acetonitrile. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.20-7.80 (m, 8H), 5.45 (m, 1H), 3.45 (s, 3H), 2.20 (m, 3H), 2.00-1.60 (m, 5H). MS [M + H]<sup>+</sup> 445.

10

**Example 19**

{[(Aminocyclopentyl)carbonylamino]cyclopentyl}-N-((S)1-methyl-2-oxo-5-phenyl(3H-benzo[f]1,4-diazepin-3-yl))carboxamide




15

The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.20-7.60 (m, 9H), 5.45 (d, 1H), 3.45 (s, 3H), 2.80-2.00 (m, 8H), 1.90-1.50 (m, 8H). MS [M + H]<sup>+</sup> 445.

20

**Example 20**

(2R)-2-Hydroxy-3-imidazol-2-yl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]propanamide




The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  
 5 <sup>1</sup>H-NMR(CDCl<sub>3</sub>) 9.16 (d, 1H), 7.69 - 7.52 (m, 5H), 7.33 (d, 1H), 7.24 - 7.15 (m, 3H), 5.45 (d, 1H), 3.42 (s, 3H), 2.24 - 2.14 (m, 3H), 2.11 - 1.84 (m, 1H), 1.83 - 1.72 (m, 4H), 1.66 - 1.56 (m, 2H); MS [M + H]<sup>+</sup> 583.

#### Example 21

10


2-Ethoxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]acetamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  
 15 <sup>1</sup>H-NMR(CDCl<sub>3</sub>) 8.17 (d, 1H), 7.76 - 7.60 (m, 5H), 7.40 (d, 1H), 7.32 - 7.23 (m, 1H), 6.99 (s, 1H), 5.52 (d, 1H), 4.01 (d, 2H), 3.67 - 3.60 (q, 2H), 3.48 (s, 3H), 2.48 - 2.40 (m, 2H), 2.14 - 2.08 (m, 2H), 1.89 - 1.83 (m, 3H), 1.64 (s, 2H), 1.29 (s, 3H); MS [M + H]<sup>+</sup> 531.

#### Example 22


25 3-Cyclopentyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]propanamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  
<sup>1</sup>H-NMR(CDCl<sub>3</sub>) 8.00 (d, 1H), 7.68 - 7.51 (m, 5H), 7.32 (d, 1H), 7.23 - 7.17 (m, 2H), 5.85 (s, 1H), 5.41 (d, 1H), 3.39 (s, 3H), 2.42 - 2.22 (m, 2H), 2.20 (t, 2H), 2.10 - 1.90 (m, 2H), 1.76 - 1.44 (m, 13H), 1.10 - 1.0 (m, 2H); MS [M + H]<sup>+</sup> 569.

#### Example 23


(2S)-2-Hydroxy-3-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl]butanamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  
<sup>1</sup>H-NMR(CDCl<sub>3</sub>) 8.50 (d, 1H), 7.76 - 7.61 (m, 4H), 7.41 (d, 1H), 7.32 - 7.28 (m, 1H), 7.03 (s, 1H), 5.53 - 5.51 (m, 1H), 4.06 (d, 1H), 3.48 (s, 3H), 2.57 - 2.35 (m, 2H), 2.30 - 2.10 (m, 2H), 2.09 - 1.90 (m, 1H), 1.80 - 1.70 (m, 5H), 1.05 (d, 3H), .94 (d, 3H); MS [M + H]<sup>+</sup> 545.

#### Example 24


(2S)-2-Cyclohexyl-2-hydroxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]acetamide



5 The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  
<sup>1</sup>H-NMR(CDCl<sub>3</sub>) 8.04 (d, 1H), 7.67 - 7.51 (m, 4H), 7.31 (d, 1H), 7.23 - 7.18 (m, 1H), 7.02 (s, 1H), 5.42 (d, 1H), 3.94  
 10 (m, 1H), 3.78 (s, 3H), 2.42 - 2.25 (m, 2H), 2.18 - 1.90 (m, 2H), 1.80 - 1.65 (m, 9H), 1.30 - 1.00 (m, 6H); MS [M + H]<sup>+</sup> 585.

#### Example 25


15 (2R)-2-Cyclohexyl-2-hydroxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]acetamide



20 The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  
<sup>1</sup>H-NMR(CDCl<sub>3</sub>) 8.17 (d, 1H), 7.67 - 7.52 (m, 4H), 7.32 (d, 1H), 7.23 - 7.15 (m, 1H), 6.89 (s, 1H), 5.45 (d, 1H), 3.92  
 (d, 1H), 3.39 (s, 3H), 2.45 - 2.25 (m, 2H), 2.10 - 1.95 (m, 2H), 1.80 - 1.50 (m, 10H), 1.25 - 1.00 (m, 6H); MS [M + H]<sup>+</sup>  
 25 585.

## Example 26

(2S)-2-Amino-4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbonyl)cyclopentyl]pentanamide



5


The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil. <sup>1</sup>H-NMR(CDCl<sub>3</sub>) 8.95 (s, 1H), 7.79 - 7.63 (m, 5H), 7.40 -

10 7.30 (m, 2H), 5.46 (s, 1H), 4.20 (d, 2H), 4.0 - 3.90 (m, 1H), 3.51 (s, 3H), 2.40 - 2.20 (m, 2H), 2.10 2.00 (m, 2H), 1.90 - 1.70 (m, 4H), 1.40 - 1.20 (m, 2H), 1.10 - 1.00 (m, 3H), 1.00 - .90 (m, 3H); MS [M + H]<sup>+</sup> 559.

15

## Example 27

[(Cyclohexylcarbonylamino)cyclopentyl]-N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carboxamide



20


The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil. <sup>1</sup>H-NMR(CDCl<sub>3</sub>) 8.10 (d, 1H), 7.75 - 7.62 (m, 3H), 7.42 -

25

7.39 (m, 3H), 7.30 - 7.20 (m, 1H), 6.11 (s, 1H), 5.47 (d, 1H), 3.46 (s, 3H), 2.50 - 2.45 (m, 2H), 2.30 - 2.10 (m, 1H), 2.09-1.75 (m, 9H), 1.70 - 1.60 (m, 1H), 1.50 - 1.40 (m, 2H), 1.39 - 1.20 (m, 3H); MS [M + H]<sup>+</sup> 555.

**Example 29**


{[N-(3-Methylbutyl)carbamoyl]cyclopentyl}-N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carboxamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  
<sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.78-7.60 (m, 5H), 7.48-7.22 (m, 3H), 5.47 (d, 1H), 3.49 (s, 3H), 3.30 (m, 2H), 2.38-2.22 (m, 4H), 1.84-1.38 (m, 7H), 0.90 (d, 6H). MS [M + H]<sup>+</sup> 543.

**Example 30**


4-Methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]pentanamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil.  
<sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.78-7.56 (m, 5H), 7.42-7.20 (m, 3H), 5.46 (d, 1H), 3.44 (s, 3H), 2.48-2.20 (m, 4H), 2.05 (m, 2H), 1.80 (m, 4H), 1.58 (m, 3H), 0.88 (d, 6H). MS [M + H]<sup>+</sup> 543.

**Example 31**


(2S)-2-Hydroxy-4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]pentanamide



5 The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.78-7.58 (m, 5H), 7.43-7.20 (m, 3H), 5.49 (d, 1H), 4.17 (m, 1H), 3.45 (s, 3H), 2.40 (m, 10 2H), 2.10 (m, 2H), 1.92-1.50 (m, 8H), 0.92 (m, 6H). MS [M + H]<sup>+</sup> 559.

#### Example 32

3-Methoxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl)cyclopentyl]propanamide




The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.78-7.56 (m, 5H), 7.40-7.20 (m, 3H), 5.51 (d, 1H), 3.72 (m, 2H), 3.44 (s, 3H), 3.39 (s, 3H), 2.58-2.30 (m, 4H), 2.02 (m, 2H), 1.88 (m, 4H). MS [M + H]<sup>+</sup> 531.

#### Example 33




(2S)-2-Hydroxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]-3-phenylpropanamide



5 The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.72-7.57 (m, 5H), 7.40-7.20 (m, 3H), 5.48 (d, 1H), 4.37 (m, 1H), 3.42 (s, 3H), 3.20 (q, 1H), 2.97 (q, 1H), 2.38 (m, 2H), 1.96 (m, 2H), 1.80-1.52 (m, 4H). MS [M + H]<sup>+</sup> 593.

#### Example 34

15 N-[(N-{1-Methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]-2-(phenylmethoxy)acetamide




20 The title compound was prepared in a manner similar to that described for Example 4 using the amino benzodiazepine employed in Example 1. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.74-7.55 (m, 5H), 7.40-7.20 (m, 3H), 5.48 (d, 1H), 4.61 (q, 2H), 4.12 (q, 2H), 3.44 (s, 3H), 2.42 (m, 2H), 2.05 (m, 2H), 1.80 (m, 4H). MS [M + H]<sup>+</sup> 593.

25

#### Example 35


(2S)-2-Hydroxy-3-methyl-N-([N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl)-butanamide



- 5 The title compound was prepared in a manner similar to that described for Example 4 using the amino bisbenzazepine employed in Example 10. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.64-7.35 (m, 8H), 5.25 (d, 1H), 4.06 (d, 1H), 3.35 (s, 3H), 2.42-2.05 (m, 6H), 1.80 (m, 10 4H), 1.05 (d, 3H), 0.95 (d, 3H). MS [M + H]<sup>+</sup> 450.

#### Example 36


- (2S)-2-Hydroxy-4-methyl-N-([N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl)pentanamide



- The title compound was prepared in a manner similar to that described for Example 4 using the amino bisbenzazepine employed in Example 10. The product was obtained as an oil. 20 <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.64-7.32 (m, 8H), 5.24 (d, 1H), 4.20 (q, 1H), 3.34 (s, 3H), 2.38 (m, 2H), 2.20-1.60 (m, 9H), 0.97 (m, 6H). MS [M + H]<sup>+</sup> 464.

#### Example 37


- 25 3-Cyclopentyl-N-([N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl)propanamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino bisbenzazepine employed in Example 10. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.64-7.35 (m, 8H), 5.25 (d, 1H), 3.36 (s, 3H), 2.42-1.45 (m, 21H). MS [M + H]<sup>+</sup> 474.

### Example 38


(2S)-2-Cyclohexyl-2-hydroxy-N-([N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl)-acetamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino bisbenzazepine employed in Example 10. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.62-7.36 (m, 8H), 5.24 (d, 1H), 3.98 (d, 1H), 3.33 (s, 3H), 2.42-1.04 (m, 19 H). MS [M + H]<sup>+</sup> 490.

### Example 39


3-Cyclopropyl-N-([N-((S)-5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl)-propanamide



The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.56-7.24 (m, 8H), 5.16 (d, 1H), 3.27 (s, 3H), 2.38-2.15 (m, 4H), 2.10-1.82 (m, 2H), 1.78-1.42 (m, 6H), 0.64 (m, 1H), 0.36 (m, 2H), 0.02 (m, 2H). MS [M + H]<sup>+</sup> 446.

## Example 40


N-([N-(1-Butyl-5-cyclopentyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl)-4-methylpentanamide



5 The amino benzodiazepine core was made in a manner similar to that described in the Scheme 6. The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.60-7.22 (m, 4H), 5.25 (d, 1H), 4.36 (m, 1H), 3.56 (m, 1H), 3.31 (m, 1H), 2.40-0.78 (m, 34H). MS [M + H]<sup>+</sup> 509.

## Example 41

15 N-([N-(5-Cyclopentyl-1-methyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl)-4-methylpentanamide




20 The amino benzodiazepine core was made in a manner similar to that described in the Scheme 6. The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.58-7.20 (m, 4H), 5.30 (d, 1H), 3.38 (s, 3H), 3.30 (m, 1H), 2.40-1.20 (m, 21H), 0.89 (d, 6H). MS [M + H]<sup>+</sup> 467.

25

## Example 42


(2S)-2-Hydroxy-3-methyl-N-((N-[2-oxo-1-benzyl(3H,4H,5H-benzo[f]azaperhydroepin-3-yl)]carbamoyl)cyclopentyl)butanamide



The amino benzazepine core was made in a manner similar to that described in J. Med. Chem. **1999**, 42, 2621. The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.34-7.10 (m, 9H), 5.16 (m, 1H), 4.76 (m, 1H), 4.42 (m, 1H), 3.94 (m, 1H), 2.64-1.64 (m, 13H), 1.00-0.86 (m, 6H). MS [M + H]<sup>+</sup> 478.

#### Example 43


(2S)-4-Methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl}-2-[(propylsulfonyl)aminol]pentanamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino bisbenzazepine employed in Example 10. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.62-7.32 (m, 8H), 5.40 (d, 1H), 5.24 (d, 1H), 4.02 (m, 1H), 3.34 (s, 3H), 2.98 (m, 2H), 2.42-1.58 (m, 13H), 0.94-0.85 (m, 9H). MS [M + H]<sup>+</sup> 569.

#### Example 44


(2S)-2-Amino-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl} pentanamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino bisbenzazepine employed in Example 10. The product was obtained as an oil.  
<sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.60-7.30 (m, 8H), 5.22 (d, 1H), 3.32 (s, 3H), 3.08 (m, 1H), 2.48 (s, 3H), 2.46-1.45 (m, 11H), 0.98-0.92 (q, 6H). MS [M + H]<sup>+</sup> 477.

#### Example 45


2,2-Difluoro-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl}-pentanamide



The title compound was prepared in a manner similar to that described for Example 4 using the amino bisbenzazepine employed in Example 10. The product was obtained as an oil.  
<sup>1</sup>H NMR (300 MHz CDCl<sub>3</sub>) 7.62-7.30 (m, 8H), 5.23 (d, 1H), 3.34 (s, 3H), 2.42-1.80 (m, 11H), 1.00 (d, 6H). MS [M + H]<sup>+</sup> 484.

#### Example 56

4-Methyl-N-{[N-(6-oxo(5H,7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl}pentanamide




The title compound was prepared in a manner similar to that described for Example 4. The product was obtained as an oil. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 7.91 (d, J = 6.7 Hz, 1 H), 7.63 (m, 1 H), 7.51-7.28 (m, 7 H), 7.08 (d, J = 7.0 Hz,

1 H), 5.84 (s, 1 H), 5.25 (d,  $J = 6.7$  Hz, 1 H), 2.41-0.89 (m, 19 H); ESI MS  $m/z = 434$   $[C_{26}H_{31}N_3O_3+H]^+$ .

### Example 57

- 5 N-({N-[5-(3,3-Dimethyl-2-oxobutyl)-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)]carbamoyl}cyclopentyl)-4-methylpentanamide




- To a solution of 4-methyl-N-([N-(6-oxo(5H,7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl)pentanamide (540 mg, 1.3 mmol), in DMF (25 mL) was added  $K_2CO_3$  (0.52 g, 3.7 mmol) and bromopinacolone (0.45 g, 2.5 mmol), and the solution was allowed to stir for 40 h at room temperature. The contents of the flask were partitioned between EtOAc and a 5% LiCl solution (150 mL each), the organic phase washed with 5% LiCl (2 x 50 mL), dried over anhydrous  $Na_2SO_4$  and concentrated to yield a white solid. This was further purified by column chromatography [silica gel, EtOAc/hexanes (35:65)] to yield the title compound (340 mg, 51%) as a white solid. The title compound were separated by chiral HPLC using the following conditions: Column, Chiralpak AD column (5 cm x 50 cm); Eluent, 96:4 Hexanes/2-Propanol; Flow rate, 100 mL/min; Monitoring wavelength, 220 nm.
- 25 **Enantiomer A:** 158 mg: mp 126-130 °C;  $^1H$  NMR (300 MHz,  $CDCl_3$ )  $\delta$  7.89 (d,  $J = 6.7$  Hz, 1 H), 7.62-7.13 (m, 8 H), 5.82 (s, 1 H), 5.35 (d,  $J = 7.4$  Hz, 1 H), 4.62 (q<sub>ab</sub>,  $J = 14.1$  Hz, 2 H), 2.47-1.59 (m, 13 H), 1.22 (s, 9 H), 0.92 (d,  $J = 5.8$  Hz, 6 H); IR (KBr) 3410, 2958, 2475, 1724, 1663  $cm^{-1}$ ; ESI MS  $m/z = 532$   $[C_{32}H_{41}N_3O_4+H]^+$ ; HPLC 97.8 %,  $t_r = 24.83$  min. (HPLC Conditions A).
- 30

**Enantiomer B:** 165 mg; mp 126-130 °C;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  7.89 (d,  $J$  = 6.7 Hz, 1 H), 7.62-7.13 (m, 8 H), 5.82 (s, 1 H), 5.35 (d,  $J$  = 7.4 Hz, 1 H), 4.62 (q<sub>ab</sub>,  $J$  = 14.1 Hz, 2 H), 2.47-1.59 (m, 13 H), 1.22 (s, 9 H), 0.92 (d,  $J$  = 5.8 Hz, 6 H); IR (KBr) 3410, 2958, 2475, 1724, 1663  $\text{cm}^{-1}$ ; ESI MS  $m/z$  = 532 [ $\text{C}_{32}\text{H}_{41}\text{N}_3\text{O}_4 + \text{H}$ ] $^+$ ; HPLC 97.8 %,  $t_r$  = 24.83 min. (HPLC Conditions A).

#### Example 58

10 4-Methyl-N-[(N-{6-oxo-5-[(3-phenoxyphenyl)methyl](7H-dibenzo[d,f]azaperhydroepin-7-yl)}carbamoyl)cyclopentyl]pentanamide




The title compound was prepared in a manner similar to that described for Example 57. The product was obtained as a white solid: mp 94-100 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.99 (d,  $J$  = 6.9 Hz, 1 H), 7.58-6.43 (m, 17 H), 5.82 (s, 1 H), 5.39 (d,  $J$  = 7.4 Hz, 1 H), 5.12 (q<sub>ab</sub>,  $J$  = 14.5 Hz, 2 H), 2.47-1.57 (m, 13 H), 0.82 (d,  $J$  = 6.1 Hz, 6 H); IR (KBr) 3332, 2955, 1660, 1584, 1487  $\text{cm}^{-1}$ ; ESI MS  $m/z$  = 616 [ $\text{C}_{39}\text{H}_{41}\text{N}_3\text{O}_4 + \text{H}$ ] $^+$ ; HPLC 99.4%,  $t_r$  = 19.54 min. (HPLC Conditions A).

#### Example 59

25 N-[[N-(5-Butyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl]-4-methylpentanamide






The title compound was prepared in a manner similar to that described for Example 57. The product was obtained as a white solid. The enantiomers were separated by chiral HPLC using the following conditions: Column, Chiralcel OD  
 5 HPLC using the following conditions: Column, Chiralcel OD column (5 cm x 50 cm); Eluent, 95:5 Hexanes/2-Propanol; Flow rate, 100 mL/min; Monitoring wavelength, 270 nm.

**Enantiomer A:** 197 mg: mp 123-126 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.99 (d, *J* = 7.0 Hz, 1 H), 7.58-6.43 (m, 8 H),  
 10 5.91 (s, 1 H), 5.26 (d, *J* = 7.4 Hz, 1 H), 4.29 (m, 2 H), 3.52 (m, 2 H), 2.43-1.19 (m, 15 H), 0.95 (d, *J* = 6.1 Hz, 6 H), 0.62 (m, 3 H); IR (KBr) 3325, 2957, 2871, 1655, 1498 cm<sup>-1</sup>; ESI MS *m/z* = 490 [C<sub>30</sub>H<sub>39</sub>N<sub>3</sub>O<sub>3</sub>+H]<sup>+</sup>; HPLC 100 %, *t<sub>r</sub>* = 20.25 min. (HPLC Conditions A).

**Enantiomer B:** 167 mg: mp 110-115 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.99 (d, *J* = 7.0 Hz, 1 H), 7.58-6.43 (m, 8 H),  
 15 5.91 (s, 1 H), 5.26 (d, *J* = 7.4 Hz, 1 H), 4.29 (m, 2 H), 3.52 (m, 2 H), 2.43-1.19 (m, 15 H), 0.95 (d, *J* = 6.1 Hz, 6 H), 0.62 (m, 3 H); IR (KBr) 3325, 2957, 2871, 1655, 1498  
 20 cm<sup>-1</sup>; ESI MS *m/z* = 490 [C<sub>30</sub>H<sub>39</sub>N<sub>3</sub>O<sub>3</sub>+H]<sup>+</sup>; HPLC 100 %, *t<sub>r</sub>* = 20.26 min. (HPLC Conditions A).

#### Example 60


4-Methyl-N-({N-[6-oxo-5-benzyl(7H-  
 25 dibenzo[d,f]azaperhydroepin-7-yl)]carbamoyl}cyclopentyl)pentanamide




The title compound was prepared in a manner similar to that described for Example 57. The product was obtained as a white solid: mp 103-106 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.01 (d, *J* = 6.8 Hz, 1 H), 7.52-7.25 (m, 8 H), 7.05 (m, 3 H), 6.78 (m, 2 H), 5.84 (s, 1 H), 5.36 (d, *J* = 7.4 Hz, 1 H), 5.04 (q<sub>ab</sub>, *J* = 14.7 Hz, 2 H), 2.41-1.26 (m, 13 H), 0.91 (d, *J* = 5.8 Hz, 6 H); IR (KBr) 3325, 2956, 1655, 1498, 1396 cm<sup>-1</sup>; ESI MS *m/z* = 524 [C<sub>33</sub>H<sub>37</sub>N<sub>3</sub>O<sub>3</sub>+H]<sup>+</sup>; HPLC 100 %, *t<sub>r</sub>* = 27.04 min. (HPLC Conditions A).

### Example 61

N-({N-[5-(tert-Butyl)-1-methyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl)]carbamoyl}cyclopentyl)-4-methylpentanamide



Scheme 7



15

### c) Preparation of 25

To a stirred solution of 23 (see Scheme 6) (1.0 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (0.1 M) was added a 30% solution of HBr in acetic acid (16 equiv). The mixture was stirred for 14 h. The reaction mixture was concentrated in vacuo and dissolved in EtOAc and water and separated. The aqueous layer was made basic using 6 N NaOH and was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The resulting solid was


dissolved in  $\text{CH}_2\text{Cl}_2$  and added to a stirring solution of the acid 24 (1.2 equiv), EDC-HCl (1.5 equiv), HOBT (1.5 equiv), and DIPEA (5.0 equiv) in  $\text{CH}_2\text{Cl}_2$  (0.15 M). The reaction was stirred overnight, quenched with water, washed with 20% citric acid (3x), sat  $\text{NaHCO}_3$  (2x), brine, dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. Crude material was recrystallized from EtOAc and  $\text{Et}_2\text{O}$  to give 25 (4.4 g, 95%) as a white powder:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.71-6.98 (m, 6 H), 5.87 (s, 1 H), 5.29 (d, 1 H), 2.38 (m, 2 H), 2.21 (t, 2 H), 2.01 (m, 2 H), 1.52 (m, 7 H), 1.23 (s, 9 H), 0.88 (d, 6 H).

d) Preparation of Example 61.

To a suspension of 25 (1 equiv) and freshly powdered  $\text{K}_2\text{CO}_3$  (3.0 equiv) in DMF (0.05 M) was added methyl iodide (1.5 equiv). The mixture was stirred (5 h). To the reaction was added EtOAc and water and the layers separated. The organic layer was washed with 5% LiCl (2x), brine, dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The resulting material was dissolved in  $\text{Et}_2\text{O}$  and concentrated in vacuo providing N-({N-[5-(tert-butyl)-1-methyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl)]carbamoyl}-cyclopentyl)-4-methylpentanamide (60 mg, 66%) as a white powder: mp 175-178 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  7.71-7.17 (m, 5 H), 5.89 (s, 1 H), 5.23 (d, 1 H), 3.34 (s, 3 H), 2.41-2.29 (m, 3 H), 2.21 (m, 2 H), 2.04 (m, 3 H), 1.80 (m, 4 H), 1.60 (m, 1 H), 1.18 (s, 9 H), 0.90 (d, 6 H); ESI MS  $m/z$  = 455  $[\text{C}_{26}\text{H}_{38}\text{N}_4\text{O}_3+\text{H}]^+$ ; IR (KBr) = 3324, 2958, 1677, 1508, 1366, 1197  $\text{cm}^{-1}$ ; HPLC 96.8%,  $t_r$  = 15.75 min. (HPLC Conditions A).

Example 62


N-({N-[5-(tert-Butyl)-1-butyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl)]carbamoyl}cyclopentyl)-4-methylpentanamide



The title compound was prepared in a manner similar to that described for Example 62. The product was obtained as a white powder (450 mg, 70%): mp 175-177 °C; <sup>1</sup>H NMR (500  
 5 MHz, CDCl<sub>3</sub>) δ 7.71-7.13 (m, 5 H), 5.89 (s, 1 H), 5.20 (d, 1 H), 4.36 (m, 1 H), 3.50 (m, 1 H), 2.32 (m, 3 H), 2.20 (m, 2 H), 2.02 (m, 3 H), 1.80 (m, 4 H), 1.57 (m, 1 H), 1.35 (m, 2 H), 1.26 (s, 9 H), 1.21 (m, 2 H), 0.89 (d, 6 H), 0.83 (t, 3 H); ESI MS m/z = 497 [C<sub>29</sub>H<sub>44</sub>N<sub>4</sub>O<sub>3</sub>+H]<sup>+</sup>; IR (KBr) = 3321, 2959,  
 10 2363, 1676, 1508, 1365 cm<sup>-1</sup>; HPLC 95.4%, t<sub>r</sub> = 19.69 min. (HPLC Conditions A).

#### Example 63


N-({N-[5-Butyl-2-oxo-1-(2-pyridylmethyl)(3H-benzo[f]1,4-  
 15 diazepin-3-yl)]carbamoyl}cyclopentyl)-4-methylpentanamide



The title compound was prepared in a manner similar to that described for Example 62. The product was obtained as a white powder: mp 63-67 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.46-7.11 (m,  
 20 8 H), 5.89 (s, 1 H), 5.40 (d, J = 6.87 Hz, 1 H), 5.28 (d, J = 15.77 Hz, 1 H), 5.12 (d, J = 15.82 Hz, 1 H), 2.74 (m, 2 H), 2.43-0.77 (m, 27 H); ESI MS m/z = 532 [C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub>+H]<sup>+</sup>; IR (KBr) 3310 (br.), 1670 cm<sup>-1</sup>; HPLC >95% t<sub>r</sub> = 17.07 min. (HPLC Conditions A). Anal. Calcd for [C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub>·0.5H<sub>2</sub>O]: C,  
 25 68.86; H, 7.83; N, 12.95. Found: C, 68.73; H, 7.86; N, 12.79.

Tables 1-4 below provide representative Examples of the compounds of Formula (I) of the present invention.

Table 1



5


Ex#	R <sup>3</sup>	L	C	-WXYZ	R <sup>11</sup>
2	3-Me-butyl	NHC(=O)	cyclopentyl	Me	phenyl
3	n-butyl	NHC(=O)	cyclopentyl	Me	phenyl
4	3,5-diF-benzyl	C(=O)NH	cyclohexyl	Me	phenyl
5	3,5-diF-benzyl	C(=O)NH	cyclopentyl	Me	phenyl
6	3,5-diF-benzyl	C(=O)NH	cyclopropyl	Me	phenyl
7	cyclopentyl	C(=O)NH	cyclohexyl	Me	phenyl
	ethyl				
8	3,5-diF-benzyl	C(=O)NH	4-piperidyl	Me	phenyl
9	3,5-diF-benzyl	C(=O)NH	N-benzyloxy-carbonyl-4-piperidyl	Me	phenyl
11	benzyl	O-C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
14	3-phenyl-1,1-diF-propyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
15	2-(4-piperidyl)ethyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
16	1-hydroxy-3-Me-butyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
17	2-cyclopropyl-ethyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
19	1-amino	C(=O)NH	cyclopentyl	Me	phenyl

	cyclopentyl				
20	1-hydroxy-2-imidazol-2-yl-ethyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
21	ethoxy-methyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
22	2-cyclopentyl-ethyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
23	1-hydroxy-2-Me-propyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
24*	1-hydroxy-1-cyclohexyl-methyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
25*	1-hydroxy-1-cyclohexyl-methyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
26	1-NH <sub>2</sub> -3-Me-butyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
27	cyclohexyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
29	3-Me-butyl	NHC(=O)	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
30	3-Me-butyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
31	1-hydroxy-3-Me-butyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
32	2-methoxy-ethyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
33	1-hydroxy-2-phenyl-ethyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
34	benzyloxy-methyl	C(=O)NH	cyclopentyl	Me	4-CF <sub>3</sub> -phenyl
39	2-cyclopropyl-ethyl	C(=O)NH	cyclopentyl	Me	phenyl
40	3-Me-butyl	C(=O)NH	cyclopentyl	n-butyl	cyclopentyl
41	3-Me-butyl	C(=O)NH	cyclopentyl	Me	cyclopentyl
61	3-Me-butyl	C(=O)NH	cyclopentyl	Me	t-butyl
62	3-Me-butyl	C(=O)NH	cyclopentyl	n-butyl	t-butyl

63	3-Me-butyl	C(=O)NH	cyclopentyl	2- pyridyl -methyl	n-butyl
----	------------	---------	-------------	--------------------------	---------


\* stereoisomers

Table 2



Ex. #	R <sup>3</sup>	L	C	Z-Y-X-W-
1	3-Me-butyl	NHC(=O)	cyclopentyl	Me
10	3-Me-butyl	C(=O)NH	cyclopentyl	Me
35	1-hydroxy-2-Me-propyl	C(=O)NH	cyclopentyl	Me
36	1-hydroxy-3-Me-butyl	C(=O)NH	cyclopentyl	Me
37	2-cyclopentyl-ethyl	C(=O)NH	cyclopentyl	Me
38	1-hydroxy-1-cyclohexyl-methyl	C(=O)NH	cyclopentyl	Me
43	1-(propyl-sulfamide)-3-Me-butyl	C(=O)NH	cyclopentyl	Me
44	1-(N-Me-amino)-3-Me-butyl	C(=O)NH	cyclopentyl	Me
45	1,1-diF-3-Me-butyl	C(=O)NH	cyclopentyl	Me
56	3-Me-butyl	C(=O)NH	cyclopentyl	H
57	3-Me-butyl	C(=O)NH	cyclopentyl	3,3-dimethyl-2-oxobutyl
58	3-Me-butyl	C(=O)NH	cyclopentyl	3-phenoxy-benzyl
59	3-Me-butyl	C(=O)NH	cyclopentyl	n-butyl
60	3-Me-butyl	C(=O)NH	cyclopentyl	benzyl


Table 3



Ex. #	R <sup>3</sup>	L	C	Z-Y-X-W-
12	1-hydroxy-3-Me-butyl	C(=O)NH	cyclopropyl	3-(4-F-phenoxy)-benzyl
13	1-hydroxy-3-Me-propyl	C(=O)NH	cyclopentyl	3-(4-F-phenoxy)-benzyl

5

Table 4



Ex. #	R <sup>3</sup>	L	C	Z-Y-X-W-
42	1-hydroxy-2-Me-propyl	C(=O)NH	cyclopentyl	benzyl

#### UTILITY

- 10 A $\beta$  production has been implicated in the pathology of Alzheimer's Disease (AD). The compounds of the present invention have utility for the prevention and treatment of AD by inhibiting A $\beta$  production. Methods of treatment target formation of A $\beta$  production through the enzymes
- 15 involved in the proteolytic processing of  $\beta$  amyloid precursor protein. Compounds that inhibit  $\beta$  or  $\gamma$  secretase activity, either directly or indirectly, control the production of A $\beta$ . Such inhibition of  $\beta$  or  $\gamma$  secretases reduces production of A $\beta$ , and is expected to reduce or



prevent the neurological disorders associated with A $\beta$  protein, such as Alzheimer's Disease.

Cellular screening methods for inhibitors of A $\beta$  production, testing methods for the *in vivo* suppression of A $\beta$  production, and assays for the detection of secretase activity are known in the art and have been disclosed in numerous publications, including *J. Med. Chem.* 1999, 42, 3889-3898, PCT publication number WO 98/22493, EPO publication number 0652009, US patent 5703129 and US patent 5593846; all hereby incorporated by reference.

The compounds of the present invention have utility for the prevention and treatment of disorders involving A $\beta$  production, such as cerebrovascular disorders.

Compounds of Formula (I) are expected to possess  $\gamma$ -secretase inhibitory activity. The  $\gamma$ -secretase inhibitory activity of the compound of the present invention is demonstrated using assays for such activity, for example, using the assay described below. Compounds of the present invention have been shown to inhibit the activity of  $\gamma$ -secretase, as determined by the A $\beta$  immunoprecipitation assay.

Compounds provided by this invention should also be useful as a standard and reagent in determining the ability of a potential pharmaceutical to inhibit A $\beta$  production. These would be provided in commercial kits comprising a compound of this invention.

As used herein " $\mu$ g" denotes microgram, "mg" denotes milligram, "g" denotes gram, " $\mu$ L" denotes microliter, "mL" denotes milliliter, "L" denotes liter, "nM" denotes nanomolar, " $\mu$ M" denotes micromolar, "mM" denotes millimolar, "M" denotes molar, "nm" denotes nanometer, "SDS" denotes sodium dodecyl sulfate, and "DMSO" denotes dimethyl sulfoxide, and "EDTA" denotes ethylenediaminetetraacetic acid.

A compound is considered to be active if it has an IC<sub>50</sub> or K<sub>i</sub> value of less than about 100 $\mu$ M for the inhibition of A $\beta$  production. Preferably the IC<sub>50</sub> or K<sub>i</sub>

value is less than about 10 $\mu$ M; more preferably the IC<sub>50</sub> or K<sub>i</sub> value is less than about 0.1 $\mu$ M. The present invention has been shown to inhibit A $\beta$  protein production with an IC<sub>50</sub> or K<sub>i</sub> value of less than 100 $\mu$ M.

5

$\beta$  amyloid precursor protein accumulation assay

A novel assay to evaluate the accumulation of A $\beta$  protein was developed to detect potential inhibitors of secretase. The assay uses the N 9 cell line, characterized for expression of exogenous APP by immunoblotting and immunoprecipitation.

The effect of test compounds on the accumulation of A $\beta$  in the conditioned medium is tested by immunoprecipitation. Briefly, N 9 cells are grown to confluency in 6-well plates and washed twice with 1 x Hank's buffered salt solution. The cells are starved in methionine/cysteine deficient media for 30 min, followed by replacement with fresh deficient media containing 150 $\mu$ Ci S35 Translabel (Amersham). Test compounds dissolved in DMSO (final concentration 1%) are added together with the addition of radiolabel. The cells are incubated for 4 h at 37 °C in a tissue culture incubator.

At the end of the incubation period, the conditioned medium is harvested and pre-cleared by the addition of 5  $\mu$ l normal mouse serum and 50 $\mu$ l of protein A Sepharose (Pharmacia), mixed by end-over-end rotation for 30 minutes at 4 °C, followed by a brief centrifugation in a microfuge. The supernatant is then harvested and transferred to fresh tubes containing 5 $\mu$ g of a monoclonal antibody (clone 1101.1; directed against an internal peptide sequence in A $\beta$ ) and 50  $\mu$ l protein A Sepharose. After incubation overnight at 4°C, the samples are washed three times with high salt washing buffer (50mM Tris, pH 7.5, 500mM NaCl, 5mM EDTA, 0.5% Nonidet P-40), three times with low salt wash buffer (50mM Tris, pH 7.5, 150mM NaCl, 5mM EDTA, 0.5% Nonidet P-40), and three times with 10mM Tris, pH 7.5. The pellet after the last wash is resuspended in SDS sample

buffer (Laemmli, 1970) and boiled for 3 minutes. The supernatant is then fractionated on either 10-20% Tris/Tricine SDS gels or on 16.5% Tris/Tricine SDS gels. The gels are dried and exposed to X-ray film or analyzed by phosphorimaging. The resulting image is analyzed for the presence of A $\beta$  polypeptides. The steady-state level of A $\beta$  in the presence of a test compound is compared to wells treated with DMSO (1%) alone. A typical test compound blocks A $\beta$  accumulation in the conditioned medium, and is therefore considered active, with an IC<sub>50</sub> less than 100  $\mu$ M.

#### C-Terminus $\beta$ Amyloid Precursor Protein Accumulation Assay

The effect of a test compound on the accumulation of C-terminal fragments is determined by immunoprecipitation of APP and fragments thereof from cell lysates. N 9 cells are metabolically labeled as above in the presence or absence of test compounds. At the end of the incubation period, the conditioned medium are harvested and cells lysed in RIPA buffer (10 mM Tris, pH 8.0 containing 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 150mM NaCl, 0.125% NaN<sub>3</sub>). Again, lysates are precleared with 5ul normal rabbit serum / 50ul protein A Sepharose, followed by the addition of BC-1 antiserum (15ul;) and 50ul protein A Sepharose for 16 hours at 4°C. The immunoprecipitates are washed as above, bound proteins eluted by boiling in SDS sample buffer and fractionated by Tris/Tricine SDS-PAGE. After exposure to X-ray film or phosphorimager, the resulting images are analyzed for the presence of C-terminal APP fragments. The steady-state level of C-terminal APP fragments is compared to wells treated with DMSO (1%) alone. A typical test compound stimulates C-terminal fragment accumulation in the cell lysates, and is therefore considered active, with an IC<sub>50</sub> less than 100  $\mu$ M.

#### A $\beta$ -Immunoprecipitation Assay

This immunoprecipitation assay is specific for  $\gamma$ -secretase (i.e., proteolytic activity required to generate

the C-terminal end of A $\beta$  either by direct cleavage or generating a C-terminal extended species which is subsequently further proteolyzed). N 9 cells are pulse labeled in the presence of a reported  $\gamma$ -secretase inhibitor (MDL 28170) for 1 h, followed by washing to remove radiolabel and MDL 28170. The media is replaced and test compounds are added. The cells are chased for increasing periods of times and A $\beta$  is isolated from the conditioned medium and C-terminal fragments from cell lysates (see above). The test compound is characterized whether a stabilization of C-terminal fragments is observed and whether A $\beta$  is generated from these accumulated precursor. A typical test compound prevents the generation of A $\beta$  out of accumulated C-terminal fragments and is considered active with an IC<sub>50</sub> less than 100  $\mu$ M.

#### Dosage and Formulation

The compound of the present invention can be administered orally using any pharmaceutically acceptable dosage form known in the art for such administration. The active ingredient can be supplied in solid dosage forms such as dry powders, granules, tablets or capsules, or in liquid dosage forms, such as syrups or aqueous suspensions. The active ingredient can be administered alone, but is generally administered with a pharmaceutical carrier. A valuable treatise with respect to pharmaceutical dosage forms is Remington's Pharmaceutical Sciences, Mack Publishing.

The compound of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. An effective

but non-toxic amount of the compound desired can be employed to prevent or treat neurological disorders related to  $\beta$ -amyloid production or accumulation, such as Alzheimer's disease and Down's Syndrome.

5       The compound of this invention can be administered by any means that produces contact of the active agent with the agent's site of action in the body of a host, such as a human or a mammal. The compound can be administered by any conventional means available for use in conjunction with  
10       pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. The compound can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical  
15       practice.

      The dosage regimen for the compound of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration;  
20       the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired.  
25       An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

      Advantageously, the compounds of the present invention  
30       may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.

      The compound for the present invention can be administered in intranasal form via topical use of suitable  
35       intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form

of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

In the methods of the present invention, the compound  
5 herein described in detail can form the active ingredient, and is typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as carrier materials) suitably selected with respect to the intended form of  
10 administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be  
15 combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug  
20 components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into  
25 the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or  $\beta$ -lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used  
30 in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

35 The compound of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles,

and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

Compound of the present invention may also be coupled  
5 with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.  
10 Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone,  
15 polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.

Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose  
20 derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed  
25 tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can  
30 contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions  
35 for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing

agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions  
5 can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.


10



CLAIMS

What is claimed is:

1. A compound of Formula (I):



- or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, wherein:

L is  $-NR^{26}C(=O)-$ ,  $-C(=O)NR^{26}-$ ,  $-NR^{26}C(=O)O-$ ,  $-OC(=O)NR^{26}$ , or  $-NR^{26}C(=O)NR^{26}-$ ;

- $R^3$  is  $-(CR^7R^{7a})_n-R^4$ ,  
 $-(CR^7R^{7a})_1-S-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-O-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-N(R^{7b})-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-S(=O)-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-S(=O)_2-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-C(=O)-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-N(R^{7b})C(=O)-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-C(=O)N(R^{7b})-(CR^7R^{7a})_m-R^4$ ,  
 $-(CR^7R^{7a})_1-N(R^{7b})S(=O)_2-(CR^7R^{7a})_m-R^4$ , or  
 $-(CR^7R^{7a})_1-S(=O)_2N(R^{7b})-(CR^7R^{7a})_m-R^4$ ;

n is 0, 1, 2, or 3;

m is 0, 1, 2, or 3;

l is 1, 2, or 3;

Ring C is a 3 to 8 membered carbocycle,

wherein the carbocycle is saturated or partially saturated;  
optionally, the carbocycle contains a heteroatom selected from -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, and  
5 -N(R<sup>20</sup>)-; and

wherein the carbocycle is substituted with 0-4 R<sup>21</sup>;

R<sup>4</sup> is H, OH, OR<sup>14a</sup>,

10 C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>8</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>8</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, or  
5 to 10 membered heterocycle containing 1 to 4  
15 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from H,  
20 OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
25 sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>4b</sup>;

R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
30 S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>6</sup> is H;

C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>6a</sup>;  
35 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>6b</sup>; or  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>6b</sup>;

- R<sup>6a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, aryl and CF<sub>3</sub>;
- 5 R<sup>6b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;
- 10 R<sup>7</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl substituted with 0-5 R<sup>7c</sup>;
- R<sup>7a</sup>, at each occurrence, is independently selected from H, Cl, F, Br, I, CN, CF<sub>3</sub>, and C<sub>1</sub>-C<sub>4</sub> alkyl;
- 15 R<sup>7b</sup> is independently selected from H and C<sub>1</sub>-C<sub>4</sub> alkyl;
- R<sup>7c</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, CF<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkoxy, and C<sub>1</sub>-C<sub>4</sub> alkyl;
- 20 B is a 5 to 10 membered lactam, wherein the lactam is saturated, partially saturated or unsaturated; wherein each additional lactam carbon is substituted with 0-2 R<sup>11</sup>; and, optionally, the lactam contains an additional heteroatom selected from -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N=, -NH-, and -N(R<sup>10</sup>)-;
- 30 R<sup>10</sup> is H, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>R<sup>17</sup>; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>10a</sup>; C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>10b</sup>; C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>10b</sup>; or
- 35 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>10b</sup>;

5 R<sup>10a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, aryl substituted with 0-4 R<sup>10b</sup>; C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>10b</sup>, and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>10b</sup>;

15 R<sup>10b</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

20 R<sup>11</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>11a</sup>; C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>11b</sup>; C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;

30 R<sup>11a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>; phenyl substituted with 0-3 R<sup>11b</sup>; C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>11b</sup>; and 5 to 6 membered heterocycle containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;

R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

5 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10 additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-3 R<sup>13</sup>;

15 additionally, two R<sup>11</sup> substituents on the same or adjacent carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>13</sup>;

20 additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-4 R<sup>13</sup>;

W is -(CR<sup>8</sup>R<sup>8a</sup>)<sub>p</sub>-;

25 p is 0, 1, 2, 3, or 4;

R<sup>8</sup> and R<sup>8a</sup>, at each occurrence, are independently selected from H, F, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl and C<sub>3</sub>-C<sub>8</sub> cycloalkyl;

30

X is a bond;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>Xb</sup>;

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>Xb</sup>; or

5 to 10 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;

35

R<sup>Xb</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,

$S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxy,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  haloalkoxy, and  $C_1-C_4$  halothioalkoxy;

Y is a bond or  $-(CR^9R^{9a})_t-V-(CR^9R^{9a})_u-$ ;

5

t is 0, 1, 2, or 3;

u is 0, 1, 2, or 3;

10  $R^9$  and  $R^{9a}$ , at each occurrence, are independently selected from H, F,  $C_1-C_6$  alkyl and  $C_3-C_8$  cycloalkyl;

V is a bond,  $-C(=O)-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$ ,  $-S(=O)_2-$ ,  
 $-N(R^{19})-$ ,  $-C(=O)NR^{19b}-$ ,  $-NR^{19b}C(=O)-$ ,  $-NR^{19b}S(=O)_2-$ ,  
15  $S(=O)_2NR^{19b}-$ ,  $-NR^{19b}S(=O)-$ ,  $-S(=O)NR^{19b}-$ ,  $-C(=O)O-$ , or  
 $-OC(=O)-$ ;

Z is H;

20  $C_1-C_8$  alkyl substituted with 1-3  $R^{12}$ ;  
 $C_2-C_4$  alkenyl substituted with 1-3  $R^{12}$ ;  
 $C_2-C_4$  alkynyl substituted with 1-3  $R^{12}$ ;  
 $C_1-C_8$  alkyl substituted with 0-3  $R^{12a}$ ;  
 $C_2-C_4$  alkenyl substituted with 0-3  $R^{12a}$ ;  
 $C_2-C_4$  alkynyl substituted with 0-3  $R^{12a}$ ;  
25  $C_6-C_{10}$  aryl substituted with 0-4  $R^{12b}$ ;  
 $C_3-C_{10}$  carbocycle substituted with 0-4  $R^{12b}$ ; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
30 is substituted with 0-3  $R^{12b}$ ;

$R^{12}$ , at each occurrence, is independently selected from  
 $C_6-C_{10}$  aryl substituted with 0-4  $R^{12b}$ ;  
 $C_3-C_{10}$  carbocycle substituted with 0-4  $R^{12b}$ ; and  
35 5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

5 R<sup>12a</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10 R<sup>12b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

15 R<sup>13</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

20 R<sup>14</sup> is H, phenyl substituted with 0-4 R<sup>14b</sup>, benzyl substituted with 0-4 R<sup>14b</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, or C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>14a</sup> is H, C<sub>6</sub>-C<sub>10</sub> aryl, benzyl, heterocycle, or C<sub>1</sub>-C<sub>4</sub> alkyl;

25 R<sup>14b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

30 R<sup>15</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl-(C<sub>1</sub>-C<sub>6</sub> alkyl)- wherein the aryl is substituted with 0-4 R<sup>15b</sup>, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

R<sup>15b</sup>, at each occurrence, is independently selected from

H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

5

R<sup>16</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

10 R<sup>17</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl,  
aryl substituted by 0-4 R<sup>17a</sup>, or  
-CH<sub>2</sub>-aryl substituted by 0-4 R<sup>17a</sup>;

15 R<sup>17a</sup> is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
propoxy, butoxy, -OH, F, Cl, Br, I, CF<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>,  
S(O)CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, -NH<sub>2</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

20 R<sup>18</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

25 R<sup>19</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

30 R<sup>20</sup> is H, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>,  
S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>R<sup>17</sup>;  
C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-2 R<sup>20a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>20b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>20b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>20b</sup>;

35

R<sup>20a</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, F, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, aryl



substituted with 0-4 R<sup>20b</sup>, and heterocycle substituted with 0-4 R<sup>20b</sup>;

- 5 R<sup>20b</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;
- 10 R<sup>21</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>21a</sup>; C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>21b</sup>;
- 15 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>21b</sup>; and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>21b</sup>;
- 20 R<sup>21a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>; phenyl substituted with 0-3 R<sup>21b</sup>;
- 25 C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>21b</sup>; and 5 to 6 membered heterocycle containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>21b</sup>;
- 30 R<sup>21b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,
- 35 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

additionally, two  $R^{21}$  substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-3  $R^{23}$ ;

additionally, two  $R^{21}$  substituents on the same or adjacent carbon atoms may be combined to form a  $C_3-C_6$  carbocycle substituted with 0-3  $R^{23}$ ;

additionally, two  $R^{21}$  substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-4  $R^{23}$ ;

$R^{23}$ , at each occurrence, is independently selected from H, OH,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxy, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ , and  $CF_3$ ;

$R^{26}$  is H;  
 $C_1-C_6$  alkyl substituted with 0-3  $R^{26a}$ ;  
 $C_3-C_{10}$  carbocycle substituted with 0-3  $R^{26b}$ ; or  
 $C_6-C_{10}$  aryl substituted with 0-3  $R^{26b}$ ;


$R^{26a}$ , at each occurrence, is independently selected from H,  $C_1-C_6$  alkyl,  $OR^{14}$ , Cl, F, Br, I, =O, CN,  $NO_2$ ,  $NR^{15}R^{16}$ , aryl and  $CF_3$ ; and

$R^{26b}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $CF_3$ ,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxy,  $C_1-C_4$  haloalkyl, and  $C_1-C_4$  haloalkoxy.

2. A compound of Claim 1, wherein:

L is  $-NR^{26}C(=O)-$ ,  $-C(=O)NR^{26}-$ , or  $-OC(=O)NR^{26}-$ ;

$R^3$  is  $-(CHR^7)_n-R^4$ ,



n is 0, 1 or 2;

5

m is 0, 1 or 2;

l is 1;

10 Ring C is a 3 to 8 membered carbocycle substituted with 0-4  $\text{R}^{21}$ ; optionally, the carbocycle contains a heteroatom selected from -O- and -N( $\text{R}^{20}$ )-;

15  $\text{R}^4$  is H, OH,  $\text{OR}^{14a}$ ,  
C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3  $\text{R}^{4a}$ ,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-2  $\text{R}^{4a}$ ,  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-1  $\text{R}^{4a}$ ,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3  $\text{R}^{4b}$ ,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3  $\text{R}^{4b}$ , or  
20 5 to 6 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3  $\text{R}^{4b}$ ;

25  $\text{R}^{4a}$ , at each occurrence, is independently selected from H,  
OH, F, Cl, Br, I,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ ,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3  $\text{R}^{4b}$ ,  
phenyl substituted with 0-3  $\text{R}^{4b}$ , and  
5 to 6 membered heterocycle containing 1 to 4  
30 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3  $\text{R}^{4b}$ ;

35  $\text{R}^{4b}$ , at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN,  $\text{NO}_2$ ,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ , acetyl,  $\text{SCH}_3$ ,  
 $\text{S}(=\text{O})\text{CH}_3$ ,  $\text{S}(=\text{O})_2\text{CH}_3$ , C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub>  
haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

R<sup>6</sup> is H;

5 R<sup>7</sup>, at each occurrence, is independently selected from H,  
OH, F, CF<sub>3</sub>, methyl, and ethyl;

Ring B is a 7 membered lactam,

wherein the lactam is saturated, partially saturated  
or unsaturated;

10 wherein each additional lactam carbon is substituted  
with 0-2 R<sup>11</sup>; and,  
optionally, the lactam contains a heteroatom selected  
from -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N=, -NH-, and  
-N(R<sup>10</sup>)-;

15 R<sup>10</sup> is H, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>,  
S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>R<sup>17</sup>;

C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-2 R<sup>10a</sup>;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>10b</sup>;

20 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>10b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>10b</sup>;

25

R<sup>10a</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, phenyl substituted with 0-4 R<sup>10b</sup>; and 5 to 10  
membered heterocycle containing 1 to 4 heteroatoms  
30 selected from nitrogen, oxygen, and sulphur, wherein  
said 5 to 10 membered heterocycle is substituted with  
0-3 R<sup>10b</sup>;

35 R<sup>10b</sup>, at each occurrence, is independently selected from H,  
OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>,  
NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

R<sup>11</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>, C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>; C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>11a</sup>; C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>11b</sup>; C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;

R<sup>11a</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl substituted with 0-3 R<sup>11b</sup>;

R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a benzo fused radical; wherein said benzo fused radical is substituted with 0-2 R<sup>13</sup>;

additionally, two R<sup>11</sup> substituents on adjacent atoms may be combined to form a 5 to 6 membered heteroaryl fused radical, wherein said 5 to 6 membered heteroaryl fused radical comprises 1 or 2 heteroatoms selected from N, O, and S; wherein said 5 to 6 membered heteroaryl fused radical is substituted with 0-2 R<sup>13</sup>;

additionally, two R<sup>11</sup> substituents on the same or adjacent carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-2 R<sup>13</sup>;

W is a bond, -CH<sub>2</sub>-, -CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>- or -CH(CH<sub>3</sub>)CH<sub>2</sub>-;

X is a bond;  
phenyl substituted with 0-2 R<sup>Xb</sup>;  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-2 R<sup>Xb</sup>; or  
5 to 6 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;

5

R<sup>Xb</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl,  
and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

10

Y is a bond, -CH<sub>2</sub>-V-, -V-, or -V-CH<sub>2</sub>-;

V is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-,  
-N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;

15

Z is H; C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>2</sub>-C<sub>4</sub> alkenyl; C<sub>2</sub>-C<sub>4</sub> alkynyl;

C<sub>1</sub>-C<sub>3</sub> alkyl substituted with 1-2 R<sup>12</sup>;

C<sub>2</sub>-C<sub>3</sub> alkenyl substituted with 1-2 R<sup>12</sup>;

C<sub>2</sub>-C<sub>3</sub> alkynyl substituted with 1-2 R<sup>12</sup>;

20

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>12b</sup>; or

5 to 10 membered heterocycle substituted with 0-3  
R<sup>12b</sup>;

25 R<sup>12</sup>, at each occurrence, is independently selected from

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

30

sulphur, wherein said 5 to 10 membered heterocycle

is substituted with 0-3 R<sup>12b</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from

H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,

35

SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

5 R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>2</sub>-C<sub>4</sub> alkoxyalkyl;

R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

10 R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>4</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-,  
and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

15 R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>4</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

20 R<sup>17</sup> is H, methyl, ethyl, propyl, butyl, methoxymethyl,  
ethoxymethyl, methoxyethyl, ethoxyethyl,  
phenyl substituted by 0-3 R<sup>17a</sup>, or  
-CH<sub>2</sub>-phenyl substituted by 0-3 R<sup>17a</sup>;

R<sup>17a</sup> is H, methyl, methoxy, -OH, F, Cl, CF<sub>3</sub>, or OCF<sub>3</sub>;

25 R<sup>18</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and  
phenethyl;

30 R<sup>19</sup>, at each occurrence, is independently selected from  
H, methyl, and ethyl;


R<sup>20</sup> is H or C(=O)OR<sup>17</sup>;

R<sup>26</sup> is H, methyl, or ethyl.

35

3. A compound of Claim 2, wherein:



Ring C is selected from:




wherein Ring C is substituted with 0-2  $R^{21}$ ; and

5

Ring B is selected from:



10



4. A compound of Claim 3, wherein:

15

L is  $-NHC(=O)-$ ,  $-C(=O)NH-$ , or  $-OC(=O)NH-$ ;

$R^3$  is  $R^4$ ,  $-CH_2OR^4$ , or  $-CH_2CH_2OR^4$ ;

20

$R^4$  is  $C_1$ - $C_6$  alkyl substituted with 0-3  $R^{4a}$ ,  
 $C_2$ - $C_6$  alkenyl substituted with 0-1  $R^{4a}$ , or  
 $C_2$ - $C_6$  alkynyl substituted with 0-1  $R^{4a}$ ;

$R^{4a}$ , at each occurrence, is independently selected from

25

H, OH, F,  $NR^{15}R^{16}$ ,  $CF_3$ ,



C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, and

5 to 6 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle

is substituted with 0-3 R<sup>4b</sup>; wherein said 5 to 6

membered heterocycle is selected from pyridinyl,

pyrimidinyl, triazinyl, furanyl, thienyl,

thiazolyl, pyrrolyl, piperazinyl, piperidinyl,

pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and

tetrazolyl;

R<sup>4b</sup>, at each occurrence, is independently selected from H,

OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,

S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy,

ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>

haloalkoxy;

W is a bond, -CH<sub>2</sub>-, -CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>- or -CH(CH<sub>3</sub>)CH<sub>2</sub>-;

X is a bond, phenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or  
5 to 6 membered heterocycle;

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-,

-N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-,

Z is H; C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl,

C<sub>1</sub>-C<sub>3</sub> alkyl substituted with 1-2 R<sup>12</sup>;

C<sub>2</sub>-C<sub>3</sub> alkenyl substituted with 1-2 R<sup>12</sup>;

C<sub>2</sub>-C<sub>3</sub> alkynyl substituted with 1-2 R<sup>12</sup>;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>12b</sup>; or

5 to 6 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 6 membered heterocycle

is substituted with 0-3 R<sup>12b</sup>; wherein said 5 to 6

membered heterocycle is selected from pyridinyl,

pyrimidinyl, triazinyl, furanyl, thienyl,  
thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and  
tetrazolyl;

5

R<sup>12</sup>, at each occurrence, is independently selected from  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>12b</sup>; and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle is  
substituted with 0-3 R<sup>12b</sup>; wherein said 5 to 6  
membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl,  
pyrrolyl, piperazinyl, piperidinyl, pyrazolyl,  
imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;

10

15

R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy,  
ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;

20

R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
Cl, F, Br, CN, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

25

R<sup>14</sup> is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;

30

R<sup>15</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, and butyl;

R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, benzyl,  
phenethyl, methyl-C(=O)-, ethyl-C(=O)-,  
methyl-S(=O)<sub>2</sub>-, ethyl-S(=O)<sub>2</sub>-, and propyl-S(=O)<sub>2</sub>-;

35

R<sup>18</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl;

5 R<sup>19</sup>, at each occurrence, is independently selected from H, methyl, and ethyl;

R<sup>20</sup> is H.


10 5. A compound of Claim 3, wherein:

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

R<sup>3</sup> is -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,  
 15 -CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>(CH<sub>3</sub>)<sub>2</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
 -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>,  
 -CH(OH)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH(OH)CH(CH<sub>3</sub>)<sub>2</sub>, -CH(NH<sub>2</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
 -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CF<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
 -CH(NHCH<sub>3</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH(NHSO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
 20 cyclohexyl-, cyclopentyl-, cyclopropyl-CH<sub>2</sub>-,  
 cyclobutyl-CH<sub>2</sub>-, cyclopentyl-CH<sub>2</sub>-, cyclohexyl-CH<sub>2</sub>-,  
 cyclopropyl-CH<sub>2</sub>CH<sub>2</sub>-, cyclobutyl-CH<sub>2</sub>CH<sub>2</sub>-,  
 cyclopentyl-CH<sub>2</sub>CH<sub>2</sub>-, cyclohexyl-CH(OH)-,  
 cyclohexyl-CH<sub>2</sub>CH<sub>2</sub>-, 1-NH<sub>2</sub>-cyclopentyl, phenyl-CH<sub>2</sub>-,  
 25 (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>-,  
 (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>-,  
 (2,3-diF-phenyl)CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>-,  
 (2,5-diF-phenyl)CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>-,  
 (3,4-diF-phenyl)CH<sub>2</sub>-, (3,5-diF-phenyl)CH<sub>2</sub>-,  
 30 (2,3-diCl-phenyl)CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>-,  
 (2,5-diCl-phenyl)CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>-,  
 (3,4-diCl-phenyl)CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>-,  
 (3-F-4-Cl-phenyl)CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>-,  
 (3-Cl-4-F-phenyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
 35 (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,


(2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 5 (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-piperidinyl-CH<sub>2</sub>CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>CF<sub>2</sub>-,  
 phenyl-CH<sub>2</sub>CH(OH)-, imidazolyl-CH<sub>2</sub>CH(OH)-, or  
 10 phenyl-CH<sub>2</sub>OCH<sub>2</sub>-;

Ring C is selected from:



15

Ring B is selected from:




20

wherein each benzo fused ring is substituted with 0-1 R<sup>13</sup>;

25 W is a bond or -CH<sub>2</sub>-;

X is a bond;



Y is a bond,  $-C(=O)-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$ ,  $-S(=O)_2-$ ,  $-NH-$ , or  $-N(CH_3)-$ ,

10

Z is phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl, 2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl, 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl, 2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl, 3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl, 3-F-5-Cl-phenyl, 3-Cl-4-F-phenyl, 2-MeO-phenyl, 3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl, 2-CF<sub>3</sub>O-phenyl, 3-CF<sub>3</sub>O-phenyl, 4-CF<sub>3</sub>O-phenyl, furanyl, thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl, 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl, 1-benzimidazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholino, N-piperinyl, phenyl-CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>-, (3,5-diF-phenyl)CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>-,

15

20

25

30

(2-MeO-phenyl)CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>-,  
5 4-MeS-phenyl)CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(furanyl)CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>-, (1-imidazolyl)CH<sub>2</sub>-,  
10 (oxazolyl)CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>-,  
(1-benzimidazolyl)CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>-,  
(cyclohexyl)CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>-,  
(N-pipridinyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
15 (phenyl)<sub>2</sub>CHCH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
20 (2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
25 (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
30 (4-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(furanyl)CH<sub>2</sub>CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (imidazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
35 (oxazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(benzimidazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>CH<sub>2</sub>-,

(cyclohexyl)CH<sub>2</sub>CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>CH<sub>2</sub>-, or  
(N-piperidinyl)CH<sub>2</sub>CH<sub>2</sub>-;


5 R<sup>10</sup> is H, methyl, ethyl, phenyl, benzyl, phenethyl,  
4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-CH<sub>3</sub>-phenyl, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-CF<sub>3</sub>-phenyl, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>-, or  
(4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-;

10 R<sup>11</sup>, at each occurrence, is independently selected from  
H, =O, methyl, ethyl, phenyl, benzyl, phenethyl,  
4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-F-phenyl, (3-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
15 2-F-phenyl, (2-F-phenyl)CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-Cl-phenyl, (3-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-CH<sub>3</sub>-phenyl, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-CH<sub>3</sub>-phenyl, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
20 4-CF<sub>3</sub>-phenyl, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
cyclopentyl, pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl;

R<sup>13</sup>, at each occurrence, is independently selected from  
H, F, Cl, OH, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, and -CF<sub>3</sub>; and

25 R<sup>20</sup> is H.

6. A compound of Formula (I):



or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, wherein:

L is  $-NR^{26}C(=O)-$ ,  $-C(=O)NR^{26}-$ ,  $-NR^{26}C(=O)O-$ ,  $-OC(=O)NR^{26}$ , or  $-NR^{26}C(=O)NR^{26}-$ ;

$R^3$  is  $-(CR^7R^{7a})_n-R^4$ ,  
 $-(CR^7R^{7a})_1-S-R^4$ ,  
 $-(CR^7R^{7a})_1-O-R^4$ ,  
 $-(CR^7R^{7a})_1-N(R^{7b})-R^4$ ,  
 $-(CR^7R^{7a})_1-S(=O)-R^4$ , or  
 $-(CR^7R^{7a})_1-S(=O)_2-R^4$ ;

$n$  is 0, 1 or 2;

$l$  is 1 or 2;

$R^4$  is H,

$C_1-C_8$  alkyl substituted with 0-3  $R^{4a}$ ,

$C_2-C_8$  alkenyl substituted with 0-3  $R^{4a}$ ,

$C_2-C_8$  alkynyl substituted with 0-3  $R^{4a}$ ,

$C_3-C_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,

$C_6-C_{10}$  aryl substituted with 0-3  $R^{4b}$ , or

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle

is substituted with 0-3  $R^{4b}$ ;



R<sup>4a</sup>, at each occurrence, is independently selected from  
H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
5 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

10 R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
15 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

Ring C is a 3-8 membered carbocycle;  
wherein said 3-8 membered carbocycle is saturated or  
partially unsaturated;  
20 wherein said 3-8 membered carbocycle is substituted  
with 0-4 R<sup>21</sup>; and  
optionally, the carbocycle contains a heteroatom  
selected from -O- and -N(R<sup>20</sup>)-;

25 additionally, two R<sup>21</sup> substituents on adjacent atoms may be  
combined to form a benzo fused radical; wherein said  
benzo fused radical is substituted with 0-4 R<sup>23</sup>;

30 additionally, two R<sup>21</sup> substituents on adjacent atoms may be  
combined to form a 5 to 6 membered heteroaryl fused  
radical, wherein said 5 to 6 membered heteroaryl fused  
radical comprises 1 or 2 heteroatoms selected from N,  
O, and S; wherein said 5 to 6 membered heteroaryl  
fused radical is substituted with 0-3 R<sup>23</sup>;

35

additionally, two  $R^{21}$  substituents on the same or adjacent carbon atoms may be combined to form a  $C_3-C_6$  carbocycle substituted with 0-3  $R^{23}$ ;

5  $R^{21}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN,  $NO_2$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  $S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,  $NR^{15}R^{16}$ ,  $OR^{14a}$ ,  $C_1-C_4$  alkyl,  $C_2-C_6$  alkenyl, alkynyl,  $C_1-C_4$  alkoxy,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  haloalkoxy, and  $C_1-C_4$  haloalkyl-S-,  
 10  $C_3-C_6$  carbocycle, phenyl, and a  
 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur;

15  $R^6$  is H, methyl, or ethyl;


$R^7$ , at each occurrence, is independently H or  $C_1-C_4$  alkyl;


$R^{7a}$ , at each occurrence, is independently H or  $C_1-C_4$  alkyl;

20

$R^{7b}$  is H or  $C_1-C_4$  alkyl;

Ring B is selected from:





- $R^{10}$  is H,  $C(=O)R^{17}$ ,  $C(=O)OR^{17}$ ,  $C(=O)NR^{18}R^{19}$ ,  
 $S(=O)_2NR^{18}R^{19}$ ,  $S(=O)_2R^{17}$ ;  
 5  $C_1$ - $C_6$  alkyl optionally substituted with 0-3  $R^{10a}$ ;  
 $C_6$ - $C_{10}$  aryl substituted with 0-4  $R^{10b}$ ;  
 $C_3$ - $C_{10}$  carbocycle substituted with 0-3  $R^{10b}$ ; or  
 5 to 10 membered heterocycle containing 1 to 4  
 heteroatoms selected from nitrogen, oxygen, and  
 10 sulphur, wherein said 5 to 10 membered heterocycle  
 is substituted with 0-3  $R^{10b}$ ;  
  
 $R^{10a}$ , at each occurrence, is independently selected from H,  
 $C_1$ - $C_6$  alkyl,  $OR^{14}$ , Cl, F, Br, I, =O, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  
 15  $CF_3$ , or aryl substituted with 0-4  $R^{10b}$ ;  
  
 $R^{10b}$ , at each occurrence, is independently selected from H,  
 OH, Cl, F, Br, I, CN,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  
 $S(=O)CH_3$ ,  $S(=O)_2CH_3$ ,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_4$  alkoxy,  $C_1$ - $C_4$   
 20 haloalkyl,  $C_1$ - $C_4$  haloalkoxy, and  $C_1$ - $C_4$  haloalkyl-S-;  
  
 $R^{11}$ , at each occurrence, is independently selected from  
 H,  $C_1$ - $C_4$  alkoxy, Cl, F, Br, I, =O, CN,  $NO_2$ ,  $NR^{18}R^{19}$ ,  
 $C(=O)R^{17}$ ,  $C(=O)OR^{17}$ ,  $C(=O)NR^{18}R^{19}$ ,  $S(=O)_2NR^{18}R^{19}$ ,  $CF_3$ ;  
 25  $C_1$ - $C_6$  alkyl optionally substituted with 0-3  $R^{11a}$ ;  
 $C_6$ - $C_{10}$  aryl substituted with 0-3  $R^{11b}$ ;  
 $C_3$ - $C_{10}$  carbocycle substituted with 0-3  $R^{11b}$ ; and  
 5 to 10 membered heterocycle containing 1 to 4  
 heteroatoms selected from nitrogen, oxygen, and  
 30 sulphur, wherein said 5 to 10 membered heterocycle  
 is substituted with 0-3  $R^{11b}$ ;  
  
 $R^{11a}$ , at each occurrence, is independently selected from

- H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>;  
phenyl substituted with 0-3 R<sup>11b</sup>;  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>11b</sup>; and  
5 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;
- 10 R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;
- 15 W is a bond or -(CH<sub>2</sub>)<sub>p</sub>-;
- p is 1 or 2;
- 20 X is a bond;  
phenyl substituted with 0-2 R<sup>Xb</sup>;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-2 R<sup>Xb</sup>; or  
5 to 6 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;
- 25 R<sup>Xb</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> haloalkyl, C<sub>1</sub>-C<sub>3</sub> haloalkoxy, and C<sub>1</sub>-C<sub>3</sub> halothioalkoxy;
- 30 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N(R<sup>19</sup>)-, -C(=O)NR<sup>19b</sup>-, -NR<sup>19b</sup>C(=O)-, -NR<sup>19b</sup>S(=O)<sub>2</sub>-, -S(=O)<sub>2</sub>NR<sup>19b</sup>-, -NR<sup>19b</sup>S(=O)-, -S(=O)NR<sup>19b</sup>-, -C(=O)O-, or -OC(=O)-;
- 35 Z is H;  
C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
5 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

10 R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
15 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

20 R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
25 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

30 R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, or  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;  
35

R<sup>15</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

5 R<sup>16</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

10 R<sup>17</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, aryl substituted by 0-4 R<sup>17a</sup>, or -CH<sub>2</sub>-aryl substituted by 0-4 R<sup>17a</sup>;

15 R<sup>17a</sup> is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, -OH, F, Cl, Br, I, CF<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>, S(O)CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, -NH<sub>2</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

20 R<sup>18</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

R<sup>19</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl;

25 R<sup>19b</sup>, at each occurrence, is independently is H or C<sub>1</sub>-C<sub>4</sub> alkyl;


R<sup>20</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, or C(=O)OR<sup>17</sup>;

30 R<sup>23</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>; and

R<sup>26</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

35

7. A compound of Claim 6 of Formula (Ia):



or a stereoisomer, pharmaceutically acceptable salt or  
5 prodrug thereof, wherein:

L is  $-\text{NR}^{26}\text{C}(=\text{O})-$ ,  $-\text{C}(=\text{O})\text{NR}^{26}-$ ,  $-\text{NR}^{26}\text{C}(=\text{O})\text{O}-$ ,  $-\text{OC}(=\text{O})\text{NR}^{26}$ , or  
 $-\text{NR}^{26}\text{C}(=\text{O})\text{NR}^{26}-$ ;

10  $\text{R}^3$  is  $-(\text{CHR}^7)_n-\text{R}^4$ ,  
 $-(\text{CHR}^7)_1-\text{S}-\text{R}^4$ ,  
 $-(\text{CHR}^7)_1-\text{O}-\text{R}^4$ ;  
 $-(\text{CR}^7\text{R}^{7a})_1-\text{N}(\text{R}^{7b})-\text{R}^4$ ,  
 $-(\text{CR}^7\text{R}^{7a})_1-\text{S}(=\text{O})-\text{R}^4$ , or  
15  $-(\text{CR}^7\text{R}^{7a})_1-\text{S}(=\text{O})_2-\text{R}^4$ ;

$n$  is 0, 1 or 2;

$l$  is 1 or 2;

20

$\text{R}^4$  is H,

$\text{C}_1-\text{C}_8$  alkyl substituted with 0-3  $\text{R}^{4a}$ ,  
 $\text{C}_2-\text{C}_8$  alkenyl substituted with 0-3  $\text{R}^{4a}$ ,  
 $\text{C}_2-\text{C}_8$  alkynyl substituted with 0-3  $\text{R}^{4a}$ ,  
25  $\text{C}_3-\text{C}_{10}$  carbocycle substituted with 0-3  $\text{R}^{4b}$ ,  
 $\text{C}_6-\text{C}_{10}$  aryl substituted with 0-3  $\text{R}^{4b}$ , or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
30 is substituted with 0-3  $\text{R}^{4b}$ ;

$\text{R}^{4a}$ , at each occurrence, is independently selected from  
H, OH, F, Cl, Br, I,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ ,  
 $\text{C}_3-\text{C}_{10}$  carbocycle substituted with 0-3  $\text{R}^{4b}$ ,

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>4b</sup>, and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
5 is substituted with 0-3 R<sup>4b</sup>;

R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

10 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

Ring C is a 3-8 membered carbocycle;

wherein said 3-8 membered carbocycle is saturated or  
15 partially unsaturated;

wherein said 3-8 membered carbocycle is substituted  
with 0-4 R<sup>21</sup>;

optionally, the carbocycle contains a heteroatom  
selected from -O-, and -N(R<sup>20</sup>)-;

20

additionally, two R<sup>21</sup> substituents on adjacent atoms may be  
combined to form a benzo fused radical; wherein said  
benzo fused radical is substituted with 0-4 R<sup>23</sup>;

25 additionally, two R<sup>21</sup> substituents on the same or adjacent  
carbon atoms may be combined to form a C<sub>3</sub>-C<sub>6</sub>  
carbocycle substituted with 0-3 R<sup>23</sup>;

R<sup>21</sup>, at each occurrence, is independently selected from H,  
30 OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, NR<sup>15</sup>R<sup>16</sup>, OR<sup>14a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>6</sub>  
alkenyl, alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
C<sub>3</sub>-C<sub>6</sub> carbocycle, phenyl, and a


35 5 to 6 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur;




R<sup>7</sup>, at each occurrence, is independently H, methyl, or ethyl;

5 R<sup>7b</sup> is H, methyl, or ethyl;

Ring B is selected from:



10



R<sup>11</sup>, at each occurrence, is independently selected from  
 H, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>18</sup>R<sup>19</sup>,  
 15 C(=O)R<sup>17</sup>, C(=O)OR<sup>17</sup>, C(=O)NR<sup>18</sup>R<sup>19</sup>, S(=O)<sub>2</sub>NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
 C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with 0-3 R<sup>11a</sup>;  
 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-3 R<sup>11b</sup>;  
 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and  
 5 to 10 membered heterocycle containing 1 to 4  
 20 heteroatoms selected from nitrogen, oxygen, and  
 sulphur, wherein said 5 to 10 membered heterocycle  
 is substituted with 0-3 R<sup>11b</sup>;

R<sup>11a</sup>, at each occurrence, is independently selected from  
 25 H, C<sub>1</sub>-C<sub>6</sub> alkyl, OR<sup>14</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>,  
 NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>;  
 phenyl substituted with 0-3 R<sup>11b</sup>;  
 C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-3 R<sup>11b</sup>; and  
 5 to 6 membered heterocycle containing 1 to 4  
 30 heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>11b</sup>;

5 R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10 W is a bond or -(CH<sub>2</sub>)<sub>p</sub>-;

p is 1 or 2;

X is a bond;  
15 phenyl substituted with 0-2 R<sup>Xb</sup>;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-2 R<sup>Xb</sup>; or  
5 to 6 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;

20 R<sup>Xb</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> haloalkyl, C<sub>1</sub>-C<sub>3</sub> haloalkoxy, and C<sub>1</sub>-C<sub>3</sub> halothioalkoxy;

25 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N(R<sup>19</sup>)-, -C(=O)NR<sup>19b</sup>-, -NR<sup>19b</sup>C(=O)-, -NR<sup>19b</sup>S(=O)<sub>2</sub>-, -S(=O)<sub>2</sub>NR<sup>19b</sup>-, -NR<sup>19b</sup>S(=O)-, -S(=O)NR<sup>19b</sup>-, -C(=O)O-, or -OC(=O)-;

Z is H;  
30 C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
35 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

5 R<sup>12a</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-, C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

10 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

15 R<sup>12b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

20

R<sup>13</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

25 R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, or C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

30 R<sup>15</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

35 R<sup>16</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

R<sup>17</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl,  
aryl substituted by 0-4 R<sup>17a</sup>, or  
-CH<sub>2</sub>-aryl substituted by 0-4 R<sup>17a</sup>;

5

R<sup>17a</sup> is H, methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
propoxy, butoxy, -OH, F, Cl, Br, I, CF<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>,  
S(O)CH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, -NH<sub>2</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

10 R<sup>18</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

15 R<sup>19</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, phenyl, benzyl,  
phenethyl;


R<sup>20</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, or C(=O)OR<sup>17</sup>;

20 R<sup>23</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>; and

R<sup>26</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

25

8. A compound of Claim 7 of Formula (Ic):



30 or a stereoisomer, pharmaceutically acceptable salt or  
prodrug thereof, wherein:

L is  $\text{-NHC(=O)-}$ ,  $\text{-C(=O)NH-}$ , or  $\text{-OC(=O)NH-}$ ;

5  $R^3$  is  $\text{-(CH}_2)_n\text{-R}^4$ ,  
 $\text{-(CH}_2)_1\text{-S-R}^4$ ,  
 $\text{-(CH}_2)_1\text{-O-R}^4$ , or  
 $\text{-(CH}_2)_1\text{-N(R}^{7b})\text{-R}^4$ ;

n is 0, 1 or 2;

10 l is 1 or 2;

15  $R^4$  is  $\text{C}_1\text{-C}_8$  alkyl substituted with 0-3  $R^{4a}$ ,  
 $\text{C}_2\text{-C}_8$  alkenyl substituted with 0-3  $R^{4a}$ ,  
 $\text{C}_2\text{-C}_8$  alkynyl substituted with 0-3  $R^{4a}$ ,  
 $\text{C}_3\text{-C}_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,  
 $\text{C}_6\text{-C}_{10}$  aryl substituted with 0-3  $R^{4b}$ , or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
20 is substituted with 0-3  $R^{4b}$ ;

$R^{4a}$ , at each occurrence, is independently selected from  
H, OH, F, Cl, Br, I,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ ,  
 $\text{C}_3\text{-C}_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,  
25  $\text{C}_6\text{-C}_{10}$  aryl substituted with 0-3  $R^{4b}$ , and  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $R^{4b}$ ;

30  $R^{4b}$ , at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN,  $\text{NO}_2$ ,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ , acetyl,  $\text{SCH}_3$ ,  
 $\text{S(=O)CH}_3$ ,  $\text{S(=O)}_2\text{CH}_3$ ,  
 $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_4$  alkoxy,  $\text{C}_1\text{-C}_4$  haloalkyl,  
35  $\text{C}_1\text{-C}_4$  haloalkoxy, and  $\text{C}_1\text{-C}_4$  haloalkyl-S-;

$R^{7b}$  is H, methyl, or ethyl;

Ring C is a 3-8 membered carbocycle;

wherein said 3-8 membered carbocycle is saturated or partially unsaturated;

5 wherein said 3-8 membered carbocycle is substituted with 0-3  $R^{21}$ ;

optionally, the carbocycle contains a heteroatom selected from -O-, and -N( $R^{20}$ )-;

10  $R^{21}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, NR<sup>15</sup>R<sup>16</sup>, OR<sup>14a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

15

W is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-;

X is a bond;

phenyl substituted with 0-2  $R^{Xb}$ ;

20 C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-2  $R^{Xb}$ ; or

5 to 6 membered heterocycle substituted with 0-2  $R^{Xb}$ ;

$R^{Xb}$ , at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,

25 S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-,

30 -N( $R^{19}$ )-, -C(=O)NR<sup>19b</sup>-, -NR<sup>19b</sup>C(=O)-, -NR<sup>19b</sup>S(=O)<sub>2</sub>-, -S(=O)<sub>2</sub>NR<sup>19b</sup>-, -NR<sup>19b</sup>S(=O)-, -S(=O)NR<sup>19b</sup>-, -C(=O)O-, or -OC(=O)-;

Z is H;

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3  $R^{12a}$ ;

35 C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3  $R^{12a}$ ;

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3  $R^{12a}$ ;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4  $R^{12b}$ ;

5 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

10 R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and  
15 5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

20 R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

25 R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

30 R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-,  
and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

35 R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-; and

R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

9. A compound of Claim 8, wherein:

5

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;

10

R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or

15

5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

20

R<sup>4a</sup>, at each occurrence, is independently selected from H,  
OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, and  
5 to 6 membered heterocycle containing 1 to 3

25

heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

30

R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

35

Ring C is a 3-6 membered carbocycle;  
wherein said 3-6 membered carbocycle is saturated or  
partially unsaturated;



wherein said 3-6 membered carbocycle is substituted  
with 0-2 R<sup>21</sup>;  
optionally, the carbocycle contains a heteroatom  
selected from -O-, and -N(R<sup>20</sup>)-;

- 5 R<sup>21</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, methyl,  
ethyl, methoxy, ethoxy, allyl, -OCF<sub>3</sub>, and -SCF<sub>3</sub>;
- 10 W is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-;
- X is a bond;  
phenyl substituted with 0-1 R<sup>Xb</sup>;  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-1 R<sup>Xb</sup>; or  
15 5 to 6 membered heterocycle substituted with 0-1 R<sup>Xb</sup>;
- R<sup>Xb</sup> is selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl,  
methoxy, ethoxy, propoxy, and -OCF<sub>3</sub>;
- 20 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-,  
-N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;
- Z is H;
- 25 C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
30 5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;
- 35 R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,  
CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

- C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and  
5 5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;
- 10 R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;
- 15 R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;
- 20 R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>4</sub> alkyl, and benzyl;
- R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, benzyl,  
25 phenethyl, methyl-C(=O)-, ethyl-C(=O)-,  
methyl-S(=O)<sub>2</sub>-, ethyl-S(=O)<sub>2</sub>-, and propyl-S(=O)<sub>2</sub>-; and  
R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

30 10. A compound of Claim 9, wherein:

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;

35

R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>, or

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from is  
H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,

5 C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,

phenyl substituted with 0-3 R<sup>4b</sup>, and

5 to 6 membered heterocycle containing 1 to 3

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 6 membered heterocycle

10 is substituted with 0-3 R<sup>4b</sup>; wherein said 5 to 6

membered heterocycle is selected from pyridinyl,

pyrimidinyl, triazinyl, furanyl, thienyl,

thiazolyl, pyrrolyl, piperazinyl, piperidinyl,

pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and


15 tetrazolyl;

R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

20 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

Ring C is a 3-6 membered carbocycle selected from:



wherein said 3-6 membered carbocycle is substituted  
with 0-1 R<sup>21</sup>;

30 R<sup>21</sup> is selected from H, OH, Cl, F, CN, CF<sub>3</sub>, methyl, ethyl,  
methoxy, ethoxy, allyl, and -OCF<sub>3</sub>;

W is a bond or -CH<sub>2</sub>-;

35 X is a bond, phenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or 5 to 6 membered  
heterocycle;

Y is a bond,  $-C(=O)-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$ ,  $-S(=O)_2-$ ,  $-NH-$ ,  $-N(CH_3)-$ , or  $-N(CH_2CH_3)-$ ;

5 Z is H;

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;

C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

10 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or

5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

15

R<sup>12a</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>

20

haloalkoxy;

phenyl substituted with 0-4 R<sup>12b</sup>;

C<sub>3</sub>-6 carbocycle substituted with 0-4 R<sup>12b</sup>; and

5 to 6 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

25

sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from

H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,

30

S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

R<sup>13</sup>, at each occurrence, is independently selected from

35

H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, Cl, F, Br, CN, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

R<sup>15</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl; and

5 R<sup>16</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, benzyl, and phenethyl; and


R<sup>20</sup> is H, methyl, or ethyl.

10 11. A compound of claim 10, wherein:

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

Ring C is selected from:

15




20 R<sup>3</sup> is -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,  
-CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>(CH<sub>3</sub>)<sub>2</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
-CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>,  
-CH(OH)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH(OH)CH(CH<sub>3</sub>)<sub>2</sub>, -CH(NH<sub>2</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CF<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
-CH(NHCH<sub>3</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH(NHSO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
25 cyclohexyl-, cyclopentyl-, cyclopropyl-CH<sub>2</sub>-,  
cyclobutyl-CH<sub>2</sub>-, cyclopentyl-CH<sub>2</sub>-, cyclohexyl-CH<sub>2</sub>-,  
cyclopropyl-CH<sub>2</sub>CH<sub>2</sub>-, cyclobutyl-CH<sub>2</sub>CH<sub>2</sub>-,  
cyclopentyl-CH<sub>2</sub>CH<sub>2</sub>-, cyclohexyl-CH(OH)-,  
cyclohexyl-CH<sub>2</sub>CH<sub>2</sub>-, 1-NH<sub>2</sub>-cyclopentyl, phenyl-CH<sub>2</sub>-,  
30 (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>-,  
(2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>-,  
(2,3-diF-phenyl)CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>-,  
(2,5-diF-phenyl)CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>-,  
(3,4-diF-phenyl)CH<sub>2</sub>-, (3,5-diF-phenyl)CH<sub>2</sub>-,  
(2,3-diCl-phenyl)CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>-,  
35 (2,5-diCl-phenyl)CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>-,

- (3,4-diCl-phenyl)CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>-,  
 (3-F-4-Cl-phenyl)CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>-,  
 (3-Cl-4-F-phenyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
 (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 5 (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 10 (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-piperidiny-CH<sub>2</sub>CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>CF<sub>2</sub>-,  
 15 phenyl-CH<sub>2</sub>CH(OH)-, imidazolyl-CH<sub>2</sub>CH(OH)-, or  
 phenyl-CH<sub>2</sub>OCH<sub>2</sub>-;

W is a bond or -CH<sub>2</sub>-;

- 20 X is a bond;



- 25

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, or  
 -N(CH<sub>3</sub>)-,

- Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl,  
 30 s-butyl, t-butyl, allyl, phenyl, 2-F-phenyl,  
 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl,  
 4-Cl-phenyl, 2,3-diF-phenyl,  
 2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl,  
 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl,



2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl,  
3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl,  
3-F-5-Cl-phenyl, 3-Cl-4-F-phenyl, 2-MeO-phenyl,  
3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl,  
5 4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl,  
2-CF<sub>3</sub>O-phenyl, 3-CF<sub>3</sub>O-phenyl, 4-CF<sub>3</sub>O-phenyl, furanyl,  
thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl,  
4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl,  
1-benzimidazolyl, cyclopropyl, cyclobutyl,  
10 cyclopentyl, cyclohexyl, morpholino, N-piperinyl,  
phenyl-CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-,  
(4-F-phenyl)CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>-,  
15 (2,6-diF-phenyl)CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>-,  
(3,5-diF-phenyl)CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>-,  
20 (3-F-5-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>-,  
(2-MeO-phenyl)CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>-,  
25 4-MeS-phenyl)CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(furanyl)CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>-, (1-imidazolyl)CH<sub>2</sub>-,  
30 (oxazolyl)CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>-,  
(1-benzimidazolyl)CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>-,  
(cyclohexyl)CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>-,  
(N-pipridinyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
35 (phenyl)<sub>2</sub>CHCH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,

(4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 5 (2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 10 (4-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 15 (furanyl)CH<sub>2</sub>CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (imidazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (oxazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (benzimidazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 20 (cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (cyclohexyl)CH<sub>2</sub>CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>CH<sub>2</sub>-, or  
 (N-pipridinyl)CH<sub>2</sub>CH<sub>2</sub>-;

R<sup>13</sup>, at each occurrence, is independently selected from  
 25 H, F, Cl, OH, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, or -CF<sub>3</sub>.

R<sup>20</sup> is H, methyl, or ethyl.

12. A compound of Claim 7 of Formula (Id) or Formula  
 30 (Ie),





or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, wherein:

L is  $\text{-NHC(=O)-}$ ,  $\text{-C(=O)NH-}$ , or  $\text{-OC(=O)NH-}$ ;

5

$R^3$  is  $\text{-(CH}_2\text{)}_n\text{-R}^4$ ,  
 $\text{-(CH}_2\text{)}_1\text{-S-R}^4$ ,  
 $\text{-(CH}_2\text{)}_1\text{-O-R}^4$ , or  
 $\text{-(CH}_2\text{)}_1\text{-N(R}^{7b}\text{)-R}^4$ ;

10

n is 0, 1 or 2;

l is 1 or 2;

15  $R^4$  is  $\text{C}_1\text{-C}_8$  alkyl substituted with 0-3  $R^{4a}$ ,  
 $\text{C}_2\text{-C}_8$  alkenyl substituted with 0-3  $R^{4a}$ ,  
 $\text{C}_2\text{-C}_8$  alkynyl substituted with 0-3  $R^{4a}$ ,  
 $\text{C}_3\text{-C}_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,  
20  $\text{C}_6\text{-C}_{10}$  aryl substituted with 0-3  $R^{4b}$ , or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $R^{4b}$ ;

25  $R^{4a}$ , at each occurrence, is independently selected from  
H, OH, F, Cl, Br, I,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ ,  
 $\text{C}_3\text{-C}_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,  
 $\text{C}_6\text{-C}_{10}$  aryl substituted with 0-3  $R^{4b}$ , and  
5 to 10 membered heterocycle containing 1 to 4  
30 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $R^{4b}$ ;

35  $R^{4b}$ , at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN,  $\text{NO}_2$ ,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ , acetyl,  $\text{SCH}_3$ ,  
 $\text{S(=O)CH}_3$ ,  $\text{S(=O)}_2\text{CH}_3$ ,  
 $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_4$  alkoxy,  $\text{C}_1\text{-C}_4$  haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>7b</sup> is H, methyl, or ethyl;

5 Ring C is a 3-8 membered carbocycle;

wherein said 3-8 membered carbocyclic moiety is  
saturated or partially saturated;

wherein said 3-8 membered carbocyclic moiety is  
substituted with 0-3 R<sup>21</sup>;

10 optionally, the carbocycle contains a heteroatom  
selected from -O- and -N(R<sup>20</sup>)-;

R<sup>21</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,

15 S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, NR<sup>15</sup>R<sup>16</sup>, OR<sup>14a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub>  
alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>11</sup>, at each occurrence, is independently selected from  
20 H, =O, NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;

C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1 R<sup>11a</sup>;

phenyl substituted with 0-3 R<sup>11b</sup>;

C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and

5 to 7 membered heterocycle containing 1 to 4

25 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 7 membered heterocycle  
is substituted with 0-3 R<sup>11b</sup>; wherein said 5 to 7

membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl,

30 thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,  
homopiperidinyl, and tetrazolyl;

R<sup>11a</sup>, at each occurrence, is independently selected from H,

35 C<sub>1</sub>-C<sub>4</sub> alkyl, OR<sup>14</sup>, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl  
substituted with 0-3 R<sup>11b</sup>;

R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

5

W is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-;

X is a bond;

phenyl substituted with 0-2 R<sup>Xb</sup>;  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-2 R<sup>Xb</sup>; or  
5 to 6 membered heterocycle substituted with 0-2 R<sup>Xb</sup>;

10

R<sup>Xb</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

15

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -N(R<sup>19</sup>)-, -C(=O)NR<sup>19b</sup>-, -NR<sup>19b</sup>C(=O)-, -NR<sup>19b</sup>S(=O)<sub>2</sub>-, -S(=O)<sub>2</sub>NR<sup>19b</sup>-, -NR<sup>19b</sup>S(=O)-, -S(=O)NR<sup>19b</sup>-, -C(=O)O-, or -OC(=O)-;

20

Z is H;

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

30

R<sup>12a</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

35

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and  
5 to 10 membered heterocycle containing 1 to 4  
5 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

10 R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

15 R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN,  
NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

20 R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, or  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

25 R<sup>15</sup>, at each occurrence, is independently selected from H,  
C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-,  
and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

30 R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

35 R<sup>18</sup>, at each occurrence, is independently selected from  
H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl,  
(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

R<sup>19</sup>, at each occurrence, is independently selected from

H, OH, methyl, ethyl, propyl, butyl, phenyl, benzyl, phenethyl; and

R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

5

13. A compound of Claim 12, wherein:

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

10 R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;

15 R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
20 is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from is  
H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
25 phenyl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

30

R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
35 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

Ring C is a 3-6 membered carbocycle;

wherein said 3-6 membered carbocyclic moiety is saturated or partially unsaturated;

wherein said 3-6 membered carbocyclic moiety is substituted with 0-2  $R^{21}$ ;

5 optionally, the carbocycle contains a heteroatom selected from -O- and -N( $R^{20}$ )-;

10  $R^{21}$ , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, methyl, ethyl, methoxy, ethoxy, allyl, -OCF<sub>3</sub>, and -SCF<sub>3</sub>;

$R^{11}$ , at each occurrence, is independently selected from H, =O, NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1  $R^{11a}$ ;  
15 phenyl substituted with 0-3  $R^{11b}$ ;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3  $R^{11b}$ ; and  
5 to 7 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 7 membered heterocycle  
20 is substituted with 0-3  $R^{11b}$ ; wherein said 5 to 7  
membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl,  
thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,  
25 homopiperidinyl, and tetrazolyl;

$R^{11a}$ , at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
propoxy, phenoxy, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl  
30 substituted with 0-3  $R^{11b}$ ;

$R^{11b}$ , at each occurrence, is independently selected from H,  
OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl,  
methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
35 haloalkoxy;

W is a bond, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-;

X is a bond;

phenyl substituted with 0-1 R<sup>Xb</sup>;

C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-1 R<sup>Xb</sup>; or

5 5 to 6 membered heterocycle substituted with 0-1 R<sup>Xb</sup>;

R<sup>Xb</sup> is selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl,  
methoxy, ethoxy, propoxy, and -OCF<sub>3</sub>;

10

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-,  
-N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;

Z is H;

15

C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;

C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;

C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or

20

5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

25 R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>,

CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,

30

C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;

C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle

35

is substituted with 0-3 R<sup>12b</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from

H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

5

R<sup>13</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

10 R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>2</sub>-C<sub>4</sub> alkoxyalkyl;

R<sup>15</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, benzyl, and phenethyl;

15 R<sup>16</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl, methyl-C(=O)-, ethyl-C(=O)-, methyl-S(=O)<sub>2</sub>-, and ethyl-S(=O)<sub>2</sub>-;

20 R<sup>18</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and phenethyl;

R<sup>19</sup>, at each occurrence, is independently selected from  
25 H, methyl, ethyl, propyl, and butyl;

R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

14. A compound of claim 13, wherein:

30

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;

35 R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>, C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>, or C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>;



R<sup>4a</sup>, at each occurrence, is independently selected from is  
H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,

C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,

phenyl substituted with 0-3 R<sup>4b</sup>, or

5 to 6 membered heterocycle containing 1 to 3

heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle

is substituted with 0-3 R<sup>4b</sup>; wherein said 5 to 6

membered heterocycle is selected from pyridinyl,

pyrimidinyl, triazinyl, furanyl, thienyl,

thiazolyl, pyrrolyl, piperazinyl, piperidinyl,

pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and

tetrazolyl;


R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,

S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,

C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,

C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

Ring C is a 3-6 membered carbocycle selected from:



wherein said 3-6 membered carbocycle is substituted  
with 0-1 R<sup>21</sup>;

R<sup>21</sup> is selected from H, OH, Cl, F, CN, CF<sub>3</sub>, methyl, ethyl,  
methoxy, ethoxy, allyl, and -OCF<sub>3</sub>;

R<sup>11</sup>, at each occurrence, is independently selected from

H, =O, NR<sup>18</sup>R<sup>19</sup>;

C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1 R<sup>11a</sup>;

phenyl substituted with 0-3 R<sup>11b</sup>;

- 5 to 7 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 7 membered heterocycle is substituted with 0-3 R<sup>11b</sup>; wherein said 5 to 7 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, homopiperidinyl, and tetrazolyl;
- R<sup>11a</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, phenoxy, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl substituted with 0-3 R<sup>11b</sup>;
- R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;
- W is a bond or -CH<sub>2</sub>-;
- X is a bond, phenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or 5 to 6 membered heterocycle;
- Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, -N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;
- Z is H;
- C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;
- C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;
- C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;
- C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;
- C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or
- 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

5 R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy,  
ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;  
phenyl substituted with 0-4 R<sup>12b</sup>;  
10 C<sub>3</sub>-6 carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 6 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

15 R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy,  
ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
20 haloalkoxy;

R<sup>13</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
Cl, F, Br, CN, NR<sup>15</sup>R<sup>16</sup>, and CF<sub>3</sub>;

25 R<sup>14</sup> is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;

R<sup>15</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, and butyl; and

30 R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, benzyl, and  
phenethyl.

35 R<sup>18</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and  
phenethyl;

R<sup>19</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl; and


5 R<sup>20</sup> is H, methyl, or ethyl.

15. A compound of claim 14, wherein:

L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

10

Ring C is selected from:




15 R<sup>3</sup> is -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,  
 -CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>(CH<sub>3</sub>)<sub>2</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
 -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>,  
 -CH(OH)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH(OH)CH(CH<sub>3</sub>)<sub>2</sub>, -CH(NH<sub>2</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
 -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -CF<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
 20 -CH(NHCH<sub>3</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -CH(NHSO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,  
 cyclohexyl-, cyclopentyl-, cyclopropyl-CH<sub>2</sub>-,  
 cyclobutyl-CH<sub>2</sub>-, cyclopentyl-CH<sub>2</sub>-, cyclohexyl-CH<sub>2</sub>-,  
 cyclopropyl-CH<sub>2</sub>CH<sub>2</sub>-, cyclobutyl-CH<sub>2</sub>CH<sub>2</sub>-,  
 cyclopentyl-CH<sub>2</sub>CH<sub>2</sub>-, cyclohexyl-CH(OH)-,  
 25 cyclohexyl-CH<sub>2</sub>CH<sub>2</sub>-, 1-NH<sub>2</sub>-cyclopentyl, phenyl-CH<sub>2</sub>-,  
 (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>-,  
 (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>-,  
 (2,3-diF-phenyl)CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>-,  
 (2,5-diF-phenyl)CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>-,  
 30 (3,4-diF-phenyl)CH<sub>2</sub>-, (3,5-diF-phenyl)CH<sub>2</sub>-,  
 (2,3-diCl-phenyl)CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>-,  
 (2,5-diCl-phenyl)CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>-,  
 (3,4-diCl-phenyl)CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>-,  
 (3-F-4-Cl-phenyl)CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>-,  
 35 (3-Cl-4-F-phenyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,

(2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 5 (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 10 (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-piperidinyl-CH<sub>2</sub>CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>CF<sub>2</sub>-,  
 phenyl-CH<sub>2</sub>CH(OH)-, imidazolyl-CH<sub>2</sub>CH(OH)-, or  
 phenyl-CH<sub>2</sub>OCH<sub>2</sub>-;

15 W is a bond or -CH<sub>2</sub>-;

X is a bond;



Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, or  
 -N(CH<sub>3</sub>)-,

25 Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl,  
 s-butyl, t-butyl, allyl, phenyl, 2-F-phenyl,  
 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl,  
 4-Cl-phenyl, 2,3-diF-phenyl,  
 2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl,  
 30 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl,  
 2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl,  
 3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl,  
 3-F-5-Cl-phenyl, 3-Cl-4-F-phenyl, 2-MeO-phenyl,

3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl,  
4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl,  
2-CF<sub>3</sub>O-phenyl, 3-CF<sub>3</sub>O-phenyl, 4-CF<sub>3</sub>O-phenyl, furanyl,  
thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl,  
5 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl,  
1-benzimidazolyl, cyclopropyl, cyclobutyl,  
cyclopentyl, cyclohexyl, morpholino, N-piperinyl,  
phenyl-CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-,  
(4-F-phenyl)CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>-,  
10 (4-Cl-phenyl)CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>-,  
(2,6-diF-phenyl)CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>-,  
(3,5-diF-phenyl)CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>-,  
15 (2,6-diCl-phenyl)CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>-,  
(3-F-5-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>-,  
(2-MeO-phenyl)CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>-,  
20 (3-Me-phenyl)CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>-,  
(4-MeS-phenyl)CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(furanyl)CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>-,  
25 (2-Me-pyridyl)CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>-, (1-imidazolyl)CH<sub>2</sub>-,  
(oxazolyl)CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>-,  
(1-benzimidazolyl)CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>-,  
30 (cyclohexyl)CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>-,  
(N-piperidyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
(phenyl)<sub>2</sub>CHCH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
35 (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,


(3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
5 (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
10 (4-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(furan-2-yl)CH<sub>2</sub>CH<sub>2</sub>-, (thien-2-yl)CH<sub>2</sub>CH<sub>2</sub>-, (pyrid-2-yl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Me-pyrid-2-yl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Me-pyrid-2-yl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Me-pyrid-2-yl)CH<sub>2</sub>CH<sub>2</sub>-, (imidazol-2-yl)CH<sub>2</sub>CH<sub>2</sub>-,  
15 (oxazol-2-yl)CH<sub>2</sub>CH<sub>2</sub>-, (isoxazol-2-yl)CH<sub>2</sub>CH<sub>2</sub>-,  
(benzimidazol-2-yl)CH<sub>2</sub>CH<sub>2</sub>-, (cycloprop-1-yl)CH<sub>2</sub>CH<sub>2</sub>-,  
(cyclobut-1-yl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopent-1-yl)CH<sub>2</sub>CH<sub>2</sub>-,  
(cyclohex-1-yl)CH<sub>2</sub>CH<sub>2</sub>-, (morpholin-2-yl)CH<sub>2</sub>CH<sub>2</sub>-, or  
(N-piperidin-2-yl)CH<sub>2</sub>CH<sub>2</sub>-;

20 R<sup>11</sup>, at each occurrence, is independently selected from  
H, =O, methyl, ethyl, phenyl, benzyl, phenethyl,  
4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-F-phenyl, (3-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
25 2-F-phenyl, (2-F-phenyl)CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-Cl-phenyl, (3-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-CH<sub>3</sub>-phenyl, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-CH<sub>3</sub>-phenyl, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
30 4-CF<sub>3</sub>-phenyl, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
cyclopentyl, pyrid-2-yl, pyrid-3-yl, or pyrid-4-yl; and

R<sup>13</sup>, at each occurrence, is independently selected from  
H, F, Cl, OH, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, or -CF<sub>3</sub>.

35

16. A compound of Claim 7 of Formula (If):



(If)

or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, wherein:

5

L is  $\text{-NHC(=O)-}$ ,  $\text{-C(=O)NH-}$ , or  $\text{-OC(=O)NH-}$ ;

$R^3$  is  $\text{-(CH}_2\text{)}_n\text{-R}^4$ ,

$\text{-(CH}_2\text{)}_1\text{-S-R}^4$ ,

10  $\text{-(CH}_2\text{)}_1\text{-O-R}^4$ , or

$\text{-(CH}_2\text{)}_1\text{-N(R}^{7b}\text{)-R}^4$ ;

n is 0, 1 or 2;

15 1 is 1 or 2;

$R^4$  is  $\text{C}_1\text{-C}_8$  alkyl substituted with 0-3  $R^{4a}$ ,

$\text{C}_2\text{-C}_8$  alkenyl substituted with 0-3  $R^{4a}$ ,

$\text{C}_2\text{-C}_8$  alkynyl substituted with 0-3  $R^{4a}$ ,

20  $\text{C}_3\text{-C}_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,

$\text{C}_6\text{-C}_{10}$  aryl substituted with 0-3  $R^{4b}$ , or

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle

25 is substituted with 0-3  $R^{4b}$ ;

$R^{4a}$ , at each occurrence, is independently selected from

H, OH, F, Cl, Br, I,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ ,

$\text{C}_3\text{-C}_{10}$  carbocycle substituted with 0-3  $R^{4b}$ ,

30  $\text{C}_6\text{-C}_{10}$  aryl substituted with 0-3  $R^{4b}$ , and

5 to 10 membered heterocycle containing 1 to 4

heteroatoms selected from nitrogen, oxygen, and



sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>4b</sup>;

5 R<sup>4b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

10 R<sup>7b</sup> is H, methyl, or ethyl;

Ring C is a 3-8 membered carbocycle;  
wherein said 3-8 membered carbocyclic moiety is saturated or partially saturated;  
15 wherein said 3-8 membered carbocyclic moiety is substituted with 0-3 R<sup>21</sup>;  
optionally, the carbocycle contains a heteroatom selected from -O- and -N(R<sup>20</sup>)-;

20 R<sup>21</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, NR<sup>15</sup>R<sup>16</sup>, OR<sup>14a</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

25

R<sup>11</sup> is selected from  
H, =O, NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;

C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1 R<sup>11a</sup>;  
phenyl substituted with 0-3 R<sup>11b</sup>;  
30 C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and  
5 to 7 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 7 membered heterocycle is substituted with 0-3 R<sup>11b</sup>; wherein said 5 to 7 membered heterocycle is selected from pyridinyl,  
35 pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl,

pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,  
homopiperidinyl, and tetrazolyl;

5  $R^{11a}$ , at each occurrence, is independently selected from H,  
 $C_1$ - $C_4$  alkyl,  $OR^{14}$ , F, Cl, =O,  $NR^{15}R^{16}$ ,  $CF_3$ , or phenyl  
substituted with 0-3  $R^{11b}$ ;

10  $R^{11b}$ , at each occurrence, is independently selected from H,  
OH, Cl, F,  $NR^{15}R^{16}$ ,  $CF_3$ , methyl, ethyl, propyl, butyl,  
methoxy, ethoxy, propoxy,  $C_1$ - $C_2$  haloalkyl, and  $C_1$ - $C_2$   
haloalkoxy;

W is a bond,  $-CH_2-$ ,  $-CH_2CH_2-$ ;

15 X is a bond;  
phenyl substituted with 0-2  $R^{xb}$ ;  
 $C_3$ - $C_6$  cycloalkyl substituted with 0-2  $R^{xb}$ ; or  
5 to 6 membered heterocycle substituted with 0-2  $R^{xb}$ ;

20  $R^{xb}$ , at each occurrence, is independently selected from H,  
OH, Cl, F,  $NR^{15}R^{16}$ ,  $CF_3$ , acetyl,  $SCH_3$ ,  $S(=O)CH_3$ ,  
 $S(=O)_2CH_3$ ,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_3$  alkoxy,  $C_1$ - $C_2$  haloalkyl,  
and  $C_1$ - $C_2$  haloalkoxy;

25 Y is a bond,  $-C(=O)-$ ,  $-O-$ ,  $-S-$ ,  $-S(=O)-$ ,  $-S(=O)_2-$ ,  
 $-N(R^{19})-$ ,  $-C(=O)NR^{19b}-$ ,  $-NR^{19b}C(=O)-$ ,  $-NR^{19b}S(=O)_2-$ ,  
 $-S(=O)_2NR^{19b}-$ ,  $-NR^{19b}S(=O)-$ ,  $-S(=O)NR^{19b}-$ ,  $-C(=O)O-$ ,  
or  $-OC(=O)-$ ;

30 Z is H;  
 $C_1$ - $C_8$  alkyl substituted with 0-3  $R^{12a}$ ;  
 $C_2$ - $C_6$  alkenyl substituted with 0-3  $R^{12a}$ ;  
 $C_2$ - $C_6$  alkynyl substituted with 0-3  $R^{12a}$ ;  
 $C_6$ - $C_{10}$  aryl substituted with 0-4  $R^{12b}$ ;  
35  $C_3$ - $C_{10}$  carbocycle substituted with 0-4  $R^{12b}$ ; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and

sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

5 R<sup>12a</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, -C(=O)NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-, C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>; and 10 C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R<sup>12b</sup>;

15 R<sup>12b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl, 20 C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl, or C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

25 R<sup>14a</sup> is H, phenyl, benzyl, or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>15</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

30 R<sup>16</sup>, at each occurrence, is independently selected from H, OH, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>4</sub> alkyl)-S(=O)<sub>2</sub>-;

35 R<sup>18</sup>, at each occurrence, is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, benzyl, phenethyl, (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(=O)-, and (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(=O)<sub>2</sub>-;

R<sup>19</sup>, at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, phenyl, benzyl, phenethyl; and

5

R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

17. A compound of Claim 16, wherein:

10 L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;

R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;

R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
15 C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 3  
20 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from is  
25 H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,  
phenyl substituted with 0-3 R<sup>4b</sup>, or  
5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
30 sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>;

R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
35 S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

- Ring C is a 3-6 membered carbocycle;  
wherein said 3-6 membered carbocyclic moiety is  
saturated or partially unsaturated;  
5 wherein said 3-6 membered carbocyclic moiety is  
substituted with 0-2 R<sup>21</sup>;  
optionally, the carbocycle contains a heteroatom  
selected from -O- and -N(R<sup>20</sup>)-;
- 10 R<sup>21</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, methyl,  
ethyl, methoxy, ethoxy, allyl, -OCF<sub>3</sub>, and -SCF<sub>3</sub>;
- 15 R<sup>11</sup> is selected from  
H, =O, NR<sup>18</sup>R<sup>19</sup>, CF<sub>3</sub>;  
C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1 R<sup>11a</sup>;  
phenyl substituted with 0-3 R<sup>11b</sup>;  
C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>11b</sup>; and  
20 5 to 7 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 7 membered heterocycle  
is substituted with 0-3 R<sup>11b</sup>; wherein said 5 to 7  
membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl,  
25 thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,  
homopiperidinyl, and tetrazolyl;
- 30 R<sup>11a</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, butyl, methoxy, ethoxy,  
propoxy, phenoxy, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl  
substituted with 0-3 R<sup>11b</sup>;
- 35 R<sup>11b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl,  
methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;

W is a bond,  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$ ;

X is a bond;

- 5 phenyl substituted with 0-1  $\text{R}^{\text{Xb}}$ ;  
C<sub>3</sub>-C<sub>6</sub> cycloalkyl substituted with 0-1  $\text{R}^{\text{Xb}}$ ; or  
5 to 6 membered heterocycle substituted with 0-1  $\text{R}^{\text{Xb}}$ ;

- 10  $\text{R}^{\text{Xb}}$  is selected from H, OH, Cl, F,  $\text{NR}^{15}\text{R}^{16}$ ,  $\text{CF}_3$ , acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl,  
methoxy, ethoxy, propoxy, and  $-\text{OCF}_3$ ;

Y is a bond,  $-\text{C}(=\text{O})-$ ,  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{S}(=\text{O})-$ ,  $-\text{S}(=\text{O})_2-$ ,  $-\text{NH}-$ ,  
 $-\text{N}(\text{CH}_3)-$ , or  $-\text{N}(\text{CH}_2\text{CH}_3)-$ ;

15

Z is H;

- C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3  $\text{R}^{12\text{a}}$ ;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3  $\text{R}^{12\text{a}}$ ;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3  $\text{R}^{12\text{a}}$ ;  
20 C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4  $\text{R}^{12\text{b}}$ ;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4  $\text{R}^{12\text{b}}$ ; or  
5 to 10 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
25 is substituted with 0-3  $\text{R}^{12\text{b}}$ ;

- $\text{R}^{12\text{a}}$ , at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>,  $\text{NR}^{15}\text{R}^{16}$ ,  $-\text{C}(=\text{O})\text{NR}^{15}\text{R}^{16}$ ,  
 $\text{CF}_3$ , acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
30 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-,  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4  $\text{R}^{12\text{b}}$ ;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4  $\text{R}^{12\text{b}}$ ; or  
5 to 10 membered heterocycle containing 1 to 4  
35 heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 10 membered heterocycle  
is substituted with 0-3  $\text{R}^{12\text{b}}$ ;

- R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl,  
SCH<sub>3</sub>, S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
5 C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;
- R<sup>14</sup> is H, phenyl, benzyl, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>2</sub>-C<sub>4</sub> alkoxyalkyl;
- 10 R<sup>15</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, butyl, benzyl, and phenethyl;
- R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, benzyl,  
15 phenethyl, methyl-C(=O)-, ethyl-C(=O)-,  
methyl-S(=O)<sub>2</sub>-, and ethyl-S(=O)<sub>2</sub>-;
- R<sup>18</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and  
20 phenethyl;
- R<sup>19</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, and butyl;
- 25 R<sup>20</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

18. A compound of claim 17, wherein:

- L is -NHC(=O)-, -C(=O)NH-, or -OC(=O)NH-;
- 30 R<sup>3</sup> is -R<sup>4</sup>, -CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>CH<sub>2</sub>R<sup>4</sup>, -CH<sub>2</sub>OR<sup>4</sup>, or -CH<sub>2</sub>CH<sub>2</sub>OR<sup>4</sup>;
- R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl substituted with 0-3 R<sup>4a</sup>,  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>4a</sup>, or  
35 C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>4a</sup>;

R<sup>4a</sup>, at each occurrence, is independently selected from is  
H, OH, F, Cl, Br, I, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>,

C<sub>3</sub>-C<sub>6</sub> carbocycle substituted with 0-3 R<sup>4b</sup>,


phenyl substituted with 0-3 R<sup>4b</sup>, or

5 5 to 6 membered heterocycle containing 1 to 3  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>4b</sup>; wherein said 5 to 6  
10 membered heterocycle is selected from pyridinyl,  
pyrimidinyl, triazinyl, furanyl, thienyl,  
thiazolyl, pyrrolyl, piperazinyl, piperidinyl,  
pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and  
tetrazolyl;

15 R<sup>4b</sup>, at each occurrence, is independently selected from H,  
OH, Cl, F, Br, I, CN, NO<sub>2</sub>, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>,  
S(=O)CH<sub>3</sub>, S(=O)<sub>2</sub>CH<sub>3</sub>,  
C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> haloalkyl,  
C<sub>1</sub>-C<sub>4</sub> haloalkoxy, and C<sub>1</sub>-C<sub>4</sub> haloalkyl-S-;

20

Ring C is a 3-6 membered carbocycle selected from:



25 wherein said 3-6 membered carbocycle is substituted  
with 0-1 R<sup>21</sup>;

R<sup>21</sup> is selected from H, OH, Cl, F, CN, CF<sub>3</sub>, methyl, ethyl,  
methoxy, ethoxy, allyl, and -OCF<sub>3</sub>;

30 R<sup>11</sup> is selected from

H, =O, NR<sup>18</sup>R<sup>19</sup>;

C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with 0-1 R<sup>11a</sup>;

phenyl substituted with 0-3 R<sup>11b</sup>;

5 to 7 membered heterocycle containing 1 to 4

35 heteroatoms selected from nitrogen, oxygen, and



5 sulphur, wherein said 5 to 7 membered heterocycle is substituted with 0-3 R<sup>11b</sup>; wherein said 5 to 7 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, homopiperidinyl, and tetrazolyl;

10 R<sup>11a</sup>, at each occurrence, is independently selected from H, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, phenoxy, F, Cl, =O, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, or phenyl substituted with 0-3 R<sup>11b</sup>;

15 R<sup>11b</sup>, at each occurrence, is independently selected from H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

W is a bond or -CH<sub>2</sub>-;

20 X is a bond, phenyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or 5 to 6 membered heterocycle;

25 Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, -N(CH<sub>3</sub>)-, or -N(CH<sub>2</sub>CH<sub>3</sub>)-;

30 Z is H;  
C<sub>1</sub>-C<sub>8</sub> alkyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkenyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>2</sub>-C<sub>6</sub> alkynyl substituted with 0-3 R<sup>12a</sup>;  
C<sub>6</sub>-C<sub>10</sub> aryl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-C<sub>10</sub> carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle  
35 is substituted with 0-3 R<sup>12b</sup>;

R<sup>12a</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy,  
ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;  
phenyl substituted with 0-4 R<sup>12b</sup>;  
C<sub>3</sub>-6 carbocycle substituted with 0-4 R<sup>12b</sup>; or  
5 to 6 membered heterocycle containing 1 to 4  
heteroatoms selected from nitrogen, oxygen, and  
sulphur, wherein said 5 to 6 membered heterocycle  
is substituted with 0-3 R<sup>12b</sup>;

R<sup>12b</sup>, at each occurrence, is independently selected from  
H, OH, Cl, F, NR<sup>15</sup>R<sup>16</sup>, CF<sub>3</sub>, acetyl, SCH<sub>3</sub>, S(=O)CH<sub>3</sub>,  
S(=O)<sub>2</sub>CH<sub>3</sub>, methyl, ethyl, propyl, butyl, methoxy,  
ethoxy, propoxy, C<sub>1</sub>-C<sub>2</sub> haloalkyl, and C<sub>1</sub>-C<sub>2</sub>  
haloalkoxy;

R<sup>14</sup> is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;

R<sup>15</sup>, at each occurrence, is independently selected from H,  
methyl, ethyl, propyl, and butyl; and

R<sup>16</sup>, at each occurrence, is independently selected from  
H, OH, methyl, ethyl, propyl, butyl, benzyl, and  
phenethyl.

R<sup>18</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, butyl, phenyl, benzyl, and  
phenethyl;

R<sup>19</sup>, at each occurrence, is independently selected from  
H, methyl, ethyl, propyl, and butyl; and


R<sup>20</sup> is H, methyl, or ethyl.

19. A compound of claim 18, wherein:

L is  $\text{-NHC(=O)-}$ ,  $\text{-C(=O)NH-}$ , or  $\text{-OC(=O)NH-}$ ;

Ring C is selected from:

5




$\text{R}^3$  is  $\text{-CH}_3$ ,  $\text{-CH}_2\text{CH}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  
 $\text{-CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}_2(\text{CH}_3)_2$ ,  $\text{-CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ ,  $\text{-CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 10  $\text{-CH}_2\text{C}(\text{CH}_3)_3$ ,  $\text{-CF}_3$ ,  $\text{-CH}_2\text{CF}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CF}_3$ ,  $\text{-CH}_2\text{CH}_2\text{CH}_2\text{CF}_3$ ,  
 $\text{-CH}(\text{OH})\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}(\text{OH})\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}(\text{NH}_2)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 $\text{-CH}_2\text{CH}_2\text{OCH}_3$ ,  $\text{-CH}_2\text{OCH}_2\text{CH}_3$ ,  $\text{-CF}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 $\text{-CH}(\text{NHCH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  $\text{-CH}(\text{NHSO}_2\text{CH}_2\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}(\text{CH}_3)_2$ ,  
 15 cyclohexyl-, cyclopentyl-, cyclopropyl- $\text{CH}_2$ -,  
 cyclobutyl- $\text{CH}_2$ -, cyclopentyl- $\text{CH}_2$ -, cyclohexyl- $\text{CH}_2$ -,  
 cyclopropyl- $\text{CH}_2\text{CH}_2$ -, cyclobutyl- $\text{CH}_2\text{CH}_2$ -,  
 cyclopentyl- $\text{CH}_2\text{CH}_2$ -, cyclohexyl- $\text{CH}(\text{OH})$ -,  
 cyclohexyl- $\text{CH}_2\text{CH}_2$ -, 1- $\text{NH}_2$ -cyclopentyl, phenyl- $\text{CH}_2$ -,  
 (2-F-phenyl) $\text{CH}_2$ -, (3-F-phenyl) $\text{CH}_2$ -, (4-F-phenyl) $\text{CH}_2$ -,  
 20 (2-Cl-phenyl) $\text{CH}_2$ -, (3-Cl-phenyl) $\text{CH}_2$ -, (4-Cl-phenyl) $\text{CH}_2$ -,  
 (2,3-diF-phenyl) $\text{CH}_2$ -, (2,4-diF-phenyl) $\text{CH}_2$ -,  
 (2,5-diF-phenyl) $\text{CH}_2$ -, (2,6-diF-phenyl) $\text{CH}_2$ -,  
 (3,4-diF-phenyl) $\text{CH}_2$ -, (3,5-diF-phenyl) $\text{CH}_2$ -,  
 (2,3-diCl-phenyl) $\text{CH}_2$ -, (2,4-diCl-phenyl) $\text{CH}_2$ -,  
 25 (2,5-diCl-phenyl) $\text{CH}_2$ -, (2,6-diCl-phenyl) $\text{CH}_2$ -,  
 (3,4-diCl-phenyl) $\text{CH}_2$ -, (3,5-diCl-phenyl) $\text{CH}_2$ -,  
 (3-F-4-Cl-phenyl) $\text{CH}_2$ -, (3-F-5-Cl-phenyl) $\text{CH}_2$ -,  
 (3-Cl-4-F-phenyl) $\text{CH}_2$ -, phenyl- $\text{CH}_2\text{CH}_2$ -,  
 (2-F-phenyl) $\text{CH}_2\text{CH}_2$ -, (3-F-phenyl) $\text{CH}_2\text{CH}_2$ -,  
 30 (4-F-phenyl) $\text{CH}_2\text{CH}_2$ -, (2-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
 (3-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -, (4-Cl-phenyl) $\text{CH}_2\text{CH}_2$ -,  
 (2,3-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,4-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
 (2,5-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,6-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
 (3,4-diF-phenyl) $\text{CH}_2\text{CH}_2$ -, (3,5-diF-phenyl) $\text{CH}_2\text{CH}_2$ -,  
 35 (2,3-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -, (2,4-diCl-phenyl) $\text{CH}_2\text{CH}_2$ -,

(2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
 4-piperidinyl-CH<sub>2</sub>CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>CF<sub>2</sub>-,  
 5 phenyl-CH<sub>2</sub>CH(OH)-, imidazolyl-CH<sub>2</sub>CH(OH)-, or  
 phenyl-CH<sub>2</sub>OCH<sub>2</sub>-;

W is a bond or -CH<sub>2</sub>-;

10 X is a bond;



15

Y is a bond, -C(=O)-, -O-, -S-, -S(=O)-, -S(=O)<sub>2</sub>-, -NH-, or  
 -N(CH<sub>3</sub>)-,

Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl,  
 20 s-butyl, t-butyl, allyl, phenyl, 2-F-phenyl,  
 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl,  
 4-Cl-phenyl, 2,3-diF-phenyl,  
 2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl,  
 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl,  
 25 2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl,  
 3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl,  
 3-F-5-Cl-phenyl, 3-Cl-4-F-phenyl, 2-MeO-phenyl,  
 3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl,  
 4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl,  
 30 2-CF<sub>3</sub>O-phenyl, 3-CF<sub>3</sub>O-phenyl, 4-CF<sub>3</sub>O-phenyl, furanyl,  
 thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl,  
 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl,  
 1-benzimidazolyl, cyclopropyl, cyclobutyl,  
 cyclopentyl, cyclohexyl, morpholino, N-piperinyl,

phenyl-CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>-,  
(4-F-phenyl)CH<sub>2</sub>-, (2-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>-,  
5 (2,6-diF-phenyl)CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>-,  
(3,5-diF-phenyl)CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>-,  
10 (3-F-5-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>-,  
(2-MeO-phenyl)CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>-,  
(3-Me-phenyl)CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>-,  
15 4-MeS-phenyl)CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>-,  
(furyl)CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>-, (1-imidazolyl)CH<sub>2</sub>-,  
20 (oxazolyl)CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>-,  
(1-benzimidazolyl)CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>-,  
(cyclobutyl)CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>-,  
(cyclohexyl)CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>-,  
(N-piperidinyl)CH<sub>2</sub>-, phenyl-CH<sub>2</sub>CH<sub>2</sub>-,  
25 (phenyl)<sub>2</sub>CHCH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
30 (2,6-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3,5-diF-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,3-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2,6-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3,4-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3,5-diCl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-F-4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
35 (3-F-5-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Cl-4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-MeO-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,

(3-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-Me-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-MeS-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (2-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(3-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-, (4-CF<sub>3</sub>O-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
5 (furanyl)CH<sub>2</sub>CH<sub>2</sub>-, (thienyl)CH<sub>2</sub>CH<sub>2</sub>-, (pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(2-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (3-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(4-Me-pyridyl)CH<sub>2</sub>CH<sub>2</sub>-, (imidazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(oxazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (isoxazolyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(benzimidazolyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopropyl)CH<sub>2</sub>CH<sub>2</sub>-,  
10 (cyclobutyl)CH<sub>2</sub>CH<sub>2</sub>-, (cyclopentyl)CH<sub>2</sub>CH<sub>2</sub>-,  
(cyclohexyl)CH<sub>2</sub>CH<sub>2</sub>-, (morpholino)CH<sub>2</sub>CH<sub>2</sub>-, or  
(N-pipridinyl)CH<sub>2</sub>CH<sub>2</sub>-; and

R<sup>11</sup>, at each occurrence, is independently selected from  
15 H, =O, methyl, ethyl, phenyl, benzyl, phenethyl,  
4-F-phenyl, (4-F-phenyl)CH<sub>2</sub>-, (4-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-F-phenyl, (3-F-phenyl)CH<sub>2</sub>-, (3-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
2-F-phenyl, (2-F-phenyl)CH<sub>2</sub>-, (2-F-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-Cl-phenyl, (4-Cl-phenyl)CH<sub>2</sub>-, (4-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
20 3-Cl-phenyl, (3-Cl-phenyl)CH<sub>2</sub>-, (3-Cl-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-CH<sub>3</sub>-phenyl, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
3-CH<sub>3</sub>-phenyl, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>-, (3-CH<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
4-CF<sub>3</sub>-phenyl, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>-, (4-CF<sub>3</sub>-phenyl)CH<sub>2</sub>CH<sub>2</sub>-,  
cyclopentyl, pyrid-2-yl, pyrid-3-yl, or pyrid-4-yl.

25

20. A compound of Claim 1 selected from:

30

{[N-(3-methylbutyl)carbamoyl]cyclopentyl}-N-(5-methyl-6-  
oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carboxamide;  
{[N-(3-methylbutyl)carbamoyl]cyclopentyl}-N-(1-methyl-2-  
oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-  
yl))carboxamide;

35

[(N-butylcarbamoyl)cyclopentyl]-N-(1-methyl-2-oxo-5-  
phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl))carboxamide;

- 2-(3,5-difluorophenyl)-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]cyclohexyl}acetamide;
- 5 2-(3,5-difluorophenyl)-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]cyclopentyl}acetamide;
- 10 2-(3,5-difluorophenyl)-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]cyclopropyl}acetamide;
- 15 3-cyclopentyl-N-{[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]cyclohexyl}propanamide;
- 20 2-(3,5-difluorophenyl)-N-{4-[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl](4-piperidyl)}acetamide;
- phenyl 4-[2-(3,5-difluorophenyl)acetylamino]-4-[N-(1-methyl-2-oxo-5-phenyl((S)-3H-benzo[f]1,4-diazepin-3-yl)) carbamoyl]piperidinecarboxylate;
- 25 4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;
- 30 N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}{(phenylmethoxy)carbonylamino]cyclopentyl}carboxamide;
- 35 (2S)-N-{[N-(1-{[3-(4-fluorophenoxy)phenyl]methyl}-2-oxoazaperhydroepin-3-yl) carbamoyl]cyclopropyl}-2-hydroxy-4-methylpentanamide;

(2S)-N-{{N-(1-{{3-(4-fluorophenoxy)phenyl}methyl}-2-oxoazaperhydroepin-3-yl)carbamoyl}cyclopentyl}-2-hydroxy-3-methylbutanamide;

5 2,2-difluoro-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]-4-phenylbutanamide;

10 N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]-3-(4-piperidyl)propanamide;

15 (2S)-2-hydroxy-4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]pentanamide;

20 3-cyclopropyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]propanamide;

(2R)-2-hydroxy-3-imidazol-2-yl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]propanamide;

25 2-ethoxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]acetamide;

30 3-cyclopentyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]propanamide;

35 (2S)-2-hydroxy-3-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]butanamide;



(2S)-2-cyclohexyl-2-hydroxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl]acetamide;

5 (2R)-2-cyclohexyl-2-hydroxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl]acetamide;

10 (2S)-2-amino-4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl]pentanamide;

15 [(cyclohexylcarbonylamino)cyclopentyl]-N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carboxamide;

{[N-(3-methylbutyl)carbamoyl]cyclopentyl}-N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carboxamide;

20 4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl]pentanamide;

25 (2S)-2-hydroxy-4-methyl-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl]pentanamide;

30 3-methoxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl]propanamide;

35 (2S)-2-hydroxy-N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]}(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl]-3-phenylpropanamide;

N-[(N-{1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl](3H-benzo[f]1,4-diazepin-3-yl)}carbamoyl)cyclopentyl]-2-(phenylmethoxy)acetamide;

5 (2S)-2-hydroxy-3-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl}butanamide;

10 (2S)-2-hydroxy-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl}pentanamide;

15 3-cyclopentyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl}propanamide;

(2S)-2-cyclohexyl-2-hydroxy-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl}acetamide;

20 3-cyclopropyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl}propanamide;

25 N-{[N-(1-butyl-5-cyclopentyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl}-4-methylpentanamide;

N-{[N-(5-cyclopentyl-1-methyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl))carbamoyl]cyclopentyl}-4-methylpentanamide;

30 (2S)-2-hydroxy-3-methyl-N-({N-[2-oxo-1-benzyl(3H,4H,5H-benzo[f]azaperhydroepin-3-yl)]carbamoyl}cyclopentyl)butanamide;

35 (2S)-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl))carbamoyl]cyclopentyl}-2-[(propylsulfonyl)amino]pentanamide;

- (2S)-2-amino-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;
- 5 2,2-difluoro-4-methyl-N-{[N-(5-methyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;
- 10 4-methyl-N-{[N-(6-oxo(5H,7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl}pentanamide;
- 15 N-({N-[5-(3,3-dimethyl-2-oxobutyl)-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)] carbamoyl}cyclopentyl)-4-methylpentanamide;
- 20 4-methyl-N-([N-{6-oxo-5-[(3-phenoxyphenyl)methyl](7H-dibenzo[d,f]azaperhydroepin-7-yl)} carbamoyl]cyclopentyl}pentanamide;
- 25 N-([N-(5-butyl-6-oxo(7H-dibenzo[d,f]azaperhydroepin-7-yl)) carbamoyl]cyclopentyl)-4-methylpentanamide;
- 4-methyl-N-({N-[6-oxo-5-benzyl(7H-dibenzo[d,f]azaperhydroepin-7-yl)] carbamoyl}cyclopentyl}pentanamide;
- 30 N-({N-[5-(tert-butyl)-1-methyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl)] carbamoyl}cyclopentyl)-4-methylpentanamide;
- 35 N-({N-[5-(tert-butyl)-1-butyl-2-oxo(3H-benzo[f]1,4-diazepin-3-yl)] carbamoyl}cyclopentyl)-4-methylpentanamide; and

N-({N-[5-butyl-2-oxo-1-(2-pyridylmethyl)(3H-benzo[f]1,4-diazepin-3-yl)]carbamoyl}cyclopentyl)-4-methylpentanamide.

5           21. A method for the treatment of neurological disorders associated with  $\beta$ -amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of a compound according to one of Claims 1-20 or a pharmaceutically acceptable salt or  
10           prodrug thereof.

          22. A pharmaceutical composition comprising a compound according to one of Claims 1-20 and a pharmaceutically acceptable carrier.

15

          23. A method for the treatment of neurological disorders associated with  $\beta$ -amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of a compound according to  
20           one of Claims 1-20.

          24. A method for inhibiting  $\gamma$ -secretase activity comprising administering to a host in need of such inhibition a therapeutically effective amount of a compound  
25           according to one of Claims 1-20 that inhibits  $\gamma$ -secretase activity.

## INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 01/10667

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D223/18 C07D243/24 C07D401/12 C07D223/12 C07D403/12  
 C07D223/16 C07D243/14 C07D401/06 A61K31/55 A61K31/551  
 A61K31/5513 A61P25/28 C07K5/06 C07K5/08 A61K38/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 378 844 A (DEVELLIS PATRIZIA ET AL) 3 January 1995 (1995-01-03) column 5, line 48 - line 49	1
X	WO 92 16524 A (MERCK & CO INC) 1 October 1992 (1992-10-01) example 19, step A	1-4
A	page 62, line 14; example 29	1, 21
X	US 4 897 489 A (HARADA SETSUO ET AL) 30 January 1990 (1990-01-30) examples 46A, 46B	1
X	WO 99 66934 A (AUDIA JAMES E ; ELAN PHARM INC (US); LILLY CO ELI (US); SHI QING (U) 29 December 1999 (1999-12-29) page 25; claim 41	1, 21
	--- -/-	-



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

28 August 2001

Date of mailing of the international search report

05/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Seitner, I

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/10667

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 28268 A (MCDANIEL STACEY L ;SCOTT WILLIAM LEONARD (US); THORSETT EUGENE D ( ) 2 July 1998 (1998-07-02) examples 7C-36,7C-224,7C-230,7C-236,7C-242 claim 2	1,21
A	WO 99 67221 A (MCDANIEL STACEY L ;AUDIA JAMES E (US); CWI CYNTHIA L (US); ELAN PH) 29 December 1999 (1999-12-29) claim 1	1,21

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-24 (all partially)

Present claims 1-24 relate to a compounds defined by reference to a desirable characteristic or property, namely prodrugs of Formula (I) of claim 1

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, all claims were completely searched except for those parts pertaining to prodrugs. Nevertheless, the search was also complete for acetate, formate, and benzoate derivatives of alcohol and amine functional groups in the compounds of Formula (I) of claim 1 (see page 108, lines 9-11).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/10667

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5378844	A	03-01-1995	IT 1260444 B	09-04-1996
			AT 173732 T	15-12-1998
			CA 2087922 A	25-07-1993
			CN 1082047 A,B	16-02-1994
			DE 69322177 D	07-01-1999
			DE 69322177 T	24-06-1999
			DK 552712 T	09-08-1999
			EP 0552712 A	28-07-1993
			ES 2125911 T	16-03-1999
			GR 3029476 T	28-05-1999
WO 9216524	A	01-10-1992	US 5206235 A	27-04-1993
			AT 142206 T	15-09-1996
			AU 653992 B	20-10-1994
			AU 1301292 A	24-09-1992
			BG 61448 B	29-08-1997
			BG 98112 A	27-05-1994
			CA 2063185 A	21-09-1992
			CN 1066070 A,B	11-11-1992
			DE 69213318 D	10-10-1996
			DE 69213318 T	10-04-1997
			EP 0513974 A	19-11-1992
			FI 921183 A	21-09-1992
			HU 66796 A	28-12-1994
			IE 920877 A	23-09-1992
			IL 101206 A	18-02-1997
			JP 2103149 C	22-10-1996
			JP 6172316 A	21-06-1994
			JP 8000814 B	10-01-1996
			MX 9201226 A	01-10-1992
			NO 921077 A	21-09-1992
			NZ 241958 A	27-04-1995
			US 5310737 A	10-05-1994
			ZA 9202009 A	25-11-1992
US 4897489	A	30-01-1990	WO 8603752 A	03-07-1986
			AT 80162 T	15-09-1992
			DE 3586591 A	08-10-1992
			DE 3586591 D	08-10-1992
			DE 3586591 T	21-01-1993
			DK 558885 A	19-06-1986
			EP 0191989 A	27-08-1986
			ES 550040 D	01-05-1987
			ES 8705431 A	16-07-1987
			HU 204266 B	30-12-1991
			IE 59102 B	12-01-1994
			WO 8700178 A	15-01-1987
			JP 1948446 C	10-07-1995
			JP 6074275 B	21-09-1994
			JP 62201887 A	05-09-1987
			KR 9301405 B	27-02-1993
			HU 41773 A	28-05-1987
			EP 0250096 A	23-12-1987
			JP 63107977 A	12-05-1988
			CN 87104230 A	23-12-1987
			DK 287787 A	13-12-1987
			EP 0250143 A	23-12-1987
			HU 48237 A	29-05-1989



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/10667

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4897489 A		JP 63107978 A	12-05-1988
WO 9966934 A	29-12-1999	AU 4707999 A	10-01-2000
		AU 4710199 A	10-01-2000
		AU 4710499 A	10-01-2000
		EP 1089977 A	11-04-2001
		EP 1089980 A	11-04-2001
		EP 1093372 A	25-04-2001
		WO 9967219 A	29-12-1999
		WO 9967221 A	29-12-1999
WO 9828268 A	02-07-1998	AU 5700798 A	17-07-1998
		BR 9714517 A	04-07-2000
		EP 0951466 A	27-10-1999
		HR 970705 A	31-10-1998
		HU 0001232 A	28-10-2000
		JP 2000511932 T	12-09-2000
		NO 993098 A	20-08-1999
		PL 334305 A	14-02-2000
		TR 9901343 T	21-09-1999
WO 9967221 A	29-12-1999	AU 4707999 A	10-01-2000
		AU 4710199 A	10-01-2000
		AU 4710499 A	10-01-2000
		EP 1089977 A	11-04-2001
		EP 1089980 A	11-04-2001
		EP 1093372 A	25-04-2001
		WO 9967219 A	29-12-1999
		WO 9966934 A	29-12-1999